



ISPOR 19th Annual European Congress

29 October-2 November 2016
Austria Center Vienna
Vienna, Austria



Managing Access to Medical Innovation: Strengthening the Methodology-Policy Nexus

Wednesday Research Poster Presentations

Poster Display Hours – 8:45 - 13:45
Poster Author Discussion Hour – 12:45 - 13:45

POSTER SESSION V:

PMD: MEDICAL DEVICE/DIAGNOSTICS
PCN: GASTROINTESTINAL DISORDERS

ROWS A-D
ROWS D-L

RESEARCH POSTER PRESENTATIONS - SESSION V

HEALTH CARE TREATMENT STUDIES

MEDICAL DEVICE/DIAGNOSTICS - Clinical Outcomes Studies

- PMD1 A1 HEALTH TECHNOLOGY ASSESSMENT ON CONTINUOUS AND INTERMITTENT RENAL REPLACEMENT THERAPIES FOR ACUTE KIDNEY INJURY IN ADULT PATIENTS**
Schoenfelder T, Chen X, Bleß H, IGES Institut GmbH, Berlin, Germany
- PMD2 A2 IMPLEMENTATION OF ONE STOP DIAGNOSIS IN PATIENTS WITH THYROID NODULES: IMPACT ON COST AND SURGERY**
Kandel M¹, Schlumberger M², Benhamou E², Leboulleux S², Berdelou A², Pottier E², Suci V², Borget I³, ¹Gustave Roussy, PARIS, France, ²Gustave Roussy, Villejuif, France, ³Institut Gustave Roussy, Villejuif, France
- PMD3 A3 SYSTEMATIC REVIEW AND META-ANALYSIS OF ACCURACY OF DIAGNOSTIC TESTS FOR SCREEN DETECTION OF ATRIAL FIBRILLATION**
Thom H¹, McAleenan A¹, Davies P¹, Okoli GN¹, Higgins J¹, Hollingworth W¹, Sterne J¹, Feder G¹, Eaton D², Hingorani A³, Fawsitt C¹, Lobban T⁴, Bryden PA⁵, Richards A¹, Sofat R³, Welton NJ¹, ¹University of Bristol, Bristol, UK, ²Anticoagulation Europe, Kent, UK, ³University College London, London, UK, ⁴Atrial Fibrillation Association, Warwickshire, UK, ⁵Roche, Basel, Switzerland
- PMD4 A4 EVALUATION OF BREAST CANCER HER2 STATUS ACCURACY USING A PREDICTIVE MODEL BASED ON HER-FRANCE REAL WORLD NATIONAL DATABASE**
Egele C¹, **Pau D**², Rabut J³, Fetique D¹, Martin J², Dupin J⁴, Bellocq J⁵, ¹CHRU Strasbourg, Strasbourg, France, ²Roche, Boulogne-Billancourt, France, ³Lincoln Systems, Boulogne-Billancourt, France, ⁴ITM stat, Neuilly/seine, France, ⁵Hospital of Strasbourg, Strasbourg, France
- PMD5 A5 THE 21-GENE ASSAY IN THE DECISION IMPACT ASSESSMENT OF ER+, HER2- BREAST CANCER: A FRENCH REAL LIFE PROSPECTIVE STUDY**
Mouysset J¹, Laplaige P², Fignon A³, Jallais L⁴, **Lafuma A**⁵, Michaud P⁶, Dohollou N⁷, Gligorov J⁸, ¹Clinique Rambot-Provençale, Aix en Provence, France, ²Polyclinique de Blois, La Chaussee St Victor, France, ³Clinique de l'Alliance, St-Cyr-sur-Loire, France, ⁴Tours, Tours, France, ⁵Cemka-Eval, Bourg La Reine, France, ⁶OncoCentre, Orleans, France, ⁷Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France, ⁸APHP, Tenon Hospital, Paris, France
- PMD6 A6 DATA MINING USED TO CHARACTERIZE DISCORDANCE IN GASTRIC CANCERS HER2 STATUS DETERMINATION TO HELP FOR A BETTER TREATMENT DECISION**
Pau D¹, Monges G², Doucet L³, Terris B⁴, Chenard M⁵, Bibeau F⁶, Penault-Llorca F⁷, Martin J¹, Rabut J⁸, Leroux D⁹, ¹Roche, Boulogne-Billancourt, France, ²Hôpital Pasteur, Nice, France, ³Hôpital Cavale Blanche, Brest, France, ⁴Hôpital Cochin, Paris, France, ⁵Hôpital Hautepierre, Strasbourg, France, ⁶Institut du Cancer de Montpellier, Montpellier, France, ⁷Centre Jean Perrin, Clermont-Ferrand, France, ⁸Lincoln Systems, Boulogne-Billancourt, France, ⁹HAYS PHARMA, Paris, France
- PMD7 A7 THE STOOL ANTIGEN TEST FOR DETECTION OF HELICOBACTER PYLORI FOR DIAGNOSE H.PYLORI INFECTION AND ASSESSMENT OF ERADICATION THERAPY**
Galiyeva A, Astana Medical University, Astana, Kazakhstan
- PMD8 A8 ASSESSMENT OF PET/CT USE IN RADIOTHERAPY PLANNING VERSUS CT SCANS USE ONLY**
Jerabkova S¹, Pangracova L², ¹University of Economics, Prague, Prague, Czech Republic, ²Czech Technical University, Kladno, Czech Republic
- PMD9 A9 QUICK ASSESSMENT ON LUNG CANCER SCREENING WITH LOW-DOSE COMPUTED TOMOGRAPHY**
Laschkolnig A, Pertl D, Gesundheit Österreich GmbH, Vienna, Austria
- PMD10 A10 ADDED BENEFIT OF UPPER AIRWAY STIMULATION FOR THE TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA IN AUSTRIA**
Pietzsch JB¹, Zauner G², Liu S¹, ¹Wing Tech Inc., Irvine, CA, USA, ²dwh GmbH, Vienna, Austria
- PMD11 A11 CLINICAL IMPACT OF ANTIMICROBIAL IMPREGNATED CATHETERS FOR REDUCTION OF INFECTION IN CEREBROSPINAL FLUID DIVERSION PROCEDURES**
Parker E¹, Velleca M², Scagliarini L², ¹DePuy Synthes, Leeds, UK, ²Johnson & Johnson Medical S.p.A., Pratica di Mare, Italy
- PMD12 A12 TRANSCATHETER AORTIC VALVE IMPLANTATION FOR INOPERABLE SEVERE AORTIC STENOSIS - A META-ANALYSIS**
Mattos AZ¹, Schroder DA², Colpani V³, Restelatto LM⁴, **Ribeiro RA**⁵, ¹PUC-RS, Porto Alegre, Brazil, ²Hospital de Caridade de Ijuí, Ijuí, Brazil, ³IMED - Faculdade Meridional, Passo Fundo, Brazil, ⁴Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁵IMED - Faculdade Meridional and Fundação IMED, Passo Fundo, Brazil
- PMD13 A13 ASSESSMENT OF CAROTID STENTING SAFETY: A FRENCH EXHAUSTIVE COHORT STUDY BASED ON THE RE-USE OF ROUTINE NATIONAL HEALTH DATABASE**
Marque S¹, Beyssen B², Congard-Chassol B³, Levesque K⁴, Nguyen T⁵, Mouton E⁶, Collignon C⁷, Chatellier G², ¹EXEPI, Paris, France, ²HEGP, Paris, France, ³SNITEM, Levallois, France, ⁴Capionis, Bordeaux, France, ⁵Johnson & Johnson Medical Devices, ISSY-LES-MOULINEAUX, France, ⁶Boston Scientific, Nanterre, France, ⁷Medtronic, Boulogne, France
- PMD15 A15 THE PREDICTION OF THE BRCA1/2-RELATED OVARIAN CANCER MORBILITY IN RUSSIA**

MEDICAL DEVICE/DIAGNOSTICS - Cost Studies

- PMD16 A16 ECONOMIC ANALYSIS OF EVARREST SEALANT MATRIX COMPARED WITH STANDARD OF CARE IN SEVERE SOFT TISSUE SURGICAL BLEEDING: A FRANCE HOSPITAL PERSPECTIVE**
Jamous N¹, Thanh TN², Ferko N³, Hogan A³, Batiller J⁴, Kocharian R⁵, Danker III W⁶,¹Ethicon Biosurgery, Berkshire, UK, ²Johnson & Johnson, Issy-les-Moulineaux, France, ³Cornerstone Research Group Inc., Burlington, ON, Canada, ⁴Ethicon Biosurgery, USA, Somerville, NJ, USA, ⁵Ethicon, Inc., Somerville, NJ, USA, ⁶Global Health Economics and Market Access, Ethicon, Inc., Somerville, NJ, USA
- PMD17 A17 DIFFUSION OF TRANS-ARTERIAL RADIOEMBOLIZATION FOR THE TREATMENT OF INTERMEDIATE-ADVANCED HEPATOCELLULAR CARCINOMA IN ITALY: A BUDGET IMPACT ANALYSIS**
Rognoni C, Ciani O, Sommariva S, Tarricone R, Bocconi University, Milan, Italy
- PMD18 A18 BUDGET IMPACT ANALYSIS OF CEMENTLESS VERSUS CEMENTED PROSTHESES FOR TOTAL HIP ARTHROPLASTY FROM A UK HOSPITAL PERSPECTIVE**
Taylor H¹, Muehlendyck C², Peden S¹,¹Johnson & Johnson Medical Limited, Leeds, UK, ²Johnson & Johnson Medical GmbH, Norderstedt, Germany
- PMD19 A19 INVESTIGATING THE ECONOMIC IMPACT OF sFLT-1/PLGF RATIO AS A PREDICTIVE TEST IN WOMEN WITH SUSPECTED PREECLAMPSIA IN ITALY**
Paolini D¹, Dionisi M¹, Frusca T², Gervasi MT³, Boscaini S¹, Cetin I⁴,¹Roche Diagnostics S.p.A., Monza, Italy, ²University of Parma, Parma, Italy, ³Hospital of Padova, Padova, Italy, ⁴University of Milan, Milan, Italy
- PMD20 A20 ECONOMIC BURDEN OF MAINTAINING VASCULAR ACCESS PATENCY IN PATIENTS WITH HEMODIALYSIS FISTULAS : A NATIONAL POPULATION-BASED STUDY**
Choi H, Lim A, Medtronic Korea, Ltd., Seoul, South Korea
- PMD21 A21 BUDGET IMPACT MODEL TO AUGMENT THE VALUE OF AN INNOVATIVE DEVICE FOR THE EARLY DETECTION OF PRESSURE ULCERS IN SCOTLAND**
Zanin A¹, Marty R¹, Akpo H¹, Burns M²,¹Deloitte, Diegem, Belgium, ²Bruin Biometrics LLC, Los Angeles, CA, USA
- PMD22 A22 THE POTENTIAL TO IMPROVE INHALATION TECHNIQUE IN PATIENTS WITH ASTHMA OR COPD BY SWITCHING FROM SYMBICORT® TURBUHALER® (BUDESONIDE + FORMOTEROL) TO DUORESP® SPIROMAX®: ESTIMATED IMPACT ON THE NUMBER AND COST OF UNSCHEDULED HEALTHCARE EVENTS IN POLAND**
Watson A¹, Bijos P², Ludwikowski R², Lewis A¹, Blackney M¹, **Torvinen S**³, Plich A³,¹Covance Market Access, London, UK, ²Teva Pharmaceuticals Polska, Warszawa, Poland, ³Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands
- PMD23 A23 COST OF EBOLA VIRUS DISEASE DIAGNOSIS USING RAPID POINT-OF-CARE DIAGNOSTICS IN SIERRA LEONE**
Evans JS, Hearmon NC, Beale RC, Marsh W, Costello Medical Consulting Ltd, Cambridge, UK
- PMD24 A24 THE ECONOMIC IMPACT OF USING ANTIMICROBIAL CATHETERS IMPREGNATED WITH RIFAMPIN AND CLINDAMYCIN TO REDUCE INFECTION RATES IN EXTERNAL VENTRICULAR DRAINAGE: A BUDGET IMPACT ANALYSIS**
Mercurio M¹, Paragó V¹, Velleca M¹, Scagliarini L¹, Parker E², Garziera G¹,¹Johnson & Johnson Medical S.p.A., Pratica di Mare, Italy, ²DePuy Synthes, Leeds, UK
- PMD25 A25 ECONOMIC ANALYSES OF FLAIR® AND FLUENCY® PLUS ENDOVASCULAR STENT GRAFTS FOR THE TREATMENT OF VASCULAR ACCESS STENOSIS: A U.S. HOSPITAL AND PAYER PERSPECTIVE**
Barclay B¹, Hogan A², Hollmann S², Ferko N², Delatore P³,¹C.R. Bard Inc., Murray Hill, NJ, USA, ²Cornerstone Research Group Inc., Burlington, ON, Canada, ³CR Bard Inc., Murray Hill, NJ, USA
- PMD26 A26 BUDGET IMPACT ANALYSIS OF THE PERMANENT ENDOVASCULAR ADHESIVE CLOSURE SYSTEM IN THE TREATMENT OF VENOUS REFLUX AND CHRONIC VENOUS INSUFFICIENCY (CVI) IN TURKEY**
Ozdemir Saltik Z, Akgul T, Can H, Copur F, Askin E, Medtronic, Istanbul, Turkey
- PMD27 A27 BUDGET IMPACT ANALYSIS OF NATIONAL CERVICAL CANCER SCREENING PROGRAM IN DENMARK: CYTOLOGY WITH HPV TRIAGE VS. HPV PRIMARY SCREENING WITH REFLEX CYTOLOGY TRIAGE & CINTEC PLUS CYTOLOGY**
Kempers J¹, Narvestad J², Kofod M², Mikkelsen RM², **Ersek K**¹,¹Roche Diagnostics, Almere, The Netherlands, ²Roche Diagnostics, Hvidovre, Denmark
- PMD28 A28 INCREASED CLINICAL AND ECONOMIC BENEFIT IN SPAIN ASSOCIATED WITH IMPROVEMENT TO ±8.5% OF THE ACCURACY OF GLUCOSE METERS ADAPTED TO THE CURRENT ISO 15197:2013 (±15%)**
Sanz-Granda Á¹, Artola-Menéndez S², Franch-Nadal J³, Mata-Cases M³, Merino-Torres JF⁴,¹Proyectos de Farmacoeconomía, Navacerrada (Madrid), Spain, ²CS José Marvá, Madrid, Spain, ³Fundación redGPDS, DAP_CAT, Barcelona, Spain, ⁴Hospital Universitari i Politècnic La Fe, Valencia, Spain
- PMD29 A29 BUDGET IMPACT OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED WITH MULTIPLE DAILY INSULIN INJECTIONS FOR THE TREATMENT OF TYPE 1 DIABETES IN SPAIN**
Elías I¹, Giménez M², Álvarez M¹, Quirós C², Conget I²,¹Medtronic Ibérica, S.A., Madrid, Spain, ²Diabetes Unit. Endocrinology Department. Hospital Clínic i Universitari de Barcelona. IDIBAPS, Barcelona, Spain

- PMD30 A30 ECONOMIC VALUE OF EPTFE STENT-GRAFTS COMPARED TO BALLOON ANGIOPLASTY FOR TREATING THROMBOSED AND DYSFUNCTIONAL ARTERIOVENOUS GRAFTS IN ENGLAND**
Mohr BA¹, **Evans RM**², W. L. Gore & Associates, Inc., Flagstaff, AZ, USA, ²W.L. Gore & Associates (UK) Limited, Livingston, UK
- PMD31 A31 A REAL WORLD COST ANALYSIS OF SERUM HBSAG QUANTIFICATION TEST IN PATIENTS WITH CHRONIC HEPATITIS B: THE CASE OF THE UNIVERSITY OF NAPLES FEDERICO II**
Aiello A¹, Guarino M², D'Ausilio A¹, Latorre E¹, Toumi M³, Caporaso N², Morisco F², ¹Creativ Ceutical, Milano, Italy, ²University of Naples "Federico II", Naples, Italy, ³Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille, France
- PMD32 A32 ECONOMIC ANALYSIS OF ENDOVASCULAR INTERVENTIONS FOR THE TREATMENT OF FEMOROPOPLITEAL PERIPHERAL ARTERY DISEASE IN AUSTRIA**
Pietzsch JB¹, Geisler BP¹, Jaff MR², Zeller T³, Brodmann M⁴, ¹Wing Tech Inc., Irvine, CA, USA, ²Harvard University, Boston, MA, USA, ³Universitaets-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany, ⁴Medizinische Universtität Graz, Graz, Austria
- PMD33 A33 A COST-MINIMIZATION ANALYSIS OF DERMATOPHYTE TEST KIT WITH TINEA UNGUIUM UNDER HEALTH CARE SYSTEM IN JAPAN**
Watanabe R¹, Igarashi A², Wakamoto H³, Osawa H³, ¹Initiative for Social & Public Health, Tokyo, Japan, ²University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, ³JNC Corporation, Tokyo, Japan
- PMD34 A34 BUDGET IMPACT ANALYSIS OF A FLASH GLUCOSE MONITORING SYSTEM FOR PATIENTS WITH DIABETES WHO ARE USING INTENSIVE INSULIN**
Hellmund R, Abbott Diabetes Care, Alameda, CA, USA
- PMD35 A35 OPEN VERSUS ENDOVASCULAR REPAIR IN PATIENTS WITH ABDOMINAL AORTIC ANEURYSM IN SPAIN – A COST COMPARISSON**
Egea M¹, Fernandez-Samos R², Lechón JA³, Reparaz LM⁴, Álvarez M⁵, Cairols M⁶, ¹Medtronic Iberica, Madrid, Spain, ²Complejo Asistencial Universitario de León, León, Spain, ³Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁴Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁵Medtronic Ibérica, Madrid, Spain, ⁶Hospital Delfos, Barcelona, Spain
- PMD36 A36 DAY SURGERY VS REGULAR ADMISSION: ACTIVITY-BASED COST ANALYSIS OF PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) PROCEDURES FROM HOSPITAL PERSPECTIVE**
Monti F, Boggi A, Colantonio R, Rotolo FL, Bruno E, Serdoz R, San Pietro FBF Rome hospital, Rome, Italy
- PMD37 A37 ECONOMIC BURDEN OF COLORECTAL RESECTIONS: INCREMENTAL EFFECTS IN CANCER PATIENTS**
Yoo A¹, Hsiao C², Cheng H², Kalsekar I¹, ¹Johnson & Johnson Co., New Brunswick, NJ, USA, ²Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA
- PMD38 A38 INCREMENTAL BURDEN OF CANCER IN PATIENTS UNDERGOING HEPATIC RESECTIONS: RESULTS FROM A NATIONAL HOSPITAL BILLING DATA**
Kalsekar I¹, Hsiao C², Cheng H², Yoo A³, ¹Johnson & Johnson Co., New Brunswick, NJ, USA, ²Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA, ³Medical Device - Epidemiology, Johnson and Johnson, New Brunswick, NJ, USA
- PMD39 B1 A RETROSPECTIVE PREMIER DATABASE STUDY TO EVALUATE DIFFERENCES BETWEEN PROGEL™ PLEURAL AIR LEAK SEALANT AS COMPARED WITH OTHER SEALANTS IN THE INPATIENT SURGICAL SETTING**
Mortman K¹, Corral M², Zhang X², Berhane I², Bourque M³, Ferko N³, ¹George Washington University Hospital, Washington, DC, USA, ²C.R. Bard Inc., Murray Hill, NJ, USA, ³Cornerstone Research Group Inc., Burlington, ON, Canada
- PMD40 B2 MICRO-COSTING ANALYSIS OF PROCEDURES ON VARICOSE VEINS PERFORMED IN OUTPATIENT SETTING**
Baccaglini U, Pavei P, AOU Padova, Padova, Italy
- PMD41 B3 PRELIMINARY COST-EFFECTIVENESS ASSESSMENT OF 3D PRINTED ANATOMIC MODELS FOR CONGENITAL HEART DISEASES**
Tack P¹, Annemans L², ¹Ghent University, Ghent, Belgium, ²Ghent University - Brussels University, Ghent, Belgium
- PMD42 B4 COST PATTERNS IN PATIENTS TREATED WITH SPINAL CORD STIMULATION FOLLOWING SPINE SURGERY—A REGISTER BASED STUDY**
Hansson-Hedblom A¹, **Jonsson E**¹, Kirketeig T², Hägg O³, Fritzell P⁴, Borgström F¹, ¹Quantify Research, Stockholm, Sweden, ²Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden, ³Spine Center Göteborg, Gothenburg, Sweden, ⁴Capio St Göran Hospital, Stockholm, Sweden
- PMD43 B5 DIRECT HEALTHCARE COSTS AND CLINICAL OUTCOMES OF OPEN ABDOMINAL AORTIC ANEURYSM REPAIR IN SPAIN. RECAPTA STUDY**
Egea M¹, Fernandez-Samos R², Lechón JA³, Reparaz LM⁴, Álvarez M⁵, Cairols M⁶, ¹Medtronic Iberica, Madrid, Spain, ²Complejo Asistencial Universitario de León, León, Spain, ³Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁴Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁵Medtronic Ibérica, Madrid, Spain, ⁶Hospital Delfos, Barcelona, Spain
- PMD44 B6 A PROPENSITY SCORE MATCHED STUDY OF PLASMA BLADE VS COBLATION TECHNOLOGY DURING PEDIATRIC TONSILLECTOMY AND ADENOIDECTOMY PROCEDURES**

Nichols CI, Vose JG, Medtronic Advanced Energy, Portsmouth, NH, USA

PMD45 B7 ECONOMIC BENEFITS OF CPAP TREATMENT FOR OBSTRUCTIVE SLEEP APNEA IN THE ELDERLY

Park SS, **Menzin J**, Boston Health Economics, Waltham, MA, USA

PMD46 B8 COST-EFFECTIVENESS OF EARLY TIPS WITH EXPANDED POLYTETRAFLUOROETHYLENE (EPTFE) COVERED STENT-GRAFTS COMPARED TO ENDOSCOPIC PROCEDURES TO MANAGE ACUTE VARICEAL BLEEDING – A SPANISH SCENARIO

Pérez-Mitru A¹, Villacampa Lordan A¹, **Scarpa F**², Oblique Consulting, Barcelona, Spain, ²W.L.GORE & Associates, Verona, Italy

PMD47 B9 COST-EFFECTIVENESS EVALUATION OF TIPS PROCEDURES WITH EXPANDED POLYTETRAFLUOROETHYLENE (EPTFE) COVERED STENT-GRAFTS COMPARED TO LARGE VOLUME PARACENTESIS IN PATIENTS WITH REFRACTORY ASCITES – A SPANISH SCENARIO

Pérez-Mitru A¹, Villacampa Lordan A¹, **Scarpa F**², Oblique Consulting, Barcelona, Spain, ²W.L.GORE & Associates, Verona, Italy

PMD48 B10 COST ANALYSIS OF HUMAN GENOME SEQUENCING IN CANCER DIAGNOSIS IN FRANCE: NEXT GENERATION SEQUENCING

Kossi DS¹, Touzani R², Borget I³, Zhaomin Z⁴, Vaur D⁵, Rouleau E⁶, Preudhomme C⁷, Lacroix L⁴, Perrier L⁸, Durand-Zaleski I⁹, Marino P², Baffert S¹, ¹Fondation Ophtalmologique Adolphe de Rothschild, Paris, France, ²Institut Paoli Calmettes, Marseille, France, ³Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France, ⁴Institut Gustave Roussy, Villejuif, France, ⁵Centre François Baclesse-Inserm U1079 - Génétique du cancer et Maladies Neuropsychiatriques, Caen, France, ⁶Institut Curie, Paris, France, ⁷CHRU de Lille - Centre de Biologie Pathologie Génétique, Lille, France, ⁸Cancer Centre Leon Berard, Lyon, France, ⁹URC Eco, Paris, France

PMD49 B11 COST-BENEFIT ANALYSIS FOR DIRECT VISUAL OBSERVATION OF NASOGASTRIC ENTERAL FEEDING TUBE PLACEMENT

Saunders R¹, Ozols A², ¹Coreva Scientific, Freiburg im Breisgau, Germany, ²Medtronic, Boulder, CO, USA

PMD50 B12 COST-BENEFIT ANALYSIS OF DENTAL PROSTHESIS IN UKRAINE

Got S, Zaliskyy O, Zaliska O, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PMD51 B13 EVALUATING THE COST-BENEFIT OF A COGNITIVE ASSESSMENT AND TRAINING PROGRAM ACROSS A SMART CITY POPULATION IN THE UK

Sparrowhawk K¹, Cliveden P¹, Ratto M¹, Ogle-Welbourn W², Sunley A², ¹MyCognition, London, UK, ²Peterborough City Council, Peterborough, UK

PMD52 B14 POTENTIAL COST SAVINGS OF A POINT-OF-CARE DIAGNOSTIC TEST MEASURING ANTIPSYCHOTIC PLASMA LEVELS FOR TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN SPAIN

Pobre MA¹, Riley R², Predmore Z³, Horvitz-Lennon M³, Mattke S³, ¹Johnson & Johnson Medical, Madrid, Spain, ²Janssen Diagnostics, Titusville, NJ, USA, ³RAND Health, Boston, MA, USA

PMD53 B15 COST-EFFECTIVENESS OF RADIAL ACCESS VERSUS FEMORAL FOR DIAGNOSTIC CARDIAC CATHETERIZATION AND CORONARY INTERVENTION IN COLOMBIA

Borja H¹, Gil-Rojas Y², Castañeda-Cardona C³, Rosselli D², ¹Universidad de Antioquia, Medellín, Colombia, ²Pontificia Universidad Javeriana, Bogota, Colombia, ³Neuroeconomix, Bogota, DC, Colombia

PMD54 B16 COST - EFFECTIVENESS ANALYSIS OF PRESEPSIN COMPARED WITH C-REACTIVE PROTEIN AND PROCALCITONIN IN DETECTING SEVERE BACTERIAL INFECTION IN CHILDREN AGED 29 DAYS TO 36 MONTHS OLD WITH FEVER WITHOUT SOURCE

Amatha J, Berdejo L, Acosta-Reyes J, Universidad del Norte, Barranquilla, Colombia

PMD55 B17 COST-EFFECTIVENESS OF DIFFERENT CERVICAL CANCER PRIMARY SCREENING USING CYTOLOGY, HPV OR P16/KI-67 TESTING ALONE OR IN COMBINATIONS FOR THE AUSTRIAN HEALTH CARE CONTEXT

Sroczynski G¹, Esteban E¹, Widschwendter A², Oberaigner W³, Hintringer K⁴, Endel G⁵, Siebert U⁶, ¹UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL - Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria, ²Medical University Innsbruck, Innsbruck, Austria, ³Tirol Kliniken Innsbruck, Innsbruck, Austria, ⁴TGKK-Tyrolean Sickness Fund, Innsbruck, Austria, ⁵Main Association of Austrian Social Insurance Institutions, Vienna, Austria, ⁶and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria

PMD56 B18 COST-EFFECTIVENESS ANALYSIS OF DIAGNOSTICS OF TUBERCULOSIS INFECTION IN THE RUSSIAN FEDERATION WITH THE USE OF TUBERCULOUS RECOMBINANT ALLERGEN

Holownia M, Solodun I, Bashlakova E, Ermolaeva T, Davydovskaya M, Evdoshenko E, State Budgetary Institution of Moscow City «Center of Clinical Trials Management and Performance of Moscow Department of Healthcare», Moscow, Russia

PMD57 B19 THE COST-EFFECTIVENESS OF WHOLE-EXOME SEQUENCING IN COMPLEX PAEDIATRIC NEUROLOGY

van Nimwegen K, Vissers L, Willemsen M, Schieving J, Veltman J, van Der Wilt G, Grutters JP, Radboud university medical center, Nijmegen, The Netherlands

PMD58 B20 COST-EFFECTIVENESS OF SCREENING FOR SEVERE SLEEP-DISORDERED BREATHING IN JAPAN

Takegami M¹, Moriwaki K², Nishimura K¹, Miyamoto Y¹, ¹National Cerebral and Cardiovascular Center, Suita, Japan, ²Kobe Pharmaceutical University, Kobe, Japan

- PMD59 B21 INVESTIGATING THE COST-EFFECTIVENESS OF GENETIC COUNSELLING FOR COUPLES AT KNOWN RISK OF HAVING CHILDREN WITH TAY-SACHS DISEASE: A TWO-GENERATION MODEL**
Ghosh W, Griffiths M, Griffiths A, Costello Medical Consulting Ltd, Cambridge, UK
- PMD60 B22 COST-EFFECTIVENESS OF ACTIVE SURVEILLANCE OF BETA-D-GLUCAN IN INTENSIVE CARE UNITS IN HONG KONG**
Pang Y, Ip M, **You J**, The Chinese University of Hong Kong, Shatin, Hong Kong
- PMD61 B23 COST-EFFECTIVENESS OF D-DIMER IN THE DIAGNOSIS OF VENOUS THROMBOEMBOLISM IN COLOMBIA**
Gil-Rojas Y¹, Castañeda-Cardona C², Rosselli D¹, Pontificia Universidad Javeriana, Bogota, Colombia, ²Neuroeconomix, Bogota, DC, Colombia
- PMD62 B24 COST-EFFECTIVENESS ANALYSIS OF TELEMONITORING IN GYNAECOLOGY AND OBSTETRICS**
Gajdoš O, Hrubý J, Czech Technical University in Prague, Kladno, Czech Republic
- PMD63 B25 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSIS (CEA) OF THE CELL FREE DNA (CFDNA) / NON-INVASIVE PRENATAL TEST (NIPT) FOR TRISOMY 21 (T21) SCREENING**
Bourdoncle M¹, Li J², Berthelot A², **Cognet M**³, Sambuc C³, Scemama O³, Rumeau-Pichon C³, ¹CHU Toulouse, Toulouse, France, ²Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France, ³Haute Autorité de Santé (HAS), Saint-Denis La Plaine, France
- PMD64 B26 COST-EFFECTIVENESS OF TEST STRIPS FOR GLUCOSE MONITORING**
Martin Saborido C, Antón Rodriguez C, Monge Martín D, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain
- PMD65 B27 FAECAL CALPROTECTIN AS A DIAGNOSTIC MARKER OF INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH GASTROINTESTINAL SYMPTOMS - IS IT COST-EFFECTIVE PROCEDURE IN PRIMARY CARE IN POLAND?**
Petryszyn P¹, Trznadel A¹, Staniak A¹, Well M², Ekk-Cierniakowski P³, ¹Wroclaw Medical University, Wroclaw, Poland, ²Wroclaw University of Economics, Wroclaw, Poland, ³Warsaw School of Economics, Warsaw, Poland
- PMD66 B28 VALUE OF IMPROVED ACCURACY FOR SELF-MONITORING OF BLOOD GLUCOSE DEVICES IN GERMANY**
McQueen RB¹, Breton M², Ott M³, Campbell JD⁴, ¹University of Colorado, Aurora, CO, USA, ²University of Virginia, Charlottesville, CO, USA, ³Ascensia Diabetes Care, Leverkusen, Germany, ⁴University of Colorado Anschutz Medical Campus, Denver, CO, USA
- PMD67 B29 COST-EFFECTIVENESS OF A PREVENTIVE TESTING STRATEGY IN RELATIVES OF PATIENTS WITH BRCA MUTATED OVARIAN CANCER VERSUS A NO TEST STRATEGY**
Cicchetti A¹, Ruggeri M², Di Brino E³, ¹Catholic University of Sacred Heart, Rome, Italy, ²ALTEMS, Università Cattolica del Sacro Cuore (UCSC), Postgraduate School of Health Economics and Management, Rome, Italy, ³ALTEMS (Post-graduate School of Health Economics and Management), Catholic University of the Sacred Heart, Roma, Italy
- PMD68 B30 COST-EFFECTIVENESS ANALYSIS OF SERUM FREE LIGHT CHAIN ASSAY (FREELITE®) FOR THE DIAGNOSIS OF MONOCLONAL GAMMOPATHY IN THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS**
Riveros BS¹, Caporal F¹, Soares E², Facco F², ¹Federal University of Parana, Curitiba, Brazil, ²The Binding Site, Curitiba, Brazil
- PMD69 B31 WHAT IS THE MOST COST-EFFECTIVE WAY TO SET-UP ORGANISED CERVICAL CANCER SCREENING IN FRANCE? A COST-EFFECTIVENESS ANALYSIS**
Massetti M¹, Leleu H², Barre S³, De Bels F³, ¹PUBLIC HEALTH EXPERTISE, Paris, France, ²Public Health Expertise, Paris, France, ³French Cancer Institut, Boulogne, France
- PMD70 B32 ASSESSING THE COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN INOPERABLE PATIENTS WITH SEVERE AORTIC STENOSIS IN UK**
Ramos M¹, Lamotte M¹, Chevalier P¹, Goodall G², ¹IMS Health, Zaventem, Belgium, ²Edwards Lifesciences, Nyon, Switzerland
- PMD71 B33 COST-EFFECTIVENESS OF SEQUENTIAL USE OF ELF/ARFI TEST VERSUS BIOPSY TO ASSESS LIVER FIBROSIS IN CHRONIC HCV**
Soto M¹, Sampietro-Colom L¹, Lasalvia L², Jimenez W³, Mira A³, Navasa M³, ¹Hospital Clínic Barcelona, Barcelona, Spain, ²Siemens Healthcare, Tarrytown, NY, USA, ³Hospital Clínic Barcelona, Barcelona, Spain
- PMD72 B34 DEEP BRAIN STIMULATION COMPARED TO DEVICE-AIDED INFUSION THERAPIES FOR PARKINSON'S DISEASE WITH EARLY MOTOR COMPLICATIONS: A UK COST-EFFECTIVENESS ANALYSIS**
Green AL¹, **Fundament T**², ¹University of Oxford, Oxford, UK, ²HTA Consulting, Krakow, Poland
- PMD73 B35 COST-EFFECTIVENESS OF MECHANICAL THROMBECTOMY USING STENT-RETRIEVER AFTER INTRAVENOUS T-PA COMPARED WITH INTRAVENOUS T-PA ALONE IN THE TREATMENT OF ACUTE ISCHEMIC STROKE DUE TO LARGE VESSEL OCCLUSION IN SPAIN**
de Andrés-Nogales F¹, **Álvarez M**², de Miquel MÁ³, Segura T⁴, Gil A⁵, Cardona P³, Casado MÁ¹, Nogueira RG⁶, Dávalos A⁷, ¹Pharmacoeconomics & Outcomes Research Iberia, Pozuelo de Alarcón (Madrid), Spain, ²Medtronic Ibérica, S.A., Madrid, Spain, ³Hospital Univeritari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Complejo Hospitalario Universitario de Albacete, Albacete, Spain, ⁵Hospital Universitario de Cruces, Barakaldo, Spain, ⁶Emory University School of Medicine, Atlanta, GA, USA, ⁷Hospital Univeritari Germans Trias i Pujol, Badalona, Spain
- PMD74 B36 COST EFFECTIVENESS ANALYSIS OF A FLASH GLUCOSE MONITORING SYSTEM FOR TYPE 1 DIABETES (T1DM) PATIENTS RECEIVING INTENSIVE INSULIN TREATMENT IN EUROPE AND AUSTRALIA**
Bilir SP¹, Li H², **Wehler EA**³, Hellmund R⁴, Munakata J¹, ¹IMS Health, San Francisco, CA, USA, ²IMS Health, Fairfax, VA,

USA, ³IMS Health, Plymouth Meeting, PA, USA, ⁴Abbott Diabetes Care, Alameda, CA, USA

PMD75 B37 COST EFFECTIVENESS ANALYSIS OF A FLASH GLUCOSE MONITORING SYSTEM FOR TYPE 2 DIABETES (T2DM) PATIENTS RECEIVING INTENSIVE INSULIN TREATMENT IN EUROPE

Li H¹, Bilir SP², **Wehler EA**³, Hellmund R⁴, Munakata J²,¹IMS Health, Fairfax, VA, USA, ²IMS Health, San Francisco, CA, USA, ³IMS Health, Plymouth Meeting, PA, USA, ⁴Abbott Diabetes Care, Alameda, CA, USA

PMD76 B38 A PRELIMINARY COST-UTILITY ANALYSIS OF NON-INVASIVE VAGUS NERVE STIMULATION THERAPY IN PATIENTS SUFFERING WITH HEADACHE AND FUNCTIONAL DISORDER MULTI-MORBIDITY

Jenks M¹, Davis S², Amato F³, Errico J³, Strickland I³,¹York Health Economics Consortium, York, UK, ²Interface Clinical Services, Leeds, UK, ³electroCore LLC, Basking Ridge, NJ, USA

PMD77 C1 COST-EFFECTIVENESS ANALYSIS OF USING PROCALCITONIN-BASED ANTIBIOTICS STEWARDSHIP FOR COMMUNITY ACQUIRED PNEUMONIA

Hsu W¹, Lee S¹, Lee MG¹, **Lee C**²,¹National Taiwan University Hospital, Taipei City, Taiwan, ²National Taiwan University Hospital, Yunlin Branch, Douliou, Taiwan

PMD78 C2 COMPARISON OF MIRENA INTRAUTERINE DEVICE WITH ORAL PROGESTERONE TREATMENT AND SURGICAL TREATMENT IN IDIOPATHIC MENORRHAGIA PATIENTS: RESULTS OF A COST-MINIMISATION ANALYSIS

Buyuktuna N, Sumer F, Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey

PMD79 C3 SPINAL CORD STIMULATION VERSUS CONVENTIONAL MEDICAL MANAGEMENT FOR FAILED BACK SURGERY SYNDROME: A DUTCH COST-EFFECTIVENESS ANALYSIS

Huygen FJ¹, Eggington S², **De Brouwer BF**³,¹University Hospital Erasmus Medical Centre, Rotterdam, The Netherlands, ²Medtronic International Trading Sarl, Tolochenaz, Switzerland, ³Medtronic Trading NL BV, Heerlen, The Netherlands

PMD80 C4 HEALTH-ECONOMIC ANALYSIS OF THE USE OF SENSOR-AUGMENTED PUMP WITH PREDICTIVE SUSPEND FUNCTION (SAP) THERAPY IN SWEDEN COMPARED TO INSULIN PUMP THERAPY ALONE (CSII), IN TYPE 1 DIABETIC PATIENTS

Roze S¹, Gherardi A¹, de Portu S², Jendle J³,¹HEVA HEOR Sarl, Lyon, France, ²Medtronic International Sarl, Tolochenaz, Switzerland, ³Örebro University, Örebro, Sweden

PMD81 C5 COST UTILITY ANALYSIS OF MONITORING OSTEOPOROSIS FRACTURE RISK BY A CIRCULATING MICRORNA BASED STRATEGY COMPARED TO STANDARD MEASURE AND NO MONITORING

Walter E¹, Grillari J², Kanzler O³, Hackl M³,¹Institute for Pharmaeconomic Research, Vienna, Austria, ²University of Natural Resources and Life Sciences, Vienna, Austria, ³TAmiRNA GmbH, Vienna, Austria

PMD82 C6 COST-UTILITY OF IN-AMBULANCE TELEMEDICINE FOR SUSPECTED STROKE PATIENTS

Valenzuela Espinoza A¹, Devos S¹, Van Hooff R², Fobelets M¹, Dupont A³, Brouns R², Putman K¹,¹Vrije Universiteit Brussel, Brussels, Belgium, ²Universitair Ziekenhuis Brussel, Brussels, Belgium, ³Vrije Universiteit Brussel, Brussel, Belgium

PMD83 C7 COST-EFFECTIVENESS OF DIAGNOSTIC TESTS FOR PEOPLE AT RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN THE UK

Floros L¹, Day C², Wonderling D¹, Glen J¹, Harker M¹,¹Royal College of Physicians, London, UK, ²Faculty of Medical Sciences, Newcastle University, Newcastle, UK

PMD84 C8 USE OF SUTURELESS PROSTHESIS NEUTRALIZES EXPECTED WORSE ECONOMIC IMPACT OF HIGH RISK PATIENTS UNDERGOING AORTIC VALVE REPLACEMENT

Villa E, Trenta A, Dalla Tomba M, Messina A, Brunelli F, Cirillo M, Mhagna Z, Valerio M, Troise G, Poliambulanza Foundation Hospital, Brescia, Italy

MEDICAL DEVICE/DIAGNOSTICS - Patient-Reported Outcomes & Patient Preference Studies

PMD85 C9 USING A SMARTPHONE BASED SELF-MANAGEMENT PLATFORM TO SUPPORT MEDICATION ADHERENCE AND CLINICAL CONSULTATION IN PARKINSON'S DISEASE RESULTS FROM THE SMART-PD RANDOMISED CONTROLLED TRIAL

Lakshminarayana R¹, Wang D², Burn D³, Chaudhuri KR⁴, Hellman B¹, SMART-PD Investigators¹,¹uMotif, London, UK, ²Liverpool School of Troical Medicine, Liverpool, UK, ³Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK, Newcastle University, UK, ⁴King's College Hospital NHS FOundation Trust, London, UK

PMD86 C10 FROM THE UNIFIED PARKINSON'S DISEASE RATING SCALE (UPDRS) TO THE EQ-5D UTILITY INDEX: DEVELOPMENT OF A NEW MAPPING ALGORITHM IN PARKINSON'S DISEASE (PD)

Grifi M¹, Gorecki M², Schuepbach M³,¹Medtronic International, Tolochenaz, Switzerland, ²HTA Consulting, Krakow, Poland, ³CHU Pitié-Salpêtrière, paris, France

PMD87 C11 GENERATING HEALTH UTILITY VALUES FROM US SF-36 SCORES FOR FRENCH ASSESSMENT: COMPARISON OF 3 MAPPING METHODS

Baschet L, Grassi V, Levesque K, Capionis, Bordeaux, France

PMD88 C12 BENEFITS OF AN AUTOMATIC TOOL FOR GLUCOSE PATTERN DETECTION

Comellas MJ¹, Albiñana E², **Artés M**³, Corcoy R⁴, Fernández-García D⁵, García-Alemán J⁵, García-Cuartero B⁶, González C⁴, Rivero M⁷,¹Roche Diabetes Care Spain SL, Barcelona, Spain, ²Vithas Hospital Internacional Medimar, Alicante, Spain, ³Adelphi

Spain, Barcelona, Spain, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Hospital Universitario Virgen de la Victoria, Málaga, Spain, ⁶Hospital Ramón y Cajal, Madrid, Spain, ⁷Complejo Hospitalario de Orense, Orense, Spain

PMD89 C13 BEHAVIOR OF VAS MEASURES OF PATIENT SATISFACTION WITH REMOTE MONITORING OF CARDIAC IMPLANTABLE ELECTRONIC DEVICES. THE VALIOSA QUESTIONNAIRE

Ruiz MA¹, Egea M², Muñoz R³, Viñolas X⁴, Silvestre J⁵, Álvarez M⁶, Martínez-Ferrer JB⁷, ¹Universidad Autónoma de Madrid, Madrid, Spain, ²Medtronic Iberica, Madrid, Spain, ³Hospital Universitario Infanta Leonor, Madrid, Spain, ⁴Hospital Santa Creu i Sant Pau, Barcelona, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Medtronic Ibérica, Madrid, Spain, ⁷Hospital Universitario Araba, Vitoria, Spain

PMD90 C14 AUTOINJECTOR PREFERENCE AMONG PATIENTS WITH MULTIPLE SCLEROSIS: RESULTS FROM A NATIONAL SURVEY

Schreiner T¹, Reischl J¹, Mann B², Morosov X¹, Kokoschka A¹, Weller I¹, ¹Bayer Vital GmbH, Leverkusen, Germany, ²IFAK Institut GmbH & Co. KG, Taunusstein, Germany

PMD91 C15 IMPROVING PATIENTS QUALITY OF LIFE BY VALUATION OF PATIENT SATISFACTION WITH SPECIFIC CHARACTERISTICS OF REHABILITATION MEDICAL DEVICES - WEIGHT, FIT, APPEARANCE, COMFORT, PAIN FREE, FREE OF ABRASIVENESS, EASE OF APPLICATION AND DURABILITY

Malovecka I¹, Minarikova D¹, Minarik P², Foltan V¹, ¹Comenius University, Faculty of Pharmacy, Bratislava, Slovak Republic, ²College of Health and Social Work St. Elizabeth, Bratislava, Slovakia

PMD92 C16 WHICH MEDICAL DEVICE FOR URINARY INCONTINENCE PROVIDES PATIENT THE HIGHER QUALITY OF LIFE?

Minarikova D¹, Malovecka I¹, Minarik P², Fazekas T³, Szucs G⁴, ¹Comenius University, Faculty of Pharmacy, Bratislava, Slovak Republic, ²College of Health and Social Work St. Elizabeth, Bratislava, Slovakia, ³Comenius University, Faculty of Pharmacy, Bratislava, Slovakia, ⁴Comenius University, Faculty of Mathematics, Physics and Informatics, Bratislava, Slovakia

PMD93 C17 PATIENT REPORTED OUTCOMES - PATIENT SATISFACTION WITH SELECTED CHARACTERISTICS OF REHABILITATION MEDICAL DEVICES - USAGE, ACQUISITION, OFFER, RANGE AND QUALITY

Malovecka I¹, Minarikova D¹, Fazekas T², Szucs G³, ¹Comenius University, Faculty of Pharmacy, Bratislava, Slovak Republic, ²Comenius University, Bratislava, Slovak Republic, ³Comenius University, Faculty of Mathematics, Physics and Informatics, Bratislava, Slovakia

PMD94 C18 COMPARATIVE EXPLORATORY ANALYSIS ON EFFECTIVENESS, TOLERABILITY AND PATIENT/NURSE SATISFACTION WITH TWO NON-INVASIVE PATIENT CONTROLLED ANALGESIA TREATMENTS FOR ACUTE POST-OPERATIVE PAIN MANAGEMENT

Katz P¹, Takyar S², Palmer PP³, DiDonato K³, Liedgens H¹, ¹Grünenthal GmbH, Aachen, Germany, ²PAREXEL International, Chandigarh, India, ³AcelRx Pharmaceuticals, Inc., Redwood City, CA, USA

PMD95 C19 THE CURRENT STATUS AND INFLUENTIAL FACTORS OF INSULIN PEN NEEDLE REUSE IN T2D PATIENTS FROM CHINA

Han S, Guan XD, Shi LW, International Research Center of Medical Administration, Peking University, Beijing, China

PMD96 C20 IMPROVING PATIENTS QUALITY OF LIFE BY VALUATION OF PATIENT SATISFACTION WITH SPECIFIC CHARACTERISTICS OF MEDICAL DEVICES FOR URINARY INCONTINENCE

Minarikova D¹, Malovecka I², Minarik P³, ¹Comenius University, Faculty of Pharmacy, Bratislava, Slovak Republic, ²Comenius University, Bratislava, Slovak Republic, ³College of Health and Social Work St. Elizabeth, Bratislava, Slovakia

PMD98 C21 NON-INVASIVE VAGUS NERVE STIMULATION AS A TREATMENT FOR HEADACHE PATIENTS WITH MULTI-MORBIDITY: REAL WORLD EXPERIENCE IN ENGLISH PRIMARY CARE

Strickland I¹, Davis S², Ward J³, Amato F¹, Errico J¹, ¹electroCore LLC, Basking Ridge, NJ, USA, ²Interface Clinical Services, Leeds, UK, ³Oaklands Health Centre, Holmfirth, UK

PMD99 C22 ACCEPTABILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES IN CLINICAL CARE OF HIV

Duracinsky M¹, Jouannigot J², Grace A³, Power B⁴, Desai R⁴, Lalanne C², Herrmann S³, Chassany O², ¹Assistance Publique-Hopitaux de Paris, Paris, France, ²University Paris-Diderot, Sorbonne Paris Cité, Paris, France, ³Murdoch University, Murdoch, Australia, ⁴e) School of Arts Murdoch University, Murdoch, Australia

MEDICAL DEVICE/DIAGNOSTICS - Health Care Use & Policy Studies

PMD100 C23 THE INCREASING ROLE OF WEARABLE DIGITAL TECHNOLOGY IN DISEASE MANAGEMENT - AN ASSESSMENT OF THE OPPORTUNITIES AND CHALLENGES FROM A MULTI-STAKEHOLDER (PATIENT, PAYER, PHYSICIAN, MANUFACTURER) PERSPECTIVE

Entwistle J, Okoye J, Teale CW, Tombrink H, Kleebach J, GfK, Melton Mowbray, UK

PMD101 C24 THE EFFECTS OF CONTINUES GLUCOSE MONITORING SYSTEM ON PATIENT OUTCOMES AND ASSOCIATED COSTS

Fund N¹, Azuri J², Levi L¹, Porath A¹, Triki N¹, ¹Maccabi Healthcare Services, Tel-Aviv, Israel, ²Tel Aviv University, Tel Aviv, Israel

PMD102 C25 A DYNAMIC SIMULATION TO INVESTIGATE HEALTH ECONOMIC IMPACT OF A PULMONARY ARTERY PRESSURE SENSOR FOR HEART FAILURE TELEMONITORING

Kolominsky-Rabas P¹, Kriza C², Uffenorde S³, Zhang S⁴, Gaiser S⁵, ¹Interdisciplinary Centre for Health Technology Assessment and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg; National Leading-Edge Cluster Medical Technologies 'Medical Valley EMN', Erlangen, Germany, ²Interdisciplinary Centre for Health Technology Assessment and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany, ³St Jude Medical GmbH, Eschborn,

Germany, ⁴Interdisciplinary Centre for Health Technology Assessment and Public Health (IZPH), Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany, ⁵St Jude Medical, Zaventem, Belgium

PMD103 C26 VARIATION IN THE NUMBER AND TYPE OF HEART VALVE PROCEDURES PERFORMED IN THE UK – IS PATIENT ACCESS EQUITABLE?

Murphy J¹, Goodall G²,¹Edwards Lifesciences, Newbury, UK, ²Edwards Lifesciences, Nyon, Switzerland

PMD104 C27 THE ASSESSMENT OF VALUE FOR MEDICAL DEVICES: USING REAL WORLD EVIDENCE (RWE) TO QUANTIFY UNMET NEEDS IN DIABETES MANAGEMENT

Charter R¹, Yeung A², Smith M², Hopley C³,¹Becton Dickinson AG, Allschwil, Switzerland, ²Becton Dickinson (BD), Allschwil, Switzerland, ³Becton Dickinson, Oxford, Switzerland

PMD105 C28 SPATIAL DISTRIBUTION OF THE TOTAL NUMBER OF MEDICAL DEVICES IN TURKEY: A CLASSIFICATION ANALYSIS

Cinaroglu S¹, Baser O²,¹Hacettepe University, Ankara, Turkey, ²Columbia University/MEF University/STATinMED Research, New York, NY, USA

PMD106 C29 REGIONAL MARKET ACCESS PATHWAYS FOR DIAGNOSTICS IN ITALY

Mantuano M¹, Dionisi M², Paolini D², Gancitano G², Urbinati D¹,¹IMS Health, Milano, Italy, ²Roche Diagnostics S.p.A., Monza, Italy

PMD107 C30 CRITERIA USED BY GERMAN PULMONOLOGISTS FOR THE SELECTION OF AN INHALER

Schwarz E¹, Redeker M¹, Mohrlang C¹, Andres J², Hellmann A³, Hering T⁴, Hering T²,¹GlaxoSmithKline GmbH & Co. KG, München, Germany, ²Wissenschaftliches Netzwerk des Bundesverbandes der Pneumologen/BdP (WinPneu), Heidenheim, Germany, ³Zentrum für Pneumologie, Onkologie und Schlafmedizin am Diako, Augsburg, Germany, ⁴Lungenarztpraxis Tegel, Berlin, Germany

PMD108 C31 WHEN COST SAVING TECHNOLOGIES ARE NOT ADOPTED DESPITE EVIDENCE AND PAYER RECOMMENDATIONS – INTRAOPERATIVE FLUID MANAGEMENT (IOFM) IN THE UK

Murphy J¹, Goodall G²,¹Edwards Lifesciences, Newbury, UK, ²Edwards Lifesciences, Nyon, Switzerland

PMD109 C32 HEALTHCARE EXPENDITURES AND EQUITY IN HEALTHCARE UTILIZATION FOR LYMPHEDEMA PATIENTS IN FRANCE

Mercier G¹, Pastor JZ¹, Clement V², Rodts U¹, Quere I¹,¹CHU Montpellier, Montpellier, France, ²Universite de Montpellier, Montpellier, France

PMD110 C33 SURGICAL SITE COMPLICATIONS: TO PREVENT OR NOT TO PREVENT? A BUDGET IMPACT ANALYSIS IN THE HOSPITAL SETTING

Foglia E¹, **Ferrario L**¹, Canonico S², Signoriello G³, Pellino G², Croce D¹,¹LIUC University, Castellanza, Italy, ²School of Medicine, Second University of Naples, Napoli, Italy, ³Department of Medicine and Public Health, Second University of Naples, Napoli, Italy

PMD111 C34 COST-BENEFIT ANALYSIS: A COMPARISON BETWEEN PRESET ARTERY BLOOD SAMPLERS AND DISPOSABLE SYRINGES IN ARTERIAL BLOOD SAMPLING

Gao M¹, Wang Y², Wang J³, Zeng F⁴, **Yang Q**⁵, Ren X⁵,¹The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, ²Shanghai Tenth People's Hospital, Shanghai, China, ³China-Japan Friendship Hospital, Beijing, China, ⁴The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ⁵Becton Dickinson Medical Devices (Shanghai) Co Ltd., Shanghai, China

PMD112 C35 SYSTEMATIC REVIEW OF THE VALUE OF SAFETY-ENGINEERED DEVICES IN REDUCING NEEDLESTICK AND SHARPS INJURIES

Shang Y¹, Ren X²,¹Shenyang Pharmaceutical University, Shenyang, China, ²Becton Dickinson Medical Devices (Shanghai) Co Ltd., Beijing, China

PMD113 C36 A TIME SERIES ANALYSIS OF SOCIAL INSURANCE AND PATIENT COSTS OF REIMBURSED MEDICAL AIDS IN HUNGARY

Takacs G, National Institute of Pharmacy and Nutrition, Budapest, Hungary

PMD114 C37 A MODELED HEALTH ECONOMIC ANALYSIS OF THE ACCUCATH® INTRAVASCULAR CATHETER SYSTEM WITH RETRACTABLE COILED TIP GUIDEWIRE COMPARED WITH CONVENTIONAL PERIPHERAL INTRAVASCULAR CATHETERS

Kara R¹, Hollmann S², Ferko N², Delatore P³,¹Bard Access Systems, Salt Lake City, UT, USA, ²Cornerstone Research Group Inc., Burlington, ON, Canada, ³CR Bard Inc., Murray Hill, NJ, USA

PMD115 C38 THE SITUATE DETECTION SYSTEM - A COST-EFFECTIVE APPROACH TO PREVENTING RETAINED SURGICAL SPONGES

Leinwand B, Hughes KE, Avalere Health LLC, Washington, DC, USA

PMD116 D1 IS BIG DATA IN HEALTHCARE ABOUT BIG HOPE OR BIG HYPE? EARLY HEALTH TECHNOLOGY ASSESSMENT OF BIG DATA ANALYTICS IN HEALTHCARE

Bakker LJ¹, Aarts J², Redekop WK³,¹institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands, ²University at Buffalo, Buffalo, NY, USA, ³Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

PMD117 D2 PERIOPERATIVE THERAPIES REDUCING HOMOLOGOUS TRANSFUSIONS DURING CARDIOVASCULAR SURGERY: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

- PMD118 D3** **IMPACT OF WHOLE EXOME SEQUENCING (WES) ON COSTS AND MEDICAL DECISION-MAKING**
Pradelli L¹, Povero M¹, Myers G²,¹AdRes Srl, Torino, Italy, ²Eastern Perfusion International, Dartmouth, NS, Canada
Middelburg P¹, Monroe G², van Gassen K², Hovels A¹, Knoers N², Vrijenhoek T², **Frederix G**²,¹Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands, ²University Medical Centre Utrecht, Utrecht, The Netherlands
- PMD119 D4** **SUBSTITUTABILITY OF DRY POWDER INHALERS: A PERSPECTIVE FROM GERMAN PULMONOLOGISTS**
Redeker M¹, Schwarz E¹, Mohrlang C¹, Hellmann A², Hering T³, Hering T⁴, Andres J³,¹GlaxoSmithKline GmbH & Co. KG, München, Germany, ²Zentrum für Pneumologie, Onkologie und Schlafmedizin am Diako, Augsburg, Augsburg, Germany, ³Wissenschaftliches Netzwerk des Bundesverbandes der Pneumologen/BdP (WinPneu), Heidenheim, Germany, ⁴Lungenarztpraxis Tegel, Berlin, Germany
- PMD120 D5** **ARE CRITERIA COMMONLY USED IN THE BENEFIT ASSESSMENT OF DRUGS ALSO APPLICABLE TO MEDICAL DEVICES? - A SYSTEMATIC LITERATURE REVIEW**
Stephan M, Sauer A, Günzel F, Italia N, Kulp W,Xcenda GmbH, Hannover, Germany
- PMD121 D6** **NEW LEGISLATIVE PATHWAY OF TURKEY FOR ASSESSING REIMBURSEMENT APPLICATIONS OF MEDICAL DEVICES**
Ozdiler Copur F, Akgul T, Ozdemir Saltik Z, Can H, Askin E,Medtronic, Istanbul, Turkey
- PMD122 D7** **A NEW ACCELERATED EARLY ACCESS PROCESS FOR DIAGNOSTICS IN FRANCE**
Hanna E, Azaiez C, Auquier P, Toumi M, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France
- PMD123 D8** **COST-EFFECTIVENESS ANALYSIS OF SCREENING STRATEGIES FOR ATRIAL FIBRILLATION IN ENGLAND AND WALES**
Thom H¹, Hollingworth W¹, McAleenan A¹, Davies P¹, Higgins J¹, Okoli GN¹, Sterne J¹, Feder G¹, Eaton D², Hingorani A³, Fawsitt C¹, Lobban T⁴, Bryden PA⁵, Richards A¹, Sofat R³, Welton NJ¹,¹University of Bristol, Bristol, UK, ²Anticoagulation Europe, Kent, UK, ³University College London, London, UK, ⁴Atrial Fibrillation Association, Warwickshire, UK, ⁵Roche, Basel, Switzerland
- PMD124 D9** **ANALYSIS OF HTA REQUIREMENTS ACROSS 10 EMERGING AND DEVELOPED COUNTRIES**
Hertz D, Vazquez V, Gavaghan M,GfK, Wayland, MA, USA
- PMD125 D10** **INFLUENCE OF MEDICAL-ECONOMIC ANALYSIS ON THE CATEGORIZATION OF SPECIAL MEDICAL EQUIPMENT**
Lehocka L, Masarykova L, Snopkova M, Bohusova S,Comenius University in Bratislava, Faculty of Pharmacy, Bratislava, Slovakia
- PMD126 D11** **EFFICIENCY IN USE OF LENSX VS PHACOEMULSIFICATION SURGERY FOR CATARACT TREATMENT: RESULTS FROM A GLOBAL OBSERVATIONAL STUDY**
Keith MS¹, Becker G², Bayer S²,¹Alcon Laboratories, Inc, Fort Worth, TX, USA, ²Q-Perior AG, Zurich, Switzerland
- PMD127 D12** **BENEFIT ASSESSMENT OF MEDICAL DEVICES OF HIGH RISK CLASSES IN GERMANY: ADAPTIVE APPROACHES TO BALANCE EARLY ACCESS AND SAFETY AND EFFICACY REQUIRED?**
Mühlbacher AC, **Juhnke C**, Mörk V,Hochschule Neubrandenburg, Neubrandenburg, Germany
- PMD128 D13** **ADOPTION OF ENDOSCOPIC LUNG VOLUME REDUCTION FOR EMPHYSEMA IN GERMANY: UTILIZATION PATTERNS AND CASE VOLUMES IN THE PERIOD 2010-2014**
Busca R¹, Rott C¹, Pietzsch JB², Herth F³,¹PneumRx Ltd, London, UK, ²Wing Tech Inc., Irvine, CA, USA, ³Thoraxklinik University of Heidelberg, Heidelberg, Germany
- PMD129 D14** **CURRENT STATUS OF ENDOSCOPIC SUBMUCOSAL DISSECTION TREATMENT FOR GASTRIC ADENOMA IN KOREA: BASED ON NATIONAL CLAIMS DATABASE**
Cha Y¹, Kim J¹, Lee NR², Lyu DH², Park C²,¹National evidence-based health care Collaborating Agency, Korea, Seoul, South Korea, ²National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea

DISEASE- SPECIFIC STUDIES

CANCER - Clinical Outcomes Studies

- PCN1 D15** **COSTS ASSOCIATED WITH TREATMENT INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH MULTIPLE MYELOMA (MM)**
Panjabi S¹, Song X², Wilson K³, Kagan J³,¹Amgen Inc., South San Francisco, CA, USA, ²Truven Health Analytics, Shrewsbury, MA, USA, ³Truven Health Analytics, Bethesda, MD, USA
- PCN2 D16** **CANCER IMMUNOTHERAPY WITH CHECKPOINT INHIBITORS IS ASSOCIATED WITH IMMUNE-MEDIATED REACTIONS: A PHARMACOVIGILANCE STUDY**
Ali AK,Eli Lilly and Company, Indianapolis, IN, USA
- PCN4 D18** **TYROSINE KINASE INHIBITORS (TKI) FOR THE TREATMENT OF ADVANCED MEDULLARY THYROID CARCINOMA: A SYSTEMATIC REVIEW AND INDIRECT COMPARISON**
Kawalec P,Jagiellonian University Medical College, Krakow, Poland
- PCN5 D19** **REAL-WORLD OUTCOMES OF IPILIMUMAB IN PATIENTS WITH ADVANCED CUTANEOUS MELANOMA IN THE NETHERLANDS**
Leeneman B¹, Jochems A², Schouwenburg M³, Aarts M⁴, van Akkooi A⁵, van den Berkmortel F⁶, van den Eertwegh A⁷,

Groenewegen G⁸, de Groot J⁹, Haanen J⁵, van der Hoeven J¹⁰, Hospers G¹¹, Kapiteijn E², Koornstra R¹⁰, Kruit W¹², Louwman M¹³, Piersma D¹⁴, van Rijn R¹⁵, ten Tije A¹⁶, Vreugdenhil G¹⁷, Wouters M⁵, van Zeijl M³, Franken M¹, Uyl - de Groot C¹, Erasmus University Rotterdam, Rotterdam, The Netherlands, ²Leiden University Medical Center, Leiden, The Netherlands, ³Dutch Institute for Clinical Auditing, Leiden, The Netherlands, ⁴Maastricht University Medical Center, Maastricht, The Netherlands, ⁵Netherlands Cancer Institute, Amsterdam, The Netherlands, ⁶Zuyderland, Heerlen, The Netherlands, ⁷VU University Medical Center, Amsterdam, The Netherlands, ⁸University Medical Center Utrecht, Utrecht, The Netherlands, ⁹Isala, Zwolle, The Netherlands, ¹⁰Radboud University Medical Center, Nijmegen, The Netherlands, ¹¹University Medical Center Groningen, Groningen, The Netherlands, ¹²Erasmus Medical Center, Rotterdam, The Netherlands, ¹³Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, ¹⁴Medical Spectrum Twente, Enschede, The Netherlands, ¹⁵Medical Center Leeuwarden, Leeuwarden, The Netherlands, ¹⁶Amphia, Breda, The Netherlands, ¹⁷Maxima Medical Center, Eindhoven, The Netherlands

- PCN6 D20 OFATUMUMAB AS A COMBINATION THERAPY VERSUS OTHER TREATMENT REGIMENS IN PATIENTS WITH UNTREATED, RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS**
Gadi HR, Patel P, Shaikh S, Rai MK, Tata Consultancy Services, Mumbai, India
- PCN7 D21 A SYSTEMATIC REVIEW AND META-ANALYSIS TO ACCESS THE EFFICACY AND SAFETY OF SORAFENIB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)**
Gollala M, Arora R, Raute L, Kumar R, Rai MK, Tata Consultancy Services, Mumbai, India
- PCN8 D22 REAL-WORLD OUTCOMES OF NOVEL TREATMENTS IN PATIENTS WITH ADVANCED CUTANEOUS MELANOMA IN THE NETHERLANDS**
Leeneman B¹, Franken M¹, Jochems A², Schouwenburg M³, Aarts M⁴, van Akkooi A⁵, van den Bergmortel F⁶, van den Eertwegh A⁷, Groenewegen G⁸, de Groot J⁹, Haanen J⁵, Hospers G¹⁰, Kapiteijn E², Koornstra R¹¹, Kruit W¹², Louwman M¹³, Piersma D¹⁴, van Rijn R¹⁵, ten Tije A¹⁶, Vreugdenhil G¹⁷, Wouters M⁵, van Zeijl M³, van der Hoeven J¹¹, Uyl - de Groot C¹, Erasmus University Rotterdam, Rotterdam, The Netherlands, ²Leiden University Medical Center, Leiden, The Netherlands, ³Dutch Institute for Clinical Auditing, Leiden, The Netherlands, ⁴Maastricht University Medical Center, Maastricht, The Netherlands, ⁵Netherlands Cancer Institute, Amsterdam, The Netherlands, ⁶Zuyderland, Heerlen, The Netherlands, ⁷VU University Medical Center, Amsterdam, The Netherlands, ⁸University Medical Center Utrecht, Utrecht, The Netherlands, ⁹Isala, Zwolle, The Netherlands, ¹⁰University Medical Center Groningen, Groningen, The Netherlands, ¹¹Radboud University Medical Center, Nijmegen, The Netherlands, ¹²Erasmus Medical Center, Rotterdam, The Netherlands, ¹³Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, ¹⁴Medical Spectrum Twente, Enschede, The Netherlands, ¹⁵Medical Center Leeuwarden, Leeuwarden, The Netherlands, ¹⁶Amphia, Breda, The Netherlands, ¹⁷Maxima Medical Center, Eindhoven, The Netherlands
- PCN9 D23 EFFICACY AND SAFETY OF PANITUMUMAB IN PATIENTS OF METASTATIC COLORECTAL CANCER BY TUMOR KRAS STATUS: A SYSTEMATIC REVIEW**
Singh R, Sharma N, Rana P, Baig S, Singh S, Rai MK, Tata Consultancy Services, Mumbai, India
- PCN10 D24 THE CHOICE OF A FLUOROPYRIMIDINE REGIMEN IN PATIENTS WITH ADVANCED COLORECTAL CANCER**
Rubtsova I, Lishchyshyna O, Shilkina O, State Expert Center of the Ministry of Health of Ukraine, Kiev, Ukraine
- PCN11 D25 INCIDENCE AND RISK FACTORS OF GLUCOCORTICOID-INDUCED DIABETES MELLITUS IN LYMPHOMA PATIENTS TREATED WITH GLUCOCORTICOID-CONTAINING CHEMOTHERAPY**
Zhou KR¹, Chu MH¹, Lo KY¹, Watanabe JH², ¹The Chinese University of Hong Kong, Shatin, Hong Kong, ²University of California San Diego, La Jolla, CA, USA
- PCN12 D26 BASELINE CHARACTERISTICS AND SURVIVAL OF PATIENTS DIAGNOSED WITH ADVANCED NSCLC IN SWEDEN BETWEEN 2006 AND 2013, MATCHED (1:4) TO A COMPARISON COHORT FROM THE GENERAL POPULATION**
Linden S¹, Banos Hernaez AM², Redig J², Justo N², Nilsson J², Montonen J¹, Verpillat P¹, ¹Boehringer Ingelheim, Ingelheim am Rhein, Germany, ²Mapi Group, Stockholm, Sweden
- PCN13 D27 EFFICACY OF PALBOCICLIB COMBINATIONS VERSUS ENDOCRINE THERAPIES IN ADVANCED/ METASTATIC BREAST CANCER: NETWORK META-ANALYSIS**
Chirila C¹, Mitra D², Colosia A¹, Ling C³, Odom D¹, Iyer S², Kaye JA⁴, ¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Pfizer, Inc., New York, NY, USA, ³RTI Health Solutions, Manchester, UK, ⁴RTI Health Solutions, Waltham, MA, USA
- PCN14 D28 COMPARATIVE EFFECTIVENESS OF TREATMENT STRATEGIES FOR MULTIPLE MYELOMA IN ELDERLY PATIENTS: A NETWORK META-ANALYSIS**
Buchberger M¹, Rochau U², Vukicevic D¹, Willenbacher W³, Chaimani A⁴, Efthimiou O⁴, Siebert U⁵, ¹UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall i.T., Austria, ²UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health, Health Services Research and HTA/ ONCOTYROL - Center for Personalized Medicine, Hall i.T./ Innsbruck, Austria, ³ONCOTYROL - Center for Personalized Cancer Medicine, Area Health Technology Assessment/Internal Medicine V—Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria, ⁴University of Ioannina School of Medicine, Ioannina, Greece, ⁵and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria
- PCN15 D29 EFFECTIVENESS AND SAFETY OF BRAF INHIBITORS IN THE TREATMENT OF BRAF-MUTATED UNRESECTABLE OR**

METASTATIC MELANOMA: REAL WORLD DATA

García-Avello A, Vega-Coca MD, Abdel-kader-Martin L, Poyatos-Ruiz L, Flores-Moreno S, Hospital Universitario Virgen del Rocío, SEVILLA, Spain

- PCN16 D30 REWEIGHTING RCT EVIDENCE TO BETTER REFLECT REAL LIFE: A CASE STUDY OF THE INNOVATION MEDICINES INITIATIVE**
Happich M¹, Brnabic A², Faries D³, Abrams KR⁴, Winfree K³, Girvan A³, Jonsson P⁵, Johnston J³, Belger M⁶,¹Lilly Deutschland GmbH, Bad Homburg, Germany, ²Eli Lilly, Sydney, Australia, ³Eli Lilly, Indianapolis, IN, USA, ⁴University of Leicester, Leicester, UK, ⁵National Institute for Health and Care Excellence (NICE), Manchester, UK, ⁶Eli Lilly, Ascot, UK
- PCN18 D31 ADJUSTED COMPARISON OF DARATUMUMAB MONOTHERAPY VERSUS REAL-WORLD HISTORICAL CONTROL DATA FROM THE CZECH REPUBLIC IN HEAVILY PRE-TREATED AND HIGHLY REFRACTORY MULTIPLE MYELOMA PATIENTS**
Diels J¹, Gatopoulou X², Besson H¹, Vesela S³, Hájek R⁴, Jarkovsky J⁵, Ito T⁶,¹Janssen Health Economics & Market Access EMEA Statistics & Modelling, Beerse, Belgium, ²Janssen Health Economics & Market Access EMEA, Athens, Greece, ³Market Access Janssen – Cilag s.r.o., Czech Republic, Prague, Czech Republic, ⁴University Hospital Ostrava and Faculty of Medicine, Ostrava, Czech Republic, ⁵Masaryk University, Brno, Czech Republic, ⁶Janssen Health Economics & Market Access EMEA, High Wycombe, UK
- PCN19 D32 COMPARATIVE EFFECTIVENESS OF CRIZOTINIB AMONG ALK+ NSCLC PATIENTS ACROSS THE UNITED STATES, WESTERN EUROPE, AND JAPAN**
DiBonaventura M¹, Higginbottom K², Meyers A³, Morimoto Y⁴, Ilacqua J²,¹Ipsos Healthcare, New York, NY, USA, ²Ipsos Healthcare, Mahwah, NJ, USA, ³Ipsos Healthcare, Washington, DC, USA, ⁴Ipsos Healthcare, Tokyo, Japan
- PCN20 D33 SUNITINIB DOSING SCHEDULES IN THE MANAGEMENT OF METASTATIC RENAL CELL CARCINOMA: A META-ANALYSIS**
Abogunrin S¹, Ashaye AO², Fahrbach K², Cappelleri JC³, Sandin R⁴, Ramaswamy K⁵,¹Evidera Ltd, London, UK, ²Evidera Inc., Lexington, MA, USA, ³Pfizer Inc, Groton, CT, USA, ⁴Pfizer AB, Stockholm, Sweden, ⁵Pfizer, Inc., New York, NY, USA
- PCN21 D34 NINTEDANIB PLUS DOCETAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC): A NETWORK META-ANALYSIS VS. NEW THERAPEUTIC OPTIONS**
Popat S¹, Mellempgaard A², Reck M³, Hastedt C⁴, Griebisch I⁴,¹Royal Marsden Hospital, London, UK, ²Herlev Hospital, Herlev, Denmark, ³LungenClinic Grosshansdorf, Grosshansdorf, Germany, ⁴Boehringer Ingelheim GmbH, Ingelheim, Germany
- PCN22 D35 MEASURES OF CLINICAL BENEFIT IN IMMUNO-ONCOLOGY STUDIES**
Zhao L, Zhang Y, Huang Y, Huang W, Mukhopadhyay P, Astrazeneca, Gaithersburg, MD, USA
- PCN23 D36 A SYSTEMATIC LITERATURE REVIEW ON THE DRIVERS OF EFFECTIVENESS AND THE EFFICACY-EFFECTIVENESS GAP IN HEMATOLOGICAL MALIGNANCIES WITH A FOCUS ON HODGKIN'S LYMPHOMA**
Liu L¹, Hummel N², Mauer M¹, Morais E³, Olivares R⁴,¹EORTC, Brussels, Belgium, ²University of Bern, Bern, Switzerland, ³Bristol-Myers Squibb, Rueil-Malmaison, France, ⁴Sanofi, Chilly-Mazarin, France
- PCN24 D37 COMPARATIVE EFFICACY AND SAFETY OF INTERVENTIONS IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA: A SYSTEMATIC REVIEW AND NETWORK META ANALYSIS**
Bertwistle D¹, D'Yachkova Y², Vickers AD³, Hawe E³, Fernandez M⁴, Drove N⁵, Lorenzo M¹, Wolowacz S³,¹Eli Lilly and Company Limited, Windlesham, UK, ²Eli Lilly Austria GmbH, Vienna, Austria, ³RTI Health Solutions, Manchester, UK, ⁴RTI Health Solutions, Research Triangle Park, NC, USA, ⁵Eli Lilly and Company Limited, Alcobendas, Spain
- PCN25 D38 LITERATURE REVIEW ON MORBIDITY AND MORTALITY ENDPOINTS IN MELANOMA PATIENTS UNDER TREATMENT WITH GM-CSF OR DACARBAZINE**
Lebioda A¹, Draheim C², Kulp W²,¹Amgen GmbH, Munich, Germany, ²Xcenda GmbH, Hannover, Germany
- PCN26 E1 EVALUATION OF INJECTABLE LANREOTIDE ACETATE IN THE TREATMENT OF LIVER CARCINOMA**
Araujo BC¹, Viana DC¹, Nunes TR¹, Galdino-Pitta MR¹, Oliveira PS², Landim MS³, Cardoso PR⁴, Rego MJ², Zanghelini F², Oliveira MD⁴, Andrade CA², Pitta MG²,¹University Federal de Pernambuco, Recife, Brazil, ²Universidade Federal de Pernambuco, Recife, Brazil, ³UFPE, Recife, Brazil, ⁴Avenida Professor Moraes Rego, Recife, Brazil
- PCN27 E2 THE THERAPEUTIC INDICATION OF CAPSULE AND INJECTABLE ETOPOSIDE TO THE TREATMENT OF OSTEOSARCOMA**
Nunes TR¹, Viana DC², Araujo BC³, Landim MS¹, Galdino-Pitta MR¹, Pereira MC⁴, Oliveira MD³, Zanghelini F⁴, Rego MJ⁴, Pitta MG⁴, Andrade CA⁴,¹UFPE, Recife, Brazil, ²Avenida Professor Moraes Rego, Recife, Brazil, ³University Federal de Pernambuco, Recife, Brazil, ⁴Universidade Federal de Pernambuco, Recife, Brazil
- PCN28 E3 USE OF A CLAIMS DATABASE TO DOCUMENT THE USE AND EFFECTIVENESS OF ORAL VINOBLASTINE (NVBO) IN A REAL WORLD SETTING FRANCE**
Emery C¹, Theret N², Berdeaux G³, Denjean F³,¹Cemka, Bourg La Reine, France, ²Pierre Fabre, Boulogne Billancourt, France, ³Pierre Fabre Medicament, Boulogne-Billancourt, France
- PCN29 E4 HEALTH OUTCOMES ASSESSMENT AND TREATMENT REGIMENS FOR PATIENTS WITH GASTRIC CANCER IN SHANGHAI CHINA**
Guo JJ¹, Du W², Chu L³, Wang X², Yue X⁴, Pruemer J¹,¹University of Cincinnati, Cincinnati, OH, USA, ²University of Cincinnati, Cincinnati, OH, USA, ³Genentech/Roche, San Francisco, CA, USA, ⁴University of Cincinnati College of Pharmacy, Cincinnati, OH, USA

USA

- PCN30 E5 PRAGMATIC REVIEW OF CLINICAL EFFICACY, SAFETY AND HEALTH CARE RELATED QUALITY OF LIFE (HRQOL) FOR TRANSTUZUMAB MONOTHERAPY IN METASTATIC HER2+ BREAST CANCER (MBC)**
Lister J¹, Windisch R², Neumann M¹, Machackova Z²,¹LASER Analytica, Lörrach, Germany, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland
- PCN31 E6 COMPARATIVE EFFICACY OF DARATUMUMAB MONOTHERAPY AND POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE (POMA+LODEX) IN THE TREATMENT OF MULTIPLE MYELOMA : A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC)**
van Sanden S¹, Ito T², Vogel M³, Diels J¹,¹Janssen Health Economics & Market Access EMEA Statistics & Modelling, Beerse, Belgium, ²Janssen Health Economics & Market Access EMEA, High Wycombe, UK, ³Janssen, Neuss, Germany
- PCN32 E7 EFFECTIVENESS OF PHOTODYNAMIC THERAPY IN PATIENTS WITH LOCALIZED ESOPHAGEAL CANCER**
Jayadevappa R, Chhatre S, University of Pennsylvania, Philadelphia, PA, USA
- PCN33 E8 GEFITINIB, ERLOTINIB OR AFATINIB FOR EGFR MUTATED NSCLC PATIENTS? A META-ANALYSIS AND INDIRECT COMPARISON ON THE EFFICACY OF FIRST-LINE TYROSINE KINASE INHIBITORS**
Holleman MS, Zaim R, Uyl-De Groot CA, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands
- PCN34 E9 USE OF NIMOTUZUMAB IN THE TREATMENT OF LOCALLY ADVANCED ESOPHAGEAL CANCER IN REAL WORLD**
Saumell Y¹, Sánchez L², Cabrera L¹, Cepeda M¹,¹Institute of Molecular immunology, Havana, Cuba, ²Center of Molecular Immunology, Havana, Cuba
- PCN35 E10 EFFECTIVENESS OF PHOTODYNAMIC THERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: A POPULATION BASED STUDY**
Jayadevappa R, Chhatre S, University of Pennsylvania, Philadelphia, PA, USA
- PCN36 E11 NETWORK META-ANALYSIS COMPARING PALBOCICLIB WITH CHEMOTHERAPIES FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/ HER2- ADVANCED/ METASTATIC BREAST CANCER**
Wilson FR¹, Varu A¹, Mitra D², Cameron C¹, Iyer S²,¹Cornerstone Research Group Inc., Burlington, ON, Canada, ²Pfizer, Inc., New York, NY, USA
- PCN37 E12 MANAGEMENT OF SOFT TISSUE SARCOMA IN FRANCE - A RETROSPECTIVE ANALYSIS OF THE FRENCH CLINICAL BIOLOGICAL SARCOMA DATABASE (CONTICANET)**
Coindre J¹, Ducimetière F², Mathoulin-Pelissier S¹, Le Cesne A³, Rochemaux P⁴, Terrier P³, Longin J⁵, van Hille B⁶, Bui Ngyuen B¹, Giraud A¹, Sana C⁵, Blay J²,¹Institut Bergonié, Bordeaux, France, ²Centre Léon Bérard, LYON, France, ³Gustave Roussy, Villejuif, France, ⁴Institut Claudius Régaud, Toulouse, France, ⁵Merck, LYON, France, ⁶MERCK, LYON, France
- PCN38 E13 ASSOCIATION BETWEEN INSULIN TREATMENT AND BREAST CANCER CHARACTERISTICS**
Overbeek JA¹, Vissers PA², van der Heijden AA¹, Bronsveld HK³, van Herk-Sukel MP⁴, Herings RM⁴, Nijpels G¹, Schmidt MK³,¹EMGO Institute, VU Medical Centre, Amsterdam, The Netherlands, ²Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, ³The Netherlands Cancer Institute, Amsterdam, The Netherlands, ⁴PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands
- PCN39 E14 THE FREQUENCY OF RELAPSED OR REFRACTORY DISEASE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN CLASSICAL HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW**
Szabo SM¹, Roop S¹, Juarez Garcia A², Hirji I³,¹Broad Street Health Economics & Outcomes Research, Vancouver, BC, Canada, ²Bristol-Myers Squibb, Ciudad de México, Mexico, ³Bristol-Myers Squibb, Princeton, NJ, USA
- PCN40 E15 METASTATIC COLORECTAL CANCER: THE BURDEN OF ILLNESS IN THE UK AND IRELAND**
Mildred M, Boehringer Ingelheim Ltd, Bracknell, UK
- PCN41 E16 INCIDENCE OF GERMLINE BRCA 1 AND 2 MUTATED BREAST CANCER IN THE EU5**
Kim RS¹, Peterson A¹, Isherwood A², Uppal H¹, Barlev A¹,¹Medivation, Inc., San Francisco, CA, USA, ²Decision Resources Group, London, UK
- PCN42 E17 TREATMENT PATTERNS OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN EUROPE (EU-28)**
Gatopoulou X¹, Bardenheuer K², Van Hoorenbeeck S³, Kempel A⁴,¹Janssen Health Economics & Market Access EMEA, Athens, Greece, ²Janssen-Cilag GmbH, Neuss, Germany, ³Janssen Health Economics & Market Access, Beerse, Belgium, ⁴Institute for Health Economics & Epidemiology, Freiburg, Germany
- PCN43 E18 A SYSTEMATIC REVIEW ON THE EPIDEMIOLOGY OF NRAS-MUTANT MELANOMA IN EUROPE AND AUSTRALIA**
Bergamasco A¹, Arredondo-Bisono T¹, Chalem Y², Lappereau-Gallot A², Berdeaux G³, Moride Y⁴,¹YolaRx Consultants, Paris, France, ²Pierre Fabre, Boulogne-Billancourt, France, ³Pierre Fabre Medicament, Boulogne-Billancourt, France, ⁴Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada
- PCN44 E19 EPIDEMIOLOGICAL ESTIMATION AND FLOW OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WHO HAVE RECEIVED PRIOR ANTI-ANGIOGENIC THERAPY IN SPAIN**
Grande E¹, Pérez-Valderrama B², García del Muro X³, Carcedo D⁴, Nieves D⁴, González García P⁵, Abad M⁵, Jiménez S⁵,¹University Hospital Ramón y Cajal, Madrid, Spain, ²University Hospital Virgen del Rocío, Seville, Spain, ³Catalan Institute of

- Oncology, L'Hospitalet. Barcelona, Spain, ⁴Oblikue Consulting, Barcelona, Spain, ⁵Bristol-Myers Squibb, Madrid, Spain
- PCN45 E20 IN-HOSPITAL MORTALITY AND COMPLICATIONS FOLLOWING SURGICAL RESECTION OF GLIOBLASTOMA**
Chevalier P, van Gils C, Lamotte M, IMS Health, Zaventem, Belgium
- PCN46 E21 EPIDEMIOLOGY AND SURVIVAL IN PROSTATE CANCER; A POPULATION BASED STUDY ANALYSING THE HUNGARIAN NATIONAL HEALTH INSURANCE FOUND DATABASE**
Brodszky V¹, Varga P², Gimesi-Országh J², Fadgyas-Freyler P², Boncz I³, Rencz F¹, Nyirády P⁴, **Gulácsi L**¹, ¹Corvinus University of Budapest, Budapest, Hungary, ²National Health Insurance Fund of Hungary, Budapest, Hungary, ³University of Pécs, Pécs, Hungary, ⁴Semmelweis University, Budapest, Hungary
- PCN47 E22 REAL LIFE PROGRESSION FREE SURVIVAL AND TREATMENT PATTERNS FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TARGETED THERAPIES IN FRANCE: ANALYSIS OF IMS RWD ONCOLOGY CROSS-SECTIONAL SURVEY DATA**
Maroun R¹, Mitrofan L², Benjamin L¹, Nachbaur G¹, Maunoury F³, Le Jeune P², Durand-Zaleski I⁴, ¹GSK France, Marly le roi, France, ²IMS Health, La Défense, France, ³Statesia, Le Mans, France, ⁴APHP URC Eco Ile de France Hôpital de l'Hotel Dieu, Paris, France
- PCN48 E23 PIVOTAL STUDIES OF ONCOLOGY DRUGS APPROVED IN EUROPE, WHICH EVIDENCE BASED-MEDICINE?**
Aissaoui A¹, Turkistani F², Bin Sawad A², Aissaoui N³, ¹Paris Dauphine University, PSL, Paris, France, ²MCPHS University, Boston, MA, USA, ³Paris Dauphine University, Paris, France
- PCN49 E24 USING SIMULATED INDIVIDUAL PATIENT DATA (IPD) FROM PUBLISHED REGISTRY AND IPD FROM THE SEER-MEDICARE REGISTRY TO EXTRAPOLATE RESULTS FROM RANDOMISED CLINICAL TRIALS (RCTS) IN METASTATIC MELANOMA**
Martina R¹, Jenkins D¹, Bujkiewicz S¹, Dequen P¹, Abrams KR¹, Lees M², Davies J³, Kalf R⁴, Makady A⁵, ¹University of Leicester, Leicester, UK, ²Bristol-Myers Squibb, Paris, France, ³F. Hoffmann-La Roche AG, Basel, Switzerland, ⁴National Healthcare Institute (ZIN), Diemen, The Netherlands, ⁵The National Healthcare Institute (ZIN), Diemen, The Netherlands
- PCN50 E25 REAL-WORLD OUTCOMES OF PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH SECOND-LINE OR LATER CHEMOTHERAPY IN A COMMUNITY ONCOLOGY SETTING IN THE UNITED STATES**
Cowey CL¹, Mahnke L², Espirito J³, Fox P⁴, Helwig C⁵, Oksen D⁵, Bharmal M⁵, ¹Baylor University Medical Center, Sammons Cancer Center, Texas Oncology, P.A., Dallas, TX, USA, ²EMD Serono, Billerica, Boston, MA, USA, ³McKesson Specialty Health, The Woodlands, TX, USA, ⁴PRA Health Sciences, Houston, TX, USA, ⁵Merck KGaA, Darmstadt, Germany
- PCN51 E26 CANCER DRUGS IN THE EU5 AND USA: CROSS-COUNTRY PRICING COMPARISON AND CORRELATION ANALYSIS BETWEEN OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS)**
Czira A¹, **Pacheco L**², ¹GfK, London, UK, ²GfK Market Access, London, UK
- PCN52 E27 OVERALL SURVIVAL VERSUS PROGRESSION-FREE SURVIVAL IN ONCOLOGY CLINICAL TRIALS**
Aissaoui A¹, Bin Sawad A², Turkistani F², Aissaoui N³, ¹Paris Dauphine University, PSL, Paris, France, ²MCPHS University, Boston, MA, USA, ³Paris Dauphine University, Paris, France

CANCER - Cost Studies

- PCN53 E28 ECONOMIC EVALUATION OF DRUG WASTAGE IMPACT ON HEALTHCARE EXPENDITURES IN FRENCH HOSPITALS**
Cornic L¹, Borget I², Tardivel C³, Cawston H³, Mahieu N³, ¹Université Paris XI, Paris, France, ²Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France, ³Amaris, London, UK
- PCN54 E29 CHOOSING FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER BASED ON BIOMARKER RAS STATUS: A BUDGET IMPACT ANALYSIS FROM BRAZILIAN HEALTH INSURANCE SYSTEM PERSPECTIVE**
Souza PV¹, Simões AC², Zanini FE¹, ¹Merck, São Paulo, Brazil, ²Merck, Rio de Janeiro, Brazil
- PCN55 E30 ECONOMIC IMPACT OF OLAPARIB IN PATIENTS WITH PLATINUM SENSITIVE RELAPSED BRCA MUTATED EPITHELIAL OVARIAN CANCER IN SPAIN**
Delgado-Ortega L¹, Moya-Alarcón C¹, Carcedo D², Villacampa A², Cordero L¹, ¹AstraZeneca Spain, Madrid, Spain, ²Oblikue Consulting, Barcelona, Spain
- PCN56 E31 A BUDGET IMPACT ANALYSIS OF ALTERNATIVE TREATMENT OPTIONS FOR COLORECTAL CANCER IN GREECE**
Athanasakis K, Tarantilis F, **Naoum P**, Kyriopoulos J, National School of Public Health, Athens, Greece
- PCN57 E32 BUDGET IMPACT ANALYSIS OF SUNITINIB VERSUS BEST SUPPORTIVE CARE FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN CHILE**
Vargas C, Espinoza MA, Pontificia Universidad Católica de Chile, Santiago, Chile
- PCN58 E33 BUDGET IMPACT ANALYSIS OF NANOLIPOSOMAL IRINOTECAN FOR TREATMENT OF PANCREATIC CANCER FOLLOWING PROGRESSION ON GEMCITABINE - A US PAYER PERSPECTIVE**
Becker C¹, Mamlouk K¹, Li H², ¹Merrimack Pharmaceuticals, Cambridge, MA, USA, ²1 Kendall Square, Cambridge, MA, USA
- PCN59 E34 NEW APPROACH TO BUDGET IMPACT ANALYSIS - IBRUTINIB IN TREATMENT OF RELAPSED/REFRACTORY CLL PATIENTS IN THE CZECH REPUBLIC**
Pribylova L¹, **Pasztor B**¹, Vesela S², Vyhnanekova M², Doleckova J¹, Duba J¹, Kolek M¹, ¹OAKS Consulting s.r.o., Prague 9, Czech

Republic, ²Market Access Janssen – Cilag s.r.o., Czech Republic, Prague, Czech Republic

- PCN60 E35 INVISIBLE LEVER FOR ACCESS TO INNOVATIVE THERAPIES IN BULGARIA**
Dobreva DP¹, Petrova T²,¹Institute for Medical Research Ltd., Sofia, Bulgaria, ²Simbula Ltd., Sofia, Bulgaria
- PCN61 E36 A BUDGET IMPACT ANALYSIS TO ESTIMATE THE COST SAVINGS FROM ALECTINIB ON PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PREVIOUSLY TREATED WITH CRIZOTINIB**
Orfanos P, Becker U,F. Hoffmann-La Roche Ltd., Basel, Switzerland
- PCN62 E37 BUDGET IMPACT ANALYSIS OF USING PAZOPANIB-EVEROLIMUS IN FIRST AND SECOND LINE OF TREATMENT, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA**
Romero Prada ME¹, Roa Cardenas NC², Acero G³, Huerfano LM², Alfonso Quiñones PA³, Celis S⁴,¹Fundación Salutia, Bogotá, Colombia, ²Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, ³Salutia Foundation, Bogotá, Colombia, ⁴Salutia Foundation, Bogota, Colombia
- PCN63 E38 RELIABILITY OF MANUFACTURERS' BUDGET IMPACT ESTIMATES FOR MELANOMA DRUGS IN POLAND**
Iwanczuk T, Tataro T, Zaremba A, Misiak J, Krakowian P, Czeczot J,Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, Poland
- PCN64 F1 BUDGET IMPACT ANALYSIS OF REGORAFENIB FOR THE TREATMENT IN THIRD AND FOURTH LINES OF METASTATIC COLORECTAL CANCER IN SPAIN**
González Flores E¹, Vera García R², Sabater Cabrera E³, **Tirado Mercier E**⁴, Granell Villalon M⁵,¹Hospital Universitario Virgen de las Nieves, Granada, Spain, ²Complejo Hospitalario de Navarra, Pamplona, Spain, ³Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, ⁴Bayer Hispania S. L., Sant Joan Despí (Barcelona), Spain, ⁵Bayer Hispania S. L., Sant Joan Despí (Barcelona), Spain
- PCN65 F2 A BUDGET IMPACT ANALYSIS TO ESTIMATE THE ECONOMIC CONSEQUENCES OF INTRODUCING THE COMBINATION OF AVASTIN + TARCEVA FOR THE TREATMENT OF FIRST LINE EPIDERMAL GROWTH FACTOR (EGFR) METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)**
Orfanos P¹, Wright EJ², C. Munk V²,¹F. Hoffmann-La Roche Ltd., Basel, Switzerland, Basel, Switzerland, ²ROCHE, Basel, Switzerland
- PCN66 F3 PHARMACOECONOMIC ASPECTS OF DIFFERENT INHIBITORS OF TYROSINE KINASE IN FIRST-LINE THERAPY OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH A MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE**
Ryazhenov VV¹, Gorokhova SG², Gorokhov V²,¹I.M. Sechenov First Moscow State Medical University, Moscow, Russia, ²Research Clinical Center of JSC Russian Railways, Moscow, Russia
- PCN67 F4 ECONOMIC ASSESSMENT OF ROUTINE ONCOTYPE DX TESTING OF ESTROGEN RECEPTOR POSITIVE (ER+) EARLY BREAST CANCER (EBC) PATIENTS WITH GRADE 2 TUMOURS IN CZECH REPUBLIC**
Hejduk K¹, Petrakova K², Petruzelka L³, Bielicikova Z⁴, Kolarova I⁵, Finek J⁶, Burger M¹, Ovesná P¹, Feigler I¹, Silar J¹, Zbozinkova Z¹,¹Masaryk University, Brno, Czech Republic, ²Masaryk memorial cancer institute Brno, Brno, Czech Republic, ³The General university hospital in Prague, Prague, Czech Republic, ⁴The General university hospital in Prague, Prague, Czech Republic, ⁵Multiscan, Pardubice, Czech Republic, ⁶Clinic of Oncology and radiotherapy (FN v PLZN), Plzen, Czech Republic
- PCN68 F5 BUDGET IMPACT ANALYSIS OF OLAPARIB USE IN PATIENTS BRCA – MUTATED PSROC IN GREECE**
Mylonas C¹, Aravantinos G², Bamias A³, Kourlaba G⁴, Maniadakis N¹,¹National School of Public Health, Athens, Greece, ²Agioi Anargyroi Anticancer Hospital of Athens, Athens, Greece, ³University of Athens School of Medicine, Athens, Greece, ⁴Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Civil Partnership, Athens, Greece
- PCN69 F6 BUDGET IMPACT ANALYSIS OF FIRST-LINE TREATMENT WITH BRANDED PEMETREXED (ALIMTA) FOR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN CHINA**
Shi Q¹, Rajan N², Davey P³, Davey R³,¹Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China, ²Eli Lilly Australia, West Ryde, Australia, ³Illuminate Health Consulting, Chatswood, Australia
- PCN70 F7 COST OF 1ST LINE TREATMENT FAILURE IN BRAF V600 MUTATED METASTATIC MELANOMA IN FRANCE**
Cozzone D¹, Dreno B², Lebbé C³, Pinguet J¹, **Tehard B**⁴,¹Roche SAS, Boulogne-Billancourt, France, ²Centre Hospitalier Universitaire, Nantes Cedex 1, France, ³Assistance Publique - Hôpitaux de Paris (AP-HP) Hôpital Saint-Louis, Paris, France, ⁴Roche, Boulogne-Billancourt, France
- PCN71 F8 COST COMPARISON IN THE MANAGEMENT OF ADULT PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA PREVIOUSLY TREATED IN SPAIN: PAZOPANIB VS. TRABECTEDINA**
Padron E, Flores L,Novartis Oncology, Madrid, Spain
- PCN72 F9 COST COMPARISON IN THE MANAGEMENT OF THE RENAL CELL CARCINOMA WITH IN SPAIN: PAZOPANIB VS. SUNITINIB**
Padron E, Flores L,Novartis Oncology, Madrid, Spain
- PCN73 F10 THE BURDEN OF STAPLE LINE INTERVENTIONS IN COLORECTAL SURGERY EUROPE**
Schiff A¹, Ghosh SK², Roy S³, Pignot M⁴, Fegelman E¹,¹Johnson & Johnson (Ethicon), Cincinnati, OH, USA, ²Global Health

Economics and Market Access, Ethicon, Inc., Cincinnati, OH, USA, ³Johnson and Johnson Global Surgery, Somerville, NJ, USA, ⁴Kantar Health, Munich, Germany

- PCN74 F11 WHAT IS AN EFFICIENT AND AFFORDABLE TRASTUZUMAB THERAPY IN A MIDDLE-INCOME COUNTRY? - ADJUVANT THERAPY WITH TRASTUZUMAB IN MANAGEMENT OF EARLY HER2-POSITIVE BREAST CANCER IN IRAN**
Ansaripour A¹, Uyl-de Groot C², Redekop WK^{3,1}, Erasmus University Rotterdam, Rotterdam, The Netherlands, ²National Health Care Institute, Diemen, The Netherlands, ³National University of Singapore, Singapore, Singapore
- PCN75 F12 COST MINIMIZATION ANALYSIS OF PEG-L-ASPARGINASE VERSUS E.COLI L-ASPARAGINASE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS: A JORDANIAN PERSPECTIVE**
Al Rabayah AA, Jaddouh S, Amireh A, King Hussein Cancer Center, Amman, Jordan
- PCN76 F13 THE INFLUENCE OF PRICE REGULATION METHOD ON PRICE TRAJECTORY – ASSESSMENT OF CANCER DRUG PRICES IN USA, THE UK AND ISRAEL**
Gordon N¹, Stemmer SM², Greenberg D¹, Chain G³, Goldstein DA^{2,1}, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²Rabin Medical Center, Petach-Tikva, Israel, ³University College London, London, UK
- PCN77 F14 COST-ANALYSIS FOR TOXICITY MANAGEMENT IN ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER: NIVOLUMAB VS DOCETAXEL**
Ortega-Joaquin N¹, Echave M², Oyagüez I³, Garrido P⁴, Felip E⁵, Trigo J⁶, Filori M⁷, **González García P**^{7,1}, PharmacoEconomics & Outcomes Research Iberia, Madrid, Spain, ²PharmacoEconomics & Outcomes Research Iberia, Pozuelo de Alarcón (Madrid), Spain, ³PharmacoEconomics & Outcomes Research Iberia, Pozuelo de Alarcón, Spain, ⁴H. Universitario Ramón y Cajal, Madrid, Spain, ⁵H. Universitario Vall d'Hebron, Barcelona, Spain, ⁶H. Universitario Virgen de la Victoria, Málaga, Spain, ⁷Bristol-Myers Squibb, Madrid, Spain
- PCN78 F15 NUMBER NEEDED TO TREAT AND COST PER CLINICALLY MEANINGFUL OUTCOME OF ENZALUTAMIDE AND ABIRATERONE ACETATE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT FAILED ANDROGEN DEPRIVATION THERAPY IN BRAZIL**
Sasse AP¹, Lopes G², Teich V³, Fay AP⁴, Abadi M⁵, Schultz NM⁶, **Stefani S**^{7,1}, Centro de Evidencias em Oncologia, Campinas, Brazil, ²Oncoclinicas do Brasil, São Paulo, Brazil, ³SENSE Company, São Paulo, Brazil, ⁴PUCRS School Of Medicine and Hospital do Câncer Mãe de Deus, Porto Alegre, Brazil, ⁵Astellas Pharma, Inc., Sao Paulo, Brazil, ⁶Astellas Pharma Global Development, Inc, Northbrook, IL, USA, ⁷Instituto do Câncer Hospital Mãe de Deus and Fundação Unimed, Porto Alegre, Brazil
- PCN79 F16 A COST COMPARISON OF 1L TREATMENT REGIMENS FOR METASTATIC COLORECTAL CANCER (MCR) IN ITALY**
Iannazzo S¹, Distante C¹, Lopatriello S¹, Proietti E², **Brioschi E**², Bordonaro R^{3,1}, SIHS SRL, Torino, Italy, ²Roche SpA, Monza, Italy, ³ARNAS Garibaldi Nesima, Catania, Italy
- PCN80 F17 COSTS OF CARE BETWEEN RESECTED AND NON-RESECTED PANCREATIC CANCER PATIENTS: FINDINGS FROM A REAL-WORLD U.S. POPULATION**
Kish J¹, Feinberg BA¹, Biggs C², Mujumdar U¹, Chopra D¹, Laney J¹, Kennedy G^{2,1}, Cardinal Health, Dublin, OH, USA, ²NewLink Genetics Inc, Austin, TX, USA
- PCN81 F18 COMPARISON OF TREND, OUTCOME, AND COST OF OPEN, LAPAROSCOPIC, AND ROBOTIC SURGICAL TREATMENT FOR COLORECTAL CANCER- A PROPENSITY SCORE MATCHED ANALYSIS OF A NATIONAL DATABASE**
Chiu C¹, Lee MG², Hsu W², Lee S², Hsu T², **Lee C**^{3,1}, Chi Mei Medical Center, Tainan City, Taiwan, ²National Taiwan University Hospital, Taipei City, Taiwan, ³National Taiwan University Hospital Yunlin Branch, Douliou, Taiwan
- PCN82 F19 COSTS EVOLUTION OF CANCER THERAPIES IN EUROPE FROM 2004 TO 2014**
Tetafort A, Aubert J, Perrot D, Brigot G, Kolahi C, Ansolabehere X, IMS Health, La Défense, France
- PCN83 F20 VIRTUAL PLANNING AND PATIENT-SPECIFIC IMPLANTS IN MANDIBULAR RECONSTRUCTION SURGERY: A MICRO-COSTING ANALYSIS**
Baj A, Bolzoni AR, Gianni AB, IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano - Università degli Studi di Milano, Milano, Italy
- PCN84 F21 BEVACIZUMAB IN THE TREATMENT OF KRAS WILD TYPE METASTATIC COLORECTAL CANCER: AN ECONOMIC ANALYSIS BASED ON THE CALGB 80405 TRIAL**
Silva C¹, Monteiro I², Tournier C^{3,1}, EuroTrials, Scientific Consultants, Lisbon, Portugal, ²Roche Farmacêutica Química, Lda, Amadora, Portugal, ³F. Hoffmann-La Roche AG, Basel, Switzerland
- PCN85 F22 COST-MINIMIZATION ANALYSIS OF LIPEGILGRASTIM IN PROPHYLAXIS OF FEBRILE NEUTROPENIA IN CANCER PATIENTS**
Ugrekheldze D, Yagudina R, Kulikov A, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- PCN86 F23 ANALYSIS OF THE COSTS ASSOCIATED WITH THE MANAGEMENT OF ADVERSE EVENTS COMPARED THROUGH TKIS IN THE TREATMENT OF PATIENTS WITH NON-SMALL CELLS LUNG CANCER EGFR MUTATED**
Villa S¹, Brioschi E², Ravasio R^{3,1}, Roche Spa, Monza, Italy, ²Roche SpA, Monza, Italy, ³Health Publishing & Services, Milano, Italy
- PCN87 F24 OVARCOST STUDY: ECONOMIC BURDEN OF EPITHELIAL OVARIAN CANCER IN SPAIN**
Delgado-Ortega L¹, Moya-Alarcón C¹, Borrás JM², González de la Haba E³, Oliva Moreno J⁴, González-Domínguez A⁵, Hidalgo A⁴, Cordero L¹, Simon S¹, OvarCost Panel.^{6,1} AstraZeneca Spain, Madrid, Spain, ²University of Barcelona, Hospitalet, Spain, ³Gregorio Marañón University General Hospital, Madrid, Spain, ⁴University of Castilla-La Mancha, Toledo, Spain, ⁵Weber,

Economía y Salud, Majadahonda, Spain, ⁶OvarCost Panel, Madrid, Spain

- PCN88 F25 COST AND BURDEN OF FEMALE BREAST CANCER IN PORTUGAL**
Sousa R¹, Fiorentino F¹, Alarcão J¹, Lopes Pereira C¹, Jesus G¹, Costa J², Gouveia M³, Borges M¹, ¹Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ²Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ³Católica Lisbon School of Business and Economics, Lisbon, Portugal
- PCN89 F26 PRIVATE AND CATASTROPHIC HEALTH EXPENDITURE OF PATIENTS WITH EARLY AND LOCALLY ADVANCED BREAST CANCER IN GREECE**
Skroumpelos A¹, Naoum V², Kyriopoulos D³, Pavi E², Kyriopoulos J², ¹Roche Pharmaceuticals (Hellas) S.A, Athens, Greece, ²National School of Public Health, Athens, Greece, ³London School of Economics and Political Science, London, UK
- PCN90 F27 ECONOMIC BURDEN OF ADVANCED GASTRIC CANCER (AGC) IN MEXICO**
Hong J¹, **Novick D²**, Botello BS³, Quintana M⁴, ¹Department of Healthcare Management, Gachon University, Seongnam, South Korea, ²Eli Lilly and Company, Windlesham, Surrey, UK, ³Eli Lilly and Company, Mexico City, Mexico, ⁴Department of Oncology, Centro Médico Nacional Siglo XXI, Mexico City, Mexico
- PCN91 F28 COST-OF-ILLNESS OF METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS IN SWEDEN – A REGISTER-LINKAGE POPULATION-BASED STUDY**
Lesén E¹, Granfeldt D¹, Houchard A², Berthon A², Dinét J³, Björstad Å¹, Björholt I¹, Elf A⁴, Johanson V⁴, ¹Nordic Health Economics, Gothenburg, Sweden, ²IPSEN, Boulogne-Billancourt, France, ³Ipsen, Boulogne-Billancourt, France, ⁴Sahlgrenska University Hospital, Gothenburg, Sweden
- PCN92 F29 THE INDIRECT COSTS OF BREAST CANCER IN THE SLOVAK REPUBLIC**
Suchansky M¹, Ondrusova M¹, **Psenkova M²**, ¹Pharm-In Ltd, Bratislava, Slovak Republic, ²Pharm-In Ltd, Bratislava, Slovakia
- PCN93 F30 INCIDENCE CANCER COSTS ASSOCIATED WITH HEAD AND NECK (H&N) CANCERS: A NATIONWIDE STUDY FROM FRANCE IN 2008-2013 (EPICORL STUDY)**
Schwarzinger M¹, Huguet F², Témam S³, Pointreau Y⁴, Sagaon Teyssier L⁵, Bec M⁶, Even C³, Geoffrois L⁷, Levy-Bachelot L⁶, ¹THEN (Translational Health Economics Network), Paris, France, ²Tenon hospital, Paris, France, ³Institut Gustave Roussy, Villejuif, France, ⁴Centre Jean Bernard-Clinique Victor Hugo, LE MANS, France, ⁵Aix Marseille University, Marseille, France, ⁶MSD France, Courbevoie, France, ⁷Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
- PCN94 F31 HEALTHCARE COSTS AMONG MULTIPLE MYELOMA (MM) PATIENTS (PTS) WITHOUT STEM CELL TRANSPLANT (SCT)**
Panjabi S¹, Hagiwara M², Sharma A², Delea TE², ¹Amgen Inc., South San Francisco, CA, USA, ²Policy Analysis Inc. (PAI), Brookline, MA, USA
- PCN95 F32 HEALTHCARE PATHWAY AND COSTS ANALYSIS IN PATIENTS WITH METASTATIC PROSTATE CANCER (MPC)**
Perrone V¹, Saragoni S¹, Crovato E¹, Buda S¹, Brigido A², **Degli Esposti L¹**, ¹CliCon S.r.l., Ravenna, Italy, ²Janssen-Cilag SpA, Cologno Monzese, Italy
- PCN96 F33 RETROSPECTIVE STUDY OF FREQUENCY AND COST OF MULTIPLE MYELOMA (MM) COMPLICATIONS AND TREATMENT RELATED ADVERSE EVENTS (AES)**
Hagiwara M¹, **Panjabi S²**, Sharma A¹, Delea TE¹, ¹Policy Analysis Inc. (PAI), Brookline, MA, USA, ²Amgen Inc., South San Francisco, CA, USA
- PCN97 F34 BURDEN OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN TURKEY**
Erdal E¹, Malhan S², Oksuz E², Cag C³, Kabasakal L⁴, Kucuk O⁵, Sozen TS⁶, Sar C¹, Kahveci B¹, ¹Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, ²Baskent University, Ankara, Turkey, ³Ege University, izmir, Turkey, ⁴Istanbul University, Istanbul, Turkey, ⁵Ankara University, Ankara, Turkey, ⁶Gazi University, Ankara, Turkey
- PCN98 F35 TIME AND COST OF HOSPITALIZATION FOR SALVAGE THERAPY AMONG ADULTS WITH PHILADELPHIA (PH)-NEGATIVE B-CELL RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN SPAIN**
Boluda B¹, Rodríguez-Veiga R¹, Martínez-Cuadrón D¹, Lorenzo L¹, Sanz G¹, Sanz J¹, Regadera A¹, Sempere A¹, Senent L¹, Cervera J¹, Reitan J², Gea S³, Sanz M¹, **Montesinos P¹**, ¹Hospital Universitario La Fe Valencia, Valencia, Spain, ²RJM Group, Crown Point, IN, USA, ³Amgen, Barcelona, Spain
- PCN99 F36 COSTS OF HPV-RELATED CANCERS IN THE NETHERLANDS**
Salem A¹, Pervaiz S¹, Breeveld-dwarkasing V², Dhont P³, Slierendregt B², van Gils CW¹, ¹IMS Health, Zaventem, Belgium, ²Sanofi Pasteur MSD, Hoofddorp, The Netherlands, ³Sanofi Pasteur MSD, Diegem, Belgium
- PCN100 F37 EVALUATING THE ECONOMIC BURDEN AND HEALTH CARE UTILIZATION OF LUNG CANCER IN THE US MEDICARE POPULATION**
Xie L¹, Vaidya N¹, Xin K¹, Keshishian A¹, Yuce H², Ozenbas D³, Baser O⁴, ¹STATinMED Research, Ann Arbor, MI, USA, ²New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, ³Montclair State University, Montclair, NJ, USA, ⁴Columbia University and STATinMED Research, New York, NY, USA
- PCN101 F38 HEALTH CARE UTILIZATION AND ECONOMIC BURDEN OF PANCREATIC CANCER IN THE US MEDICARE POPULATION**
Xie L¹, Zhang Q¹, Xin K¹, Wang Y¹, Yuce H², Ozenbas D³, Baser O⁴, ¹STATinMED Research, Ann Arbor, MI, USA, ²New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, ³Montclair State University, Montclair, NJ, USA, ⁴Columbia University and STATinMED Research, New York, NY, USA

- PCN102 G1 ASSESSING THE CLINICAL AND ECONOMIC BURDEN OF PROSTATE CANCER IN THE UNITED STATES VETERAN POPULATION**
Wang L¹, Li L¹, Zhou X¹, Pandya S¹, Baser O^{2,1}, STATinMED Research, Plano, TX, USA, ²Columbia University and STATinMED Research, New York, NY, USA
- PCN103 G2 EVALUATING THE ECONOMIC BURDEN AND HEALTH CARE UTILIZATION OF BREAST CANCER IN THE US MEDICARE POPULATION**
Xie L¹, Vaidya N¹, Xin K¹, Kariburyo MF¹, Yuce H², Baser O^{3,1}, STATinMED Research, Ann Arbor, MI, USA, ²New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, ³Columbia University and STATinMED Research, New York, NY, USA
- PCN104 G3 ECONOMIC EVALUATION OF TARGETED THERAPIES IN METASTATIC CLEAR RENAL CELL CARCINOMA IN CANADA**
Nazha S, Prevost N, Tanguay S, Vanhuysse M, Dragomir A, McGill University Health Centre, Montreal, QC, Canada
- PCN105 G4 COST OF SORAFENIB FOR RUSSIAN GOVERNMENT DRUG PROVISION PROGRAM**
Frolov M¹, Avxentyev N², Derkach EV^{3,1}, Volgograd State Medical University, Volgograd, Russia, ²Research Institute of Finance, Moscow, Russian Federation, ³The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia
- PCN106 G5 ECONOMIC BURDEN ASSOCIATED WITH CHRONIC MYELOID LEUKEMIA (CML) TREATMENTS IN THE UNITED STATES: A SYSTEMATIC LITERATURE REVIEW**
Gala S, Shah A, **Mwamburi M**, Market Access Solutions LLC, Raritan, NJ, USA
- PCN107 G6 ANTINEOPLASTIC DRUG EXPENDITURE IN PANAMA 2012-2014**
Tribaldos Causadias de Suárez M, Gomez B, Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama, Panama
- PCN108 G7 REAL-WORLD TREATMENT PATTERNS AND COSTS OF CARE AMONG BRENTUXIMAB VENDOTIN-TREATED PATIENTS WITH HODGKIN LYMPHOMA IN THE UNITED STATES**
Szabo SM¹, Hirji I², Johnston KM¹, Juarez-Garcia A³, Subar M², Connors JM^{4,1}, Broad Street Health Economics & Outcomes Research, Vancouver, BC, Canada, ²Bristol-Myers Squibb, Princeton, NJ, USA, ³Bristol-Myers Squibb Company, Ciudad de México, Mexico, ⁴British Columbia Cancer Agency Centre for Lymphoid Cancer (BCCA CLC), Vancouver, BC, Canada
- PCN109 G8 COURSE OF THERAPY, RESOURCE UTILIZATION AND COSTS FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN GERMANY**
Grabe K, Pfeifer S, Osowski U, Merck Serono, Darmstadt, Germany
- PCN110 G9 DRUG UTILISATION OF BRAF INHIBITORS FOR MELANOMA IN IRELAND**
Gorry C, McCullagh LM, Barry M, National Centre for Pharmacoeconomics, Dublin, Ireland
- PCN111 G10 DOSE EXTENSION AND COSTS OF LANREOTIDE AUTOGEL 120 MG USED IN ROUTINE NEUROENDOCRINE TUMORS CARE IN POLAND – 2- YEARS DATA FROM LANRO-NET STUDY**
Orlewska E¹, Bednarczyk T², Kaminski G³, Budlewski T⁴, Kos-Kudla B^{5,1}, Jan Kochanowski University, Kielce, Poland, ²Medical University of Warsaw, Warsaw, Poland, ³Military Institute of Medicine, Warsaw, Poland, ⁴Central Clinical Hospital, Ministry of Internal Affairs, Warsaw, Poland, ⁵Silesian Medical University, Katowice, Poland
- PCN112 G11 METASTATIC COLORECTAL CANCER IN CROATIA - COST OF DISEASE STUDY**
Bencina G, GSK, Zagreb, Croatia
- PCN113 G12 ANALYSING THE EVOLUTION OF CANCER DRUG PRICES IN FRANCE SINCE 2000**
Peirone V¹, Toueg R², Houzelot D¹, de Paz B^{1,1}, PRIORITIS Market Access, Paris, France, ²Paris Descartes University, MALAKOFF, France
- PCN114 G13 ESTIMATING THE MANAGEMENT COST OF HPV-RELATED LOW-GRADE AND PRECANCEROUS HIGH-GRADE LESIONS IN FRANCE**
Uhart M¹, Jacob JA², Gagnon JA³, Bianic F⁴, Bergeron C⁵, Largeron N^{1,1}, Sanofi Pasteur MSD, Lyon, France, ²Mapi Group, Uxbridge, UK, ³Mapi Group, London, UK, ⁴Mapi Group, Nanterre, France, ⁵Laboratoire Cerba, Saint-Ouen-l'Aumône, France
- PCN115 G14 RESOURCE UTILIZATION AND COSTS OF RESECTED PANCREATIC CANCER PATIENTS RECEIVING NEOADJUVANT TREATMENT: FINDINGS FROM A REAL-WORLD U.S. POPULATION**
Kish J¹, Feinberg BA¹, Biggs C², Mujumdar U¹, Chopra D¹, Laney J¹, Kennedy G^{2,1}, Cardinal Health, Dublin, OH, USA, ²NewLink Genetics Inc, Austin, TX, USA
- PCN116 G15 BUDGET IMPACT ANALYSIS OF PANOBINOSTAT – BORTEZOMIB AND DEXAMETHASONE, AS 3RD OR 4TH LINE OF TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN GREECE**
Vellopoulou K¹, Kourlaba G¹, Delimpasi S², Chatzikou M³, Katodritou E⁴, Konstantopoulou K³, Megalaki K⁵, Pouli A⁶, Repousis P⁵, Terpos E^{7,1}, EVROSTON LP, Athens, Greece, ²Evangelismos Hospital, Athens, Greece, ³Novartis (Hellas) S.A.C.I., Athens, Greece, ⁴Theagenion Anticancer Hospital, Thessaloniki, Greece, ⁵Metaxa Anticancer Hospital, Pireaus, Greece, ⁶Agios Savvas Anticancer Hospital, ATHENS, Greece, ⁷National and Kapodistrian University of Athens, Athens, Greece
- PCN117 G16 ESTIMATED COSTS OF LOCOREGIONAL AND METASTATIC RECURRENCES IN PATIENTS WITH HER2+ BREAST CANCER IN SPAIN**
Albanell J¹, Ciruelos E², De la Haba J³, Martín M⁴, Muñoz-Molina B⁵, **De Salas-Cansado M⁵**, Colomer R^{6,1}, Hospital del Mar,

Barcelona, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁵Roche Farma, Madrid, Spain, ⁶Hospital Universitario La Princesa, Madrid, Spain

- PCN118 G17 COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR ADVANCED MELANOMA TREATMENT IN PORTUGAL**
Silva Miguel L¹, Vargas Lopes F², Pinheiro B¹, Wang J³, Xu R³, Pellissier J³, Laires PA^{2,1}, Research Centre on the Portuguese Economy –ISEG/ULisboa, Lisboa, Portugal, ²Merck Sharp & Dohme, Oeiras, Portugal, ³Merck & Co., Inc., North Wales, PA, USA
- PCN119 G18 COST-EFFECTIVENESS ANALYSIS OF A POTENTIAL TREATMENT INTRODUCTION FOR ANOREXIA-CACHEXIA IN NON-SMALL CELL LUNG CANCER PATIENTS**
Borsoi L, Meregaglia M, Ciani O, Tarricone R, Bocconi University, Milan, Italy
- PCN121 G19 COST-EFFECTIVENESS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MELANOMA PREVIOUSLY TREATED WITH IPILIMUMAB IN PORTUGAL**
Silva Miguel L¹, Vargas Lopes F², Pinheiro B¹, Wang J³, Xu R³, Pellissier J³, Laires PA^{2,1}, Research Centre on the Portuguese Economy –ISEG/ULisboa, Lisboa, Portugal, ²Merck Sharp & Dohme, Oeiras, Portugal, ³Merck & Co., Inc., North Wales, PA, USA
- PCN122 G20 COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR TREATING PREVIOUSLY UNTREATED METASTATIC MELANOMA PATIENTS IN FRANCE**
Godard C¹, Wang J², Gauthier A³, Levy-Bachelot L¹, Annemans L^{4,1}, MSD France, Courbevoie, France, ²Merck & Co., Inc., North Wales, PA, USA, ³Amaris, London, UK, ⁴Ghent University - Brussels University, Ghent, Belgium
- PCN123 G21 COST-EFFECTIVENESS OF PIXANTRONE FOR THE THIRD-/FOURTH-LINE TREATMENT OF AGGRESSIVE NON-HODGKIN'S LYMPHOMA IN PORTUGAL**
Félix J¹, Vandewalle B¹, Andreozzi V¹, Almeida J¹, Silva N¹, Ferreira C¹, Ferreira D¹, Amorim A², Doering D³, Branscombe N^{3,1}, Exigo Consultores, Lisboa, Portugal, ²Servier Portugal, Lisboa, Portugal, ³Les Laboratoires Servier, Suresnes, France
- PCN124 G22 COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA**
Baker TM¹, Paly VF¹, **Sabater J**², Okoro T², Kotapati S², Briggs A^{3,1}, ICON Health Economics & Epidemiology, New York City, NY, USA, ²Bristol-Myers Squibb, Princeton, NJ, USA, ³University of Glasgow, Glasgow, UK
- PCN125 G23 PHARMACOECONOMIC ANALYSIS OF ABIRATERONE USED FOR METASTATIC CASTRATE-RESISTANT PROSTATE CANCER BEFORE CHEMOTHERAPY**
Avxentyev N¹, Derkach EV^{2,1}, Research Institute of Finance, Moscow, Russian Federation, ²The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia
- PCN126 G24 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN**
Baker TM¹, Paly VF¹, Thybo S², Hultberg M³, Minacori R⁴, Kotapati S², **Sabater J**^{2,1}, ICON Health Economics & Epidemiology, New York City, NY, USA, ²Bristol-Myers Squibb, Princeton, NJ, USA, ³PAREXEL International, Stockholm, Sweden, ⁴PAREXEL International, London, UK
- PCN127 G25 AZACITIDINE FOR TREATING ACUTE MYELOID LEUKAEMIA: A NICE SINGLE TECHNOLOGY APPRAISAL**
Tikhonova I¹, Hoyle M¹, Snowsill T¹, Cooper C¹, Varley-Campbell J¹, Rudin C², Mujica Mota R^{1,1}, University of Exeter, Exeter, UK, ²Royal Devon and Exeter Hospital, Exeter, UK
- PCN128 G26 USE OF NET MONETARY BENEFIT ANALYSIS TO COMPREHENSIVELY UNDERSTAND THE VALUE OF INNOVATIVE TREATMENTS**
Shafrin J¹, May SG², Skornicki M³, Hathway J⁴, Macaulay R⁵, Villeneuve J⁶, Lees M⁷, Hertel N⁸, Penrod JR⁹, **Jansen J**^{10,1}, Precision Health Economics, Los Angeles, CA, USA, ²Precision Health Economics, Austin, TX, USA, ³Precision Health Economics, New York, NY, USA, ⁴Precision Health Economics, Boston, MA, USA, ⁵Parexel Access Consulting, London, UK, ⁶Bristol-Myers Squibb, Montreal, QC, Canada, ⁷Bristol-Myers Squibb, Rueil Malmaison, France, ⁸Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK, ⁹Bristol-Myers Squibb, Princeton, NJ, USA, ¹⁰Precision Health Economics, San Francisco, CA, USA
- PCN129 G27 COST EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED MELANOMA PATIENTS IN ENGLAND**
Lee D¹, Amadi A², Sabater J³, Ellis J², Johnson H⁴, Cooper M¹, **Patterson K**¹, Roskell N¹, Meng Y^{1,1}, BresMed Health Solutions, Sheffield, UK, ²Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK, ³Bristol-Myers Squibb, Princeton, NJ, USA, ⁴Helen Johnson Consulting Ltd, Welwyn Garden City, UK
- PCN130 G28 COST-EFFECTIVENESS OF SONIDEGB VERSUS VISMODEGIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED BASAL CELL CARCINOMA NOT AMENABLE TO SURGERY OR RADIOTHERAPY**
Purser M¹, Mladi D¹, Kaye JA^{2,1}, RTI Health Solutions, Research Triangle Park, NC, USA, ²RTI Health Solutions, Waltham, MA, USA
- PCN131 G29 PHARMACOECONOMIC ANALYSIS OF PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS DOXORUBICIN IN PATIENTS WITH METASTATIC BREAST CANCER AT HIGH RISK OF CARDIAC EVENTS**
Krysanov I¹, **Tiapkina M**^{2,1}, Institute of Medical and Social Technologies, Moscow National University of Food Production, Moscow, Russia, ²Sechenov First Moscow State Medical University, Moscow, Russia
- PCN132 G30 ECONOMIC EVALUATION OF EVEROLIMUS AS SECOND-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN GREECE**

Solakidi A¹, Kourlaba G¹, Kontovinis L², Koutsoukos K³, Bournakis E⁴, Boutis A⁵, Syrios J⁶, Tzouvaras A⁷, Michailidi C⁸, Kalogeropoulou M⁸, Maniadakis N⁹,¹EVROSTON LP, Athens, Greece, ²Medical Oncology Department, Oncomedicare, Thessaloniki, Greece, ³Medical Oncology Department, Alexandra Hospital, Athens, Greece, ⁴Oncology Unit, 2nd Department of Surgery, Aretaieion Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ⁵1st Oncology Department, Theagenio Cancer Hospital, Thessaloniki, Greece, ⁶Medical Oncology Department, Hygeia Hospital, Marousi, Greece, ⁷Medical Oncology Department, Hippokrateion Hospital, Athens, Greece, ⁸Novartis (Hellas) S.A.C.I., Athens, Greece, ⁹National School of Public Health, Athens, Greece

PCN133 G31 COST-EFFECTIVENESS OF NIVOLUMAB IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN PORTUGAL

Verleger K¹, Almeida AJ², Verheggen B³, Schoeman O¹, Klijn S³, Doan J⁴, Lees M⁵, Malcolm B⁶,¹Pharmerit International, Berlin, Germany, ²Bristol-Myers Squibb, Paço de Arcos, Portugal, ³Pharmerit International, Rotterdam, The Netherlands, ⁴Bristol-Myers Squibb, Wallingford, CT, USA, ⁵Bristol-Myers Squibb, Princeton, NJ, USA, ⁶Bristol-Myers Squibb, Middlesex, UK

PCN134 G32 ECONOMIC EVALUATION OF OLAPARIB IN PATIENTS WITH BRCA – MUTATED PSROC IN GREECE

Mylonas C¹, Aravantinos G², Bamias A³, Kourlaba G⁴, Maniadakis N¹,¹National School of Public Health, Athens, Greece, ²Agioi Anargyroi Anticancer Hospital of Athens, Athens, Greece, ³University of Athens School of Medicine, Athens, Greece, ⁴Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Civil Partnership, Athens, Greece

PCN135 G33 COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER

Shah S¹, Matthews SE¹, Sarasani S¹, Noel S¹, **Blanchette CM**²,¹University of North Carolina at Charlotte, Charlotte, NC, USA, ²Precision Health Economics, Davidson, NC, USA

PCN136 G34 WORDS (EXCLUDING TĀTLE AND AUTHORS: 300) TITLE: COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB FOR THE TREATMENT OF SECOND-LINE ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

González García P¹, Felip E², Garrido P³, Trigo J⁴, Ortega-Joaquin N⁵, Echave M⁵, Jiménez S¹, Oyagüez I⁶,¹Bristol-Myers Squibb, Madrid, Spain, ²H. Universitario Vall d'Hebron, Barcelona, Spain, ³H. Universitario Ramón y Cajal, Madrid, Spain, ⁴H. Universitario Virgen de la Victoria, Málaga, Spain, ⁵Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, ⁶Pharmacoeconomics & Outcomes Research Iberia, Pozuelo de Alarcón, Spain

PCN137 G35 MODELING TREATMENTS AND OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A CASE STUDY OF DISCRETE EVENT SIMULATION AND THE CHALLENGES FOR A UK NICE EVALUATION

Sorensen S¹, **Hall F**², Reifsnider O¹, Proskorovsky I³, Dearden L⁴, Girod I², Lee J²,¹Evidera, Bethesda, MD, USA, ²Janssen UK, High Wycombe, UK, ³Evidera, Montreal, QC, Canada, ⁴Janssen EMEA HEMAR, High Wycombe, UK

PCN138 G36 MODELLING THE EFFECTIVENESS OF IBRUTINIB VERSUS RITUXIMAB-BASED CHEMOTHERAPY REGIMENS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Critchlow S¹, Lee D¹, Latour A², Wildgust M³, Goldberg J⁴, Rule S⁵, Wang M⁶,¹BresMed Health Solutions, Sheffield, UK, ²Janssen-Cilag Ltd, High Wycombe, UK, ³Janssen Research & Development, LLC, Raritan, NJ, USA, ⁴Janssen Pharmaceutical Research & Development, Raritan, NJ, USA, ⁵Plymouth University School of Medicine and Dentistry, Plymouth, UK, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, USA

PCN139 G37 MONITORING TREATMENT RESPONSE IN METASTATIC COLORECTAL CANCER: ECONOMIC EVALUATION OF CTC-TEST VERSUS CT SCAN

Antón Rodríguez C¹, Abal M², Alonso-Alconada L³, Candamio S⁴, López R³, Martin Saborido C¹,¹Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain, ²Health Research institute of Santiago, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ³Health Research Institute of Santiago, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ⁴Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain

PCN140 G38 COST-EFFECTIVENESS OF USING BRENTUXIMAB VEDOTIN IN PATIENTS WITH RECURRENT HODGKIN LYMPHOMA OR REFRACTORY TO TRANSPLANT

Romero Prada ME¹, Roa Cardenas NC², Vasquez Melo EC², Acero G³, Huerfano LM², de Los Rios de Acevedo M⁴,¹Fundación Salutia, Bogotá, Colombia, ²Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, ³Salutia Foundation, Bogotá, Colombia, ⁴Private office, Bogota, Colombia

PCN141 H1 COST-EFFECTIVENESS OF PAZOPANIB COMPARED TO SUNITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA

Fouad A¹, **Atia A**², Omar Y², Shawky M³, Sakr M³,¹Yale University, New Haven, CT, USA, ²Ministry of Health & Population, Egypt, Cairo, Egypt, ³Cairo University, Cairo, Egypt

PCN142 H2 COST-EFFECTIVENESS ANALYSIS OF ORAL FENTANYL FORMULATIONS FOR BREAKTHROUGH CANCER PAIN TREATMENT

D'Angiolella LS¹, Cortesi PA², Kheiraoui F³, Allegri M⁴, Casale G⁵, Vellucci R⁶, Mantovani LG¹,¹University of Milan Bicocca, Monza, Italy, ²University of Milano-Bicocca, Monza, Italy, ³Catholic University of the Sacred Heart, Rome, Italy, ⁴University of Parma, Parma, Italy, ⁵ANTEA Center, Rome, Italy, ⁶University Hospital of Careggi, Florence, Italy

PCN143 H3 COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA

Khachatryan GR¹, Fedyayev D¹, Avxentyeva M², Dombrovskiy VS¹, ¹The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, ²The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russian Federation

- PCN144 H4 COST-EFFECTIVENESS OF EVEROLIMUS FOR PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS OF THE GASTROINTESTINAL (GI) OR LUNG ORIGIN -A CANADIAN SOCIETAL HEALTH CARE SYSTEM PERSPECTIVE**
Perrin A¹, Chua A¹, Ricci J², Neary M³, **Thabane M**⁴, ¹LASER Analytica, New York, NY, USA, ²Wellmera, Basel, Switzerland, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ⁴Novartis Pharmaceuticals, Dorval, ON, Canada
- PCN145 H5 COST-EFFECTIVENESS OF LONG ACTING GRANULOCYTE COLONY-STIMULATING FACTOR FOR PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA IN BREAST CANCER IN THE RUSSIA**
Krysanov I¹, **Tiapkina M**², ¹Institute of Medical and Social Technologies, Moscow National University of Food Production, Moscow, Russia, ²Sechenov First Moscow State Medical University, Moscow, Russia
- PCN146 H6 UK COST-EFFECTIVENESS ANALYSIS FOR MANAGEMENT OF CMV DISEASE IN PATIENTS POST ALLOGENEIC STEM CELL TRANSPLANTATION WITH A NOVEL ADOPTIVE T CELL THERAPY**
Nuijten MJ¹, Muller H², Kielar C², Peggs K³, ¹A2M, Amsterdam, The Netherlands, ²cell medica, london, UK, ³Senior Lecturer in Stem Cell Transplantation and Immunotherapy, London, UK
- PCN147 H7 IS THE INTEGRATED ELECTRONIC HEALTH RECORD COST-EFFECTIVE FOR A CANCER CONSULTATION? RESULTS FROM THE E-SI (PREPS-SIPS) STUDY**
Pilet C¹, Augusto V¹, Hamana S¹, Durand T², Aloui S³, Doly A⁴, Heudel PE², Chauvenet L³, Perol M², Gonzalez G³, Biron P², **Perrier L**², ¹École Nationale Supérieure des Mines de Saint-Étienne, Saint-Étienne cedex 2, France, ²Cancer Centre Léon Bérard, Lyon Cedex 08, France, ³Centre Hospitalier Sens, Sens, France, ⁴Cancer Centre Jean Perrin, Clermont-Ferrand, France
- PCN148 H8 ECONOMIC EVALUATION OF PERTUZUMAB NEOADJUVANT TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED, INFLAMMATORY, OR EARLY STAGE HER2-POSITIVE BREAST CANCER IN GREECE**
Mylonas C¹, Kourlaba G², Skroumpelos A³, Maniadakis N¹, ¹National School of Public Health, Athens, Greece, ²Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Civil Partnership, Athens, Greece, ³Roche (Hellas) S.A., Athens, Greece
- PCN149 H9 COST-EFFECTIVENESS ANALYSIS OF USING EVEROLIMUS OR AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE FAILED TO USE OF PAZOPANIB OR SUNITINIB IN FIRST-LINE TREATMENT**
Romero Prada ME¹, Roa Cardenas NC², Acero G³, Huerfano LM², Alfonso Quiñones PA³, Celis S⁴, ¹Fundación Salutia, Bogotá, Colombia, ²Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, ³Salutia Foundation, Bogotá, Colombia, ⁴Salutia Foundation, Bogota, Colombia
- PCN150 H10 USE OF REAL WORLD DATA IN IDENTIFYING RELEVANT COMPARATORS IN MEDICO ECONOMIC MODELS AT EU5 LEVEL: A CASE STUDY ON MULTIPLE MYELOMA**
Jubert H, Kolahi C, Karusisi N, Mitrofan L, IMS Health, La Défense, France
- PCN151 H11 COST EFFECTIVENESS ANALYSIS OF NILOTINIB VERSUS IMATINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA FROM THE HEALTH INSURANCE PERSPECTIVE IN EGYPT**
Abourawash aS¹, Eldessouky R², Elsisy gH¹, ¹central administration of pharmaceutical affairs, cairo, Egypt, ²fayoum university, cairo, Egypt
- PCN152 H12 COST-EFFECTIVENESS ANALYSIS OF CANCER RISK REDUCTION STRATEGIES FOR BRCA MUTATION CARRIERS**
Khodorovich OS¹, Solodkiy VA¹, **Derkach EV**², ¹Russian Scientific Center of Roentgenoradiology, Moscow, Russia, ²The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia
- PCN153 H13 COST EFFECTIVENESS OF SUNITINIB VERSUS PAZOPANIB AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN CHILE**
Vargas C¹, Espinoza MA¹, Giglio A², ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Complejo Asistencial Sótero del Río, Santiago, Chile
- PCN154 H14 COST-EFFECTIVENESS ANALYSIS OF LIPEGFILGRASTIM IN PROPHYLAXIS OF FEBRILE NEUTROPENIA IN CANCER PATIENTS**
Ugrekheldze D, Yagudina R, Kulikov A, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- PCN155 H15 COST-EFFECTIVENESS ANALYSIS OF TREATMENT FOR RECURRENT MALIGNANT GLIOMA IN ROMANIA**
Turcu-Stiolica A¹, Artene S¹, Ciurea ME¹, Calina DC¹, Ungureanu L², Dricu A¹, ¹University of Medicine and Pharmacy, Craiova, Romania, ²Craiova University, Craiova, Romania
- PCN156 H16 COST-EFFECTIVENESS ANALYSIS OF AXITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA - CLINICAL DATA VS RWE**
Karbusicka M¹, Losenicky L², Mazan P², Doleckova J¹, Duba J¹, Kolek M¹, ¹OAKS Consulting s.r.o., Prague 9, Czech Republic, ²Pfizer PFE, spol. s r.o., Prague 5, Czech Republic
- PCN157 H17 ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL**
Ribeiro I¹, Lourenço O², Alves C¹, Thuresson P³, Monteiro I⁴, Batel-Marques F¹, ¹AIBILI, Coimbra, Portugal, ²University of Coimbra,

- Coimbra, Portugal, ³F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁴Roche Farmacêutica Química, Lda, Amadora, Portugal
- PCN158 H18 A FIRST COST-EFFECTIVENESS ANALYSIS BASED ON REAL LIFE CLINICAL OUTCOMES OF BEVACIZUMAB+ PACLITAXEL COMPARED TO PACLITAXEL AMONG FRENCH PATIENTS WITH HER2- METASTATIC BREAST CANCER IN FIRST LINE OF TREATMENT**
Petitjean A¹, Roze S¹, Tehard B²,¹HEVA HEOR Sarl, Lyon, France, ²Roche, Boulogne-Billancourt, France
- PCN159 H19 COST-EFFECTIVENESS OF PEMBROLIZUMAB VS. DOCETAXEL FOR TREATMENT OF PREVIOUSLY TREATED PD-L1 POSITIVE ADVANCED NSCLC PATIENTS**
Huang M¹, Lou Y², Pellissier J¹, Burke T³, Liu FX¹, Xu R¹, Velcheti V⁴,¹Merck & Co., Inc., North Wales, PA, USA, ²Mayo Clinic, Jacksonville, FL, USA, ³Merck & Co., Inc., Lebanon, NJ, USA, ⁴Cleveland Clinic, Cleveland, OH, USA
- PCN160 H20 COST-EFFECTIVENESS OF IBRUTINIB IN ADULT PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE NETHERLANDS**
Welten H¹, Ignacio TJ², Verheggen BG²,¹Janssen-Cilag BV, Tilburg, The Netherlands, ²Pharmerit International, Rotterdam, The Netherlands
- PCN161 H21 COST-EFFECTIVENESS OF FIRST-LINE S-1 THERAPY FOR METASTATIC BREAST CANCER PATIENTS COMPARED WITH TAXANES: AN ANALYSIS BASED ON THE RANDOMIZED PHASE III SELECT BC TRIAL**
Shirowa T¹, Fukuda T¹, Shimozuma K², Mouri M³, Hagiwara Y⁴, Kawahara T⁴, Ohsumi S⁵, Hozumi Y⁶, Sagara Y⁷, Ohashi Y⁸, Mukai H⁹,¹National Institute of Public Health, Wako, Japan, ²Ritsumeikan University, Kusatsu, Japan, ³Kanagawa Academy of Science and Technology, Kawasaki, Japan, ⁴The University of Tokyo, Tokyo, Japan, ⁵National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, ⁶University of Tsukuba Hospital, Tsukuba, Japan, ⁷Social medical corporation Hakuaiikai Sagara Hospital, Kagoshima, Japan, ⁸Chuo University, Tokyo, Japan, ⁹National Cancer Center Hospital East, Kashiwa, Japan
- PCN162 H22 ECONOMIC MODELING OF RISK-ADAPTED SCREEN-AND-TREAT STRATEGIES IN WOMEN AT HIGH-RISK FOR BREAST OR OVARIAN CANCER**
Danner M¹, Müller D¹, Schmutzler R¹, Rhiem K¹, Engel C², Stollenwerk B³, Stock S¹, Wassermann K¹,¹University Hospital Cologne, Cologne, Germany, ²The University of Leipzig, 04107 Leipzig, Germany, ³Helmholtz Zentrum München, Neuherberg, Germany
- PCN163 H23 PERSONALIZED MAMMOGRAPHY SCREENING AND SCREENING ADHERENCE - A SIMULATION OF COST-EFFECTIVENESS**
Arnold M¹, Quante A²,¹LMU Munich, Munich, Germany, ²Helmholtz Zentrum München, Neuherberg, Germany
- PCN164 H24 COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB COMPARED TO CETUXIMAB AND PANITUMUMAB IN FIRST-LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER IN FRANCE**
Gherardi A¹, Masia C², Plommet N³,¹HEVA HEOR Sarl, Lyon, France, ²Université Paris Dauphine, Paris, France, ³Roche SAS, Boulogne-Billancourt, France
- PCN165 H25 COST-MINIMIZATION ANALYSIS OF LAPAROSCOPIC AND OPEN SURGERY FOR RECTAL CANCER**
Gehrman J¹, Björholt I², Angenete E¹, Andersson J¹, Bonjer J³, Haglind E¹,¹Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Nordic health economics, Göteborg, Sweden, ³Department of Surgery, VUmc University Medical Centre, Amsterdam 1007 MB, The Netherlands
- PCN166 H26 COST MINIMIZATION ANALYSIS OF BEVACIZUMAB VERSUS CETUXIMAB AND PANITUMUMAB IN THE MANAGEMENT OF COLORECTAL CANCER FROM PATIENT PERSPECTIVE IN EGYPT**
Assal RA¹, Abdelrahman MM¹, Ragab MF¹, Elsisy G²,¹The German University in Cairo, Cairo, Egypt, ²Central Administration for Pharmaceutical Affairs, Cairo, Egypt
- PCN167 H27 COST-MINIMIZATION ANALYSIS OF PANITUMUMAB VS CETUXIMAB AS MONOTHERAPY FOR CHEMO-REFRACTORY PATIENTS WITH WT KRAS MCRC IN MEXICO**
Alva ME¹, Naranjo M², Zamora J¹,¹Amgen, Mexico City, Mexico, ²Amgen Mexico, Mexico City, Mexico
- PCN168 H28 COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL**
dos Santos RF¹, Riveros BS², Nita ME³, Pedro GO⁴,¹Amgen, São Paulo, Brazil, ²UFPR, Paraná, Brazil, ³Hospital Alemão Osvaldo Cruz, São Paulo, Brazil, ⁴EACH USP, São Paulo, Brazil
- PCN169 H29 PHARMACOECONOMIC ASSESSMENT OF PEGASPARGASE VERSUS ASPARAGINASE IN ACUTE LYMPHOCYTIC LEUKEMIA**
Villoro R¹, Aisa F², Domenech M², Sanz-Granda Á³, Pérez I³, Hidalgo A⁴, González-Domínguez A³, Dapena Díaz JL⁵,¹Instituto Max Weber, Madrid, Spain, ²Baxalta, Madrid, Spain, ³Weber Economía y Salud (WEYS), Majadahonda, Spain, ⁴University of Castilla-La Mancha, Toledo, Spain, ⁵Hospital Universitari Vall d'Hebron, Barcelona, Spain
- PCN170 H30 COST MINIMIZATION ANALYSIS OF USING PAZOPANIB IN FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA**
Romero Prada ME¹, Roa Cardenas NC², Acero G³, Huerfano LM², Alfonso Quiñones PA³, Celis S⁴,¹Fundación Salutia, Bogotá, Colombia, ²Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, ³Salutia Foundation, Bogotá, Colombia, ⁴Salutia Foundation, Bogota, Colombia
- PCN171 H31 COST-UTILITY ANALYSIS OF NIVOLUMAB MONOTHERAPY FOR METASTATIC MELANOMA TREATMENT**
Echave M¹, Oyagüez I², Soria A³, de la Cruz-Merino L⁴, Arance A⁵, Carrasco M⁶, **González García P**⁶,¹Pharmacoeconomics &

Outcomes Research Iberia, Madrid, Spain, ²Pharmacoeconomics & Outcomes Research Iberia, Pozuelo de Alarcón, Spain, ³H. Universitario Ramón y Cajal, Madrid, Spain, ⁴H. Virgen Macarena, Sevilla, Spain, ⁵H. Clinic, Barcelona, Spain, ⁶Bristol-Myers Squibb, Madrid, Spain

- PCN172 H32 COST-EFFECTIVENESS ANALYSIS OF GAZYVARO IN ASSOCIATION TO CHLORAMBUCIL FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHEN FULL-DOSE FLUDARABINE IS UNSUITABLE IN FRANCE**
Plommet N, Boissard F, Roche SAS, Boulogne-Billancourt, France
- PCN173 H33 COST-UTILITY ANALYSIS OF NEOADJUVANT PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED, INFLAMMATORY, OR EARLY HER-2 POSITIVE BREAST CANCER**
Ignatyeva V, Khachatryan G, The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russian Federation
- PCN174 H34 COST EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF METASTATIC MELANOMA IN CHILE**
Vargas C, Balmaceda C, Rojas R, Espinoza MA, Pontificia Universidad Catolica de Chile, Santiago, Chile
- PCN175 H35 COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+ BREAST CANCER IN SPAIN**
COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+ BREAST CANCER IN SPAIN
Colomer R¹, Ciruelos E², De la Haba J³, Martín M⁴, **De Salas-Cansado M**⁵, Muñoz-Molina B⁵, Albanell J⁶, ¹Hospital Universitario La Princesa, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁵Roche Farma, Madrid, Spain, ⁶Hospital del Mar, Barcelona, Spain
- PCN176 H36 DEVELOPMENT OF A GLOBAL MODEL FOR THE ECONOMIC EVALUATION OF PERSONALIZED MEDICINE FOR THE TREATMENT OF PROSTATE CANCER**
Piché-Richard V¹, Mathurin K¹, Savoie M², Lachaine J², ¹PeriPharm Inc., Montreal, QC, Canada, ²University of Montreal, Montreal, QC, Canada
- PCN177 H37 DEVELOPMENT OF A GLOBAL MODEL FOR THE ECONOMIC EVALUATION OF PHARMACOGENOMICS TESTS FOR EARLY-STAGE BREAST CANCER TREATMENT**
Martinho Lemay M¹, Mathurin K¹, Savoie M², Lachaine J², ¹PeriPharm Inc., Montreal, QC, Canada, ²University of Montreal, Montreal, QC, Canada
- PCN178 H38 COST-UTILITY ANALYSIS OF EXERCISE FOR THE PREVENTION OF CANCER**
O'Day K¹, Campbell DJ², ¹Xcenda, LLC, Palm Harbor, FL, USA, ²Xcenda, Palm Harbor, FL, USA
- PCN180 I1 COST-UTILITY ANALYSIS OF FIRST-LINE GEFITINIB, ERLOTINIB AND AFATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS**
Holleman MS, Zaim R, Uyl-De Groot CA, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands
- PCN181 I2 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA**
Alhammad A¹, Garrido Lecca S², ¹King Abdulaziz Medical City, Riyadh, Saudi Arabia, ²Bristol-Myers Squibb, Dubai, United Arab Emirates
- PCN182 I3 COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN GASTROINTESTINAL STROMAL TUMOURS IN ENGLAND USING CROSSOVER ADJUSTMENT METHODS**
Pitcher A¹, Grabbi E², Madin-Warburton M¹, Vadgama S¹, ¹IMS Health, London, UK, ²Bayer Pharmaceuticals, Newbury, UK
- PCN183 I4 PRODUCTIVITY LOSS OF CANCER PATIENTS IN JAPAN**
Hamashima C¹, Ikeda S², Fukuda T³, Shiroywa T³, Igarashi A⁴, Goto R⁵, ¹National Cancer Center, Tokyo, Japan, ²International University of Health and Welfare, Ohtawara, Japan, ³National Institute of Public Health, Wako, Japan, ⁴University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, ⁵Keio Business School, Yokohama, Japan
- PCN184 I5 HEALTHCARE COST AND UTILIZATION AMONG U.S. PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS (RRAL).**
Lin HM¹, **Asche CV**², Ren J², Yong C¹, Faller D¹, Seal B¹, ¹Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, ²University of Illinois College of Medicine at Peoria, Peoria, IL, USA
- PCN185 I6 DIRECT COSTS AND HEALTHCARE RESOURCE USE ASSOCIATED WITH ADVANCED NON-SMALL CELL LUNG CANCER MANAGEMENT IN PREVIOUSLY TREATED PATIENTS IN PORTUGAL**
Vargas Lopes F¹, Barata F², Teixeira E³, Almodôvar T⁴, Araújo A⁵, Barroso A⁶, Brito U⁷, Hespagnol V⁸, Soares M⁹, Laires PA¹, ¹Merck Sharp & Dohme, Oeiras, Portugal, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Centro Hospitalar Lisboa Norte, Hospital Pulido Valente, Lisboa, Portugal, ⁴Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal, ⁵Centro Hospitalar do Porto/Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto., Porto, Portugal, ⁶Centro Hospitalar de Vila de Nova de Gaia e Espinho, Vila Nova de Gaia, Portugal, ⁷Centro Hospitalar do Algarve, Faro, Portugal, ⁸Centro Hospitalar S. João/Faculdade de Medicina da Universidade de Porto, Porto, Portugal, ⁹Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal

- PCN186 17 HEALTHCARE RESOURCE USE ALONGSIDE NOVEL TREATMENTS FOR ADVANCED CUTANEOUS MELANOMA IN THE NETHERLANDS**
Leeneman B¹, Franken M¹, Jochems A², Schouwenburg M³, Aarts M⁴, van Akkooi A⁵, van den Berkmortel F⁶, van den Eertwegh A⁷, Groenewegen G⁸, de Groot J⁹, Haanen J⁵, Hospers G¹⁰, Kapiteijn E², Koornstra R¹¹, Kruit W¹², Louwman M¹³, Piersma D¹⁴, van Rijn R¹⁵, ten Tije A¹⁶, Vreugdenhil G¹⁷, Wouters M⁵, van Zeijl M³, van der Hoeven J¹¹, Uyl - de Groot C¹ ¹Erasmus University Rotterdam, Rotterdam, The Netherlands, ²Leiden University Medical Center, Leiden, The Netherlands, ³Dutch Institute for Clinical Auditing, Leiden, The Netherlands, ⁴Maastricht University Medical Center, Maastricht, The Netherlands, ⁵Netherlands Cancer Institute, Amsterdam, The Netherlands, ⁶Zuyderland, Heerlen, The Netherlands, ⁷VU University Medical Center, Amsterdam, The Netherlands, ⁸University Medical Center Utrecht, Utrecht, The Netherlands, ⁹Isala, Zwolle, The Netherlands, ¹⁰University Medical Center Groningen, Groningen, The Netherlands, ¹¹Radboud University Medical Center, Nijmegen, The Netherlands, ¹²Erasmus Medical Center, Rotterdam, The Netherlands, ¹³Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, ¹⁴Medical Spectrum Twente, Enschede, The Netherlands, ¹⁵Medical Center Leeuwarden, Leeuwarden, The Netherlands, ¹⁶Amphia, Breda, The Netherlands, ¹⁷Maxima Medical Center, Eindhoven, The Netherlands
- PCN187 18 RESPONSE TO TARGETED THERAPY AND HEALTHCARE RESOURCE UTILIZATION (HRU): A EUROPEAN RETROSPECTIVE CHART REVIEW STUDY IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER**
Colomer R¹, Hall P², szkuldecka-Debek M³, Bondi R⁴, **Flinois A**⁵, Le Cleach J⁵, ¹Hospital Universitario La Princesa, Madrid, Spain, ²Edinburgh Cancer Research UK Centre, Edinburgh, UK, ³Roche, Warsaw, Poland, ⁴Roche, Basel, Switzerland, ⁵Kantar Health, Paris, France
- PCN188 19 ONCOLOGISTS' VIEWS ON REIMBURSEMENT AND VALUE OF CANCER DRUGS IN BOSNIA AND HERZEGOVINA**
Catic T¹, Pasic A², Eminagic D², ¹ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia, ²University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina
- PCN189 110 IMPACT OF SURGICAL TECHNIQUE ON LENGTH OF STAY AND EARLY OUTCOMES IN BREAST RECONSTRUCTION: A PRELIMINARY ANALYSIS**
Gabriel A¹, Sigalove SR², Griffin L³, Parekh MH⁴, **Macarios D**⁴, Maxwell GP⁵, ¹PeaceHealth Medical Group, Vancouver, WA, USA, ²DuPage Medical Group/ DMG Aesthetics, Glen Ellyn, IL, USA, ³Acelity, San Antonio, TX, USA, ⁴LifeCell, an Acelity company, Bridgewater, NJ, USA, ⁵Loma Linda University Medical Center, Loma Linda, CA, USA
- PCN190 111 CANCER ASSOCIATED MEDICAL SPENDING: US NATIONAL DATA BETWEEN 2000 AND 2013**
Zhuo J¹, Wu E², Dasbach EJ², Pellissier J³, ¹Merck & Co., Inc., North Wales, PA 19454-2505, PA, USA, ²Merck & Co. Inc., North Wales, PA, USA, ³Merck & Co., Inc., North Wales, PA, USA
- PCN191 112 HEALTHCARE RESOURCE UTILISATION IS ASSOCIATED WITH PHASE OF CHRONIC MYELOID LEUKAEMIA (CML): RESULTS OF A CLINICAL EXPERT SURVEY IN ENGLAND AND WALES**
Robson RE¹, Chiroli S², Iannazzo S³, Thornton AC⁴, Tolley K¹, ¹Tolley Health Economics, Buxton, UK, ²Incyte Corporation, Switzerland, Switzerland, ³SIHS SRL, Torino, Italy, ⁴ACT Research Ltd, Swineshead Bridge, UK
- PCN192 113 HEALTHCARE RESOURCE UTILIZATION (HCRU) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): COMPARISON OF EU AND US COHORTS IN THE PREAMBLE STUDY**
Vij R¹, **Zyczynski T**², Daumont M², Popov S³, Davis C², Zagorska A², Goldschmidt H⁴, ¹Washington University School of Medicine, St Louis, MO, USA, ²Bristol-Myers Squibb, Princeton, NJ, USA, ³Parexel, St Petersburg, Russian Federation, ⁴Heidelberg University Hospital, Heidelberg, Germany
- PCN193 114 COSTS OF ADVERSE EVENTS ASSOCIATED WITH CANCER THERAPIES IN NON-SMALL CELL LUNG CANCER IN FRANCE**
Godard C¹, Chouaid C², Angevin E³, Loirat D⁴, Ravonimbola H¹, Clay E⁵, Millier A⁵, ¹MSD France, Courbevoie, France, ²Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, ³IGR, Institut Gustave Roussy, Villejuif, France, ⁴Institut Curie, Paris, France, ⁵Creativ-Ceutical, Paris, France
- PCN194 115 UNDERSTANDING METHODOLOGICAL DIFFERENCES BETWEEN AND THE APPROPRIATE APPLICATION OF ONCOLOGY VALUE FRAMEWORKS IN HEALTHCARE DECISION-MAKING**
McKendrick J¹, Mortaki K², McKendrick J¹, ¹PRMA Consulting, Fleet, UK, ²PRMA Consulting, Maroussi, Greece
-
- CANCER - Patient-Reported Outcomes & Patient Preference Studies**
- PCN195 116 PREDICTORS OF FIRST LINE TREATMENT PERSISTENCE AMONG PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN THE UNITED STATES, WESTERN EUROPE, AND JAPAN**
DiBonaventura M¹, Higginbottom K², Meyers A³, Morimoto Y⁴, Ilacqua J², ¹Ipsos Healthcare, New York, NY, USA, ²Ipsos Healthcare, Mahwah, NJ, USA, ³Ipsos Healthcare, Washington, DC, USA, ⁴Ipsos Healthcare, Tokyo, Japan
- PCN197 118 COST-RELATED MEDICATION NONADHERENCE AMONG ELDERLY MEDICARE CANCER SURVIVORS USING ERYTHROPOIESIS-STIMULATING AGENTS**
Li M, **Lu K**, Cai B, Norris L, Schulz RM, University of South Carolina, Columbia, SC, USA
- PCN198 119 A TRIAL-BASED EUROQOL EQ-5D HEALTH UTILITY ANALYSIS IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC**
Huang M, Pellissier J, Liao J, Merck & Co., Inc., North Wales, PA, USA
- PCN200 120 HEALTH STATE UTILITIES FOR PERSISTENT, RECURRENT OR METASTATIC CERVICAL CANCER IN FRANCE**

Chevalier J¹, **Lambert J**², Floquet A³, Alexandre J⁴, Ghazi Y⁵, Plommet N^{6,1}Mapi, Paris, France, ²Mapi, Lyon, France, ³Institut Bergonié, Bordeaux, France, ⁴Cochin Hospital/Hotel Dieu, AP-HP, Paris Descartes University (University of Paris V), Paris, France, ⁵F. Hoffmann-La Roche, Boulogne-Billancourt, France, ⁶Roche SAS, Boulogne-Billancourt, France

PCN201 I21 MEASUREMENT OF UTILITIES BY TIME TO DEATH RELATED TO ADVANCED NON-SMALL CELL LUNG CANCER IN SOUTH KOREA

Chang C¹, Park S¹, CHOI YR¹, Tan SC², Kang SH³, Back HJ³, Suh D^{1,1}Chung-Ang University, Seoul, South Korea, ²MSD, Singapore, Singapore, ³MSD, Seoul, South Korea

PCN202 I22 COMPARISON OF GERMAN, FRENCH AND POLISH UTILITY WEIGHTS FOR THE EORTC UTILITY INSTRUMENT QLU-C10D

Kemmler G¹, Gamper E², Nerich V³, Norman R⁴, King MT⁵, Holzner B^{1,1}Medical University of Innsbruck, Department of Psychiatry and Psychotherapy, Innsbruck, Austria, ²Medical University of Innsbruck, Innsbruck, Austria, ³Besançon University Hospital, Besançon, France, ⁴Curtin University, Perth, Australia, ⁵University of Sydney, Sydney, Australia

PCN203 I23 A REVIEW OF HEALTH STATE UTILITY VALUES USED IN UK NICE APPRAISALS IN ADVANCED NSCLC

Dansk V¹, Large S¹, Bertranou E¹, Bodnar C², Dyer MT³, Ryan J^{2,1}PAREXEL Access, London, UK, ²AstraZeneca, Cambridge, UK, ³AstraZeneca, Luton, UK

PCN204 I24 IMPACTS OF ADVERSE EVENTS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS RECEIVING FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER: RESULTS FROM RANDOMIZED PHASE III SELECT BC STUDY

Hagiwara Y¹, Shimoizuma K², Shiroiwa T³, Kawahara T¹, Uemura Y⁴, Watanabe T⁵, Taira N⁶, Fukuda T³, Ohashi Y⁷, Mukai H^{8,1}The University of Tokyo, Tokyo, Japan, ²Ritsumeikan University, Kusatsu, Japan, ³National Institute of Public Health, Wako, Japan, ⁴The University of Tokyo Hospital, Tokyo, Japan, ⁵National Hospital Organization Sendai Medical Center, Sendai, Japan, ⁶Okayama University Hospital, Okayama, Japan, ⁷Chuo University, Tokyo, Japan, ⁸National Cancer Center Hospital East, Kashiwa, Japan

PCN205 I25 COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AND ITS ASSOCIATION WITH QUALITY OF LIFE AMONG CANCER PATIENTS RECEIVING CHEMOTHERAPY IN ETHIOPIA: A CROSS SECTIONAL STUDY

Erku DA, Mekuria Ab, Belachew SA, University of Gondar, Gondar, Ethiopia

PCN206 I26 PATIENT PERSPECTIVES ON MERKEL CELL CARCINOMA (MCC) AND ITS TREATMENT WITH A NOVEL AGENT (AVELUMAB): FINDINGS FROM IN-DEPTH QUALITATIVE PATIENT INTERVIEWS

Kaufman H¹, Kraemer M², Dias Barbosa C³, Lambert J³, Mahnke L⁴, **Bharmal M**^{2,1}Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA, ²Merck KGaA, Darmstadt, Germany, ³Mapi Group, Lyon, France, ⁴EMD Serono, Billerica, Boston, MA, USA

PCN207 I27 INFORMAL CARE AND PRODUCTIVITY LOSSES ARE IMPORTANT IN ADVANCED CUTANEOUS MELANOMA: RESULTS OF THE DUTCH MELANOMA TREATMENT REGISTRY

Franken M¹, **Leeneman B**¹, Jochems A², Schouwenburg M², Aarts M³, van Akkooi A⁴, van den Berkmoortel F⁵, van den Eertwegh A⁶, Groenewegen G⁷, de Groot J⁸, Haanen J⁴, Hospers G⁹, Kapiteijn H¹⁰, Koornstra R¹¹, Kruit W¹², Louwman M¹³, Piersma D¹⁴, van Rijn R¹⁵, ten Tije A¹⁶, Vreugdenhil G¹⁷, Wouters M⁴, van Zeijl M², van der Hoeven J¹, Uyl-de Groot C^{18,1}Erasmus University Rotterdam, Rotterdam, The Netherlands, ²Dutch Institute for Clinical Auditing, Leiden, The Netherlands, ³Maastricht University Medical Center, Maastricht, The Netherlands, ⁴Netherlands Cancer Institute, Amsterdam, The Netherlands, ⁵Zuyderland Hospital, Heerlen, The Netherlands, ⁶VU University Medical Center, Amsterdam, The Netherlands, ⁷University Medical Center Utrecht, Utrecht, The Netherlands, ⁸Isala Hospital, Zwolle, The Netherlands, ⁹University Medical Center Groningen, Groningen, The Netherlands, ¹⁰Leiden University Medical Center, Leiden, The Netherlands, ¹¹Radboud University Medical Center, Nijmegen, The Netherlands, ¹²Erasmus Medical Center, Rotterdam, The Netherlands, ¹³Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, ¹⁴Medical Spectrum Twente, Enschede, The Netherlands, ¹⁵Medical Center Leeuwarden, Leeuwarden, The Netherlands, ¹⁶Amphia Hospital, Breda, The Netherlands, ¹⁷Maxima Medical Center, Eindhoven, The Netherlands, ¹⁸Erasmus University, Rotterdam, The Netherlands

PCN208 I28 ELICITING INDIVIDUAL PATIENT PREFERENCES ON THE BENEFITS AND RISKS OF CANCER TREATMENTS: RESULTS FROM A SURVEY CONDUCTED IN MYELOMA PATIENTS

Postmus D¹, Richard S², Bere N³, Hillege JL¹, Low E², Pignatti F^{3,1}University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ²Myeloma UK, Edinburgh, UK, ³European Medicines Agency, London, UK

PCN209 I29 TRADING-OFF QUALITY OF LIFE AND SURVIVAL TIME – FEASIBILITY OF WEB-BASED DISCRETE CHOICE EXPERIMENTS FOR QLU-C10D UTILITY ELICITATION IN CANCER PATIENTS

Gamper E¹, Holzner B¹, King MT², Norman R³, Kemmler G^{4,1}Medical University of Innsbruck, Innsbruck, Austria, ²University of Sydney, Sydney, Australia, ³Curtin University, Perth, Australia, ⁴Medical University of Innsbruck, Department of Psychiatry and Psychotherapy, Innsbruck, Austria

PCN210 I30 PSYCHOMETRIC EVALUATION OF CLINICAL OUTCOMES ASSESSMENTS IN A PHASE II TRIAL

Huang VW¹, Banderas B², Sen R^{2,1}Novartis, East Hanover, NJ, USA, ²Adelphi Values USA, Boston, MA, USA

PCN211 I31 ASSESSMENT OF KNOWLEDGE AND PERCEPTION REGARDING BREAST CANCER AMONG PATIENTS ATTENDING GYNECOLOGICAL DEPARTMENT OF TERTIARY CARE HOSPITAL IN QUETTA PAKISTAN

Nasim A, **Haq N**, Jameel L, Riaz S, University of Balochistan, Quetta, Pakistan

PCN212 I32 TREATMENT OF UPPER-EXTREMITY SARCOMA WITH LIMB-SALVAGE PROCEDURES SHOWED GOOD FUNCTIONAL OUTCOMES: A PILOT STUDY OF 13 CONSECUTIVE PATIENTS

Repo JP, Barner-Rasmussen I, Kask G, Blomqvist C, Tukiainen EJ, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

PCN213 I33 DEVELOPING A SMALL CELL LUNG CANCER CONCEPTUAL MODEL TO INFORM TREATMENT OUTCOME AND ASSESSMENT STRATEGY DECISIONS IN CLINICAL RESEARCH

Ojo O¹, **Shields A**¹, Morrissey L¹, Love E¹, Ollis S¹, Halling K², Rudell K³,¹Adelphi Values, Boston, MA, USA, ²Astra Zeneca, Molndal, Sweden, ³AZ, Melbourne, UK

PCN214 I34 QUALITY OF LIFE IN ADVANCED CUTANEOUS MELANOMA: RESULTS OF THE DUTCH MELANOMA TREATMENT REGISTRY

Franken M¹, **Leeneman B**¹, Schouwenburg M², Jochems A², Aarts M³, van Akkooi A⁴, van den Berkmoortel F⁵, van den Eertwegh A⁶, Groenewegen G⁷, de Groot J⁸, Haanen J⁴, Hospers G⁹, Kapiteijn H¹⁰, Koornstra R¹¹, Kruit W¹², Louwman M¹³, Piersma D¹⁴, van Rijn R¹⁵, ten Tije A¹⁶, Vreugdenhil G¹⁷, Wouters M⁴, van Zeijl M², van der Hoeven J¹, Uyl-de Groot C¹⁸,¹Erasmus University Rotterdam, Rotterdam, The Netherlands, ²Dutch Institute for Clinical Auditing, Leiden, The Netherlands, ³Maastricht University Medical Center, Maastricht, The Netherlands, ⁴Netherlands Cancer Institute, Amsterdam, The Netherlands, ⁵Zuyderland Hospital, Heerlen, The Netherlands, ⁶VU University Medical Center, Amsterdam, The Netherlands, ⁷University Medical Center Utrecht, Utrecht, The Netherlands, ⁸Isala Hospital, Zwolle, The Netherlands, ⁹University Medical Center Groningen, Groningen, The Netherlands, ¹⁰Leiden University Medical Center, Leiden, The Netherlands, ¹¹Radboud University Medical Center, Nijmegen, The Netherlands, ¹²Erasmus Medical Center, Rotterdam, The Netherlands, ¹³Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, ¹⁴Medical Spectrum Twente, Enschede, The Netherlands, ¹⁵Medical Center Leeuwarden, Leeuwarden, The Netherlands, ¹⁶Amphia Hospital, Breda, The Netherlands, ¹⁷Maxima Medical Center, Eindhoven, The Netherlands, ¹⁸Erasmus University, Rotterdam, The Netherlands

PCN215 I35 EVALUATION OF THE COMPARABILITY OF SCORES FROM CAT AND SHORT-FORM

Lai J, Beaumont JL, Northwestern University, Chicago, IL, USA

PCN216 I36 A NEW ORGANIZATIONAL INTEGRATED HOME-CARE MODEL: AN ITALIAN PILOT STUDY

Palla I¹, Lorenzoni V¹, D'Isidoro C², Manetti S¹, Porcelli F², Turchetti G¹,¹Scuola Superiore Sant'Anna, Pisa, Italy, ²University Hospital of Pisa, Pisa, Italy

PCN217 I37 THRESHOLDS FOR CLINICAL IMPORTANCE IN EORTC-QLQ-C30: APPLICATION IN A SAMPLE OF COLORECTAL CANCER PATIENTS

Escobar A¹, Trancho Z¹, Bilbao A¹, Quintana JM², Gonzalez Saenz de Tejada M¹, Sarasqueta C³,¹Basurto University Hospital (Osakidetza) - REDISSEC, Bilbao, Spain, ²Hospital de Galdakao-Usansolo. REDISSEC, Galdakao, Spain, ³Hospital Universitario Donostia. REDISSEC, San Sebastian, Spain

PCN218 J1 HEALTH RELATED QUALITY OF LIFE SCORES IN BREAST CANCER SURVIVOR WOMEN WITH AND WITHOUT BREAST RECONSTRUCTION SURGERY

Balderas-Peña L¹, Sat-Muñoz D², Contreras-Contreras S¹, Novoa-Martínez A³, Saucedo-Ortiz J¹, Bañuelos-Rizo M², Martínez-Herrera B¹, Ortiz-González F⁴, Cruz-Corona E¹,¹UMAE Hospital de Especialidades Centro Médico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico, ²Universidad de Guadalajara. Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, ³Universidad de Guadalajara. Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, ⁴Unidad Médica de Alta Especialidad Hospital de Especialidades. Centro Médico Nacional de Occidente, Guadalajara, Jalisco, Mexico

PCN219 J2 THE SOCIETAL AND HUMANISTIC BURDEN OF SMALL CELL LUNG CANCER (SCLC): A SYSTEMATIC REVIEW OF SOCIETAL IMPACT AND HEALTH-RELATED QUALITY OF LIFE (HRQL) LITERATURE

Enstone A¹, Panter C¹, Greaney MH¹, Bennett B¹, Penrod JR², Yuan Y²,¹Adelphi Values Ltd, Bollington, UK, ²Bristol-Myers Squibb, Princeton, NJ, USA

PCN220 J3 "CAUSAL CASCADE" AMONG OUTCOMES IN NON-SMALL CELL LUNG CANCER: ASSESSING THE DIRECT AND INDIRECT EFFECTS OF SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE (HRQL) OUTCOMES

Stull DE¹, Houghton K¹, Ainsworth C², Brown J³, Bowman L⁴, Boye ME⁵,¹RTI Health Solutions, Durham, NC, USA, ²RTI Health Solutions, MANCHESTER, UK, ³Eli Lilly & Company, Surrey, UK, ⁴Eli Lilly, Indianapolis, IN, USA, ⁵Eli Lilly and Company, Indianapolis, IN, USA

PCN221 J4 THE EFFECT OF NECITUMUMAB IN COMBINATION WITH GEMCITABINE-CISPLATIN ON HEALTH-RELATED QUALITY OF LIFE (HRQL) AND TOLERABILITY: SQUIRE TRIAL PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-EXPRESSING SQUAMOUS NSCLC TUMOURS

Reck M¹, Socinski M², Luft A³, Szczesna A⁴, Dediu M⁵, Ramlau R⁶, Losonczy G⁷, Molinier O⁸, Schumann C⁹, **Brown J**¹⁰, Soldatenkova V¹¹, Chouaki N¹², Thatcher N¹³,¹Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany, ²UPMC Cancer Pavilion, Pittsburgh, PA, USA, ³Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation, ⁴Mazowieckie Centrum Leczenia Chorób Pluc, Otwock, Poland, ⁵Institute of Oncology "Alexandru Trestioreanu", Bucharest, Romania, ⁶Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland, ⁷Semmelweis University Department of Pulmonology, Budapest, Hungary, ⁸Centre Hospitalier Le Mans, Le Mans, France, ⁹Clinic for Pulmonology, Thoracic Oncology, Sleep- and Respiratory Critical Care, Hospitals of Kempten-Oberallgaeu, Immenstadt im Allgäu, Germany, ¹⁰Eli Lilly and Company Limited, Windlesham, UK, ¹¹Eli Lilly and Company, Bad Homburg, Germany, ¹²Eli Lilly and Company, Paris, France, ¹³The Christie Hospital, Manchester, UK

PCN222 J5 PATIENT REPORTED HEALTH UTILITY IN HR+/HER2- ADVANCED/METASTATIC BREAST CANCER

- PCN223 J6** **Mitra D¹**, Wood R², De Courcy J², Iyer S^{1,1},Pfizer, Inc., New York, NY, USA, ²Adelphi Real World, Bollington, UK
QUALITY OF LIFE IN PATIENTS WITH COLORECTAL CANCER IN SLOVAK REPUBLIC
Poliakova N, **Bielik J**, Hrdá M, Trencin University, Trencin, Slovak Republic
- PCN224 J7** **SOCIAL MEDIA: A VALUABLE TOOL TO ASSESS PATIENT PERSPECTIVES REGARDING QUALITY OF LIFE**
Kalf R¹, Makady A², Ryll B³, Spurrier G⁴, Goetsch W^{5,1}, National Healthcare Institute (ZIN), Diemen, The Netherlands, ²The National Healthcare Institute (ZIN), Diemen, The Netherlands, ³Melanoma Patient Network Europe, and Uppsala University (Department EBC), Uppsala, Sweden, ⁴Melanoma France, and Melanoma Patient Network Europe, Uppsala, Sweden, ⁵National Health Care Institute, Diemen, The Netherlands
- PCN225 J8** **NATIONWIDE SURVEY ON THE OPINIONS OF CANCER PATIENTS AND PERSONNEL ON COST OF METASTATIC COLORECTAL CANCER TREATMENT**
Sailas L¹, Kuoppala J², Kataja V^{3,1}, North Karelia Health Care District, Joensuu, Finland, ²FIMEA, Kuopio, Finland, ³Central Finland Health Care District, Jyväskylä, Finland
- PCN226 J9** **WORK PRODUCTIVITY ACTIVITY IMPAIRMENT LOSS OF PATIENTS WITH HER2 METASTATIC BREAST CANCER**
Bryden P¹, Paracha N¹, Thuresson P^{2,1}, F. Hoffman-La Roche, Basel, Switzerland, ²F. Hoffmann-La Roche Ltd., Basel, Switzerland

CANCER - Health Care Use & Policy Studies

- PCN227 J10** **FACTORS INFLUENCING ATTITUDES TO COLORECTAL CANCER SCREENING**
Gede N¹, Horváthné Kívés Z¹, Vajda R¹, Pakai A², **Boncz I¹**, Gyuró M¹, Kiss I^{1,1}, University of Pécs, Pécs, Hungary, ²University of Pécs, Zalaegerszeg, Hungary
- PCN228 J11** **LEVEL OF INFORMEDNESS ABOUT COLORECTAL CANCER SCREENING AMONG LAY PERSONS**
Gede N¹, Horváthné Kívés Z¹, Vajda R¹, Pakai A², **Boncz I¹**, Gyuró M¹, Kiss I^{1,1}, University of Pécs, Pécs, Hungary, ²University of Pécs, Zalaegerszeg, Hungary
- PCN229 J12** **MISSED OPPORTUNITIES IN THE NETHERLANDS: THE NEGLIGENCE OF NON-STATISTICAL UNCERTAINTY IN CED POLICY**
Pouwels XG¹, Grutters JP², Bindels JA¹, Ramaekers BL¹, Joore MA^{3,1}, Maastricht University Medical Center+, Maastricht, The Netherlands, ²Radboud university medical center, Nijmegen, The Netherlands, ³Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands
- PCN230 J13** **INNOVATIVE CONTRACTING: EVOLVING USE OF WEB-BASED MANAGED ENTRY AGREEMENTS IN ITALY**
Privolnev Y, Decision Resources Group, Toronto, ON, Canada
- PCN231 J14** **COMPARATIVE ANALYSIS OF CLINICAL TRIAL ATTRIBUTES IN PIVOTAL STUDIES FOR ORPHAN VS. NON-ORPHAN ONCOLOGY PRODUCTS FDA-APPROVED BETWEEN 2011 AND 2015**
Ansari W, Infante K, GfK, New York, NY, USA
- PCN232 J15** **CASTRATION-RESISTANT PROSTATE CANCER (CRPC): EVALUATION OF THE QUALITY OF CARE AND DISEASE MANAGEMENT IN REAL-LIFE SETTING**
Lahcene H¹, Aprikian A², Vanhuysse M², Hu J², Cury F², Kassouf W², Prevost N², Perreault S³, **Dragomir A^{2,1}**, Université de Montréal, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Université de Montréal, Montreal, QC, Canada
- PCN233 J16** **DESCRIPTION OF FIRST-LINE TREATMENTS IN PATIENTS WITH NON-RESECTABLE COLORECTAL CANCERS IN BELGIUM**
Chevalier P, van Gils C, Lamotte M, IMS Health, Zaventem, Belgium
- PCN234 J17** **REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA RECEIVING SYSTEMIC THERAPY IN THE UNITED KINGDOM**
Mytelka DS¹, Lorenzo M², Stafkey-Mailey D³, D'yachkova Y⁴, Nagar SP⁵, Candrilli SD⁵, Kaye JA^{6,1}, Eli Lilly, Indianapolis, IN, USA, ²Eli Lilly and Company Limited, Windlesham, UK, ³Xcenda, LLC, Palm Harbor, FL, USA, ⁴Eli Lilly Austria GmbH, Vienna, Austria, ⁵RTI Health Solutions, Research Triangle Park, NC, USA, ⁶RTI Health Solutions, Waltham, MA, USA
- PCN235 J18** **REAL-WORLD EVIDENCE ON HEALTHCARE RESOURCE USE AND ASSOCIATED COST WITH MULTIPLE MYELOMA IN THE NETHERLANDS**
Blommestein HM¹, Verelst SG², Zagorska A³, **Stevanovic J⁴**, Engstrom A⁵, Sonneveld P², Huijgens PC⁶, Lefevre C³, Uyl-De Groot CA^{7,1}, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam; The Comprehensive Cancer Centers, Utrecht; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands, ²Erasmus University Medical Center, Rotterdam, The Netherlands, ³Bristol-Myers Squibb, Rueil-Malmaison, France, ⁴Bristol-Myers Squibb, Utrecht, The Netherlands, ⁵Bristol-Myers Squibb, Solna, Sweden, ⁶The Comprehensive Cancer Centers The Netherlands (IKNL), Amsterdam, The Netherlands, ⁷Institute for Medical Technology Assessment, Erasmus University Rotterdam; The Comprehensive Cancer Centers, Utrecht, Rotterdam, The Netherlands
- PCN236 J19** **INNOVATIVE THERAPIES FOR THE TREATMENT OF CANCER: AN OVERVIEW OF LATE-PHASE CLINICAL DEVELOPMENT**
Resemann H¹, Morten P¹, Chainani N², **Griffiths M^{3,1}**, Costello Medical Consulting Ltd., Cambridge, UK, ²Costello Medical Singapore Pte Ltd, Singapore, Singapore, ³Costello Medical Consulting Ltd, Cambridge, UK

- PCN237 J20 REVIEW OF MULTICRITERIA DECISION ANALYSIS APPLICATION FOR DECISION-MAKING IN ONCOLOGY**
Dombrovskiy VS¹, Omelyanovskiy V²,¹The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, ²Center for Health Technology Assessment, Russian Presidential Academy of National Economy and Public Administration, Center of Comprehensive Health Technology Assessment, Ministry of Health of the Russian Federation, Moscow, Russia
- PCN238 J21 CHANGES OF THE REIMBURSEMENT RECOMMENDATIONS FOCUSED ON ONCOLOGY DRUGS BEFORE AND AFTER THE IMPLEMENTATION OF THE 2013 BENEFIT ENHANCEMENT POLICY IN KOREA**
Hwang EJ, Jang S, So S, Health Insurance Review and Assessment Service in Korea, Seoul, South Korea
- PCN239 J22 WHICH TYPES OF ECONOMIC EVALUATIONS ARE CONSIDERED BY HEALTH TECHNOLOGY ASSESSMENT AGENCIES?**
Puig-Peiró R¹, **Roset M**², Gilabert Perramon A¹, Viayna E², Prat A¹, Gómez-Navarro V²,¹Catalan Health Service (CatSalut), Barcelona, Spain, ²IMS Health, Barcelona, Spain
- PCN240 J23 ASSESSMENT OF DECISIONS AND COST-EFFECTIVENESS CRITERIA CONSIDERED BY SEVEN HEALTH TECHNOLOGY ASSESSMENT AGENCIES**
Puig-Peiró R¹, Planellas L², Gilabert Perramon A¹, **Roset M**², Barrull C², Prat A¹, Solozabal M²,¹Catalan Health Service (CatSalut), Barcelona, Spain, ²IMS Health, Barcelona, Spain
- PCN241 J24 IMPLICATIONS OF TOTAL BUDGET IMPACT ON ONCOLOGY DRUG PRICING IN THE US AND EU5**
Xue Y, Degun R, **Montilva J**, Navigant Consulting, London, UK
- PCN242 J25 PATIENT INDIVIDUAL THERAPY AS APPROPRIATE COMPARATOR IN AMNOG-DOSSIERS IN THE FIELD OF ONCOLOGY: STATUS QUO AND STRATEGIC IMPLICATIONS FOR PHARMACEUTICAL COMPANIES**
Templin C, Italia N, Damen D, Kulp W, Xcenda GmbH, Hannover, Germany
- PCN243 J26 REAL WORLD DATA: USE OF NOVEL TREATMENTS AND BIOMARKERS IN MALIGNANT MELANOMA IN EUROPEAN COUNTRIES**
von Bredow D¹, Kolb N¹, Bernhardt M², Schmidt N²,¹IMS Health GmbH & Co OHG, Munich, Germany, ²IMS Health GmbH & Co OHG, Frankfurt, Germany
- PCN244 J27 PAIN MANAGEMENT OF LUNG CANCER PATIENT IN HUNGARY**
Kocsis T¹, Lieb T², Horváth I³,¹National Institute of Pharmacy and Nutrition, Budapest, Hungary, ²National Healthcare Service, Budapest, Hungary, ³Koranyi National Institute for Tuberculosis and Pulmonology, Budapest, Hungary
- PCN245 J28 TO WHAT EXTENT ARE THE LEARNINGS FROM THE INTRODUCTION OF BIOSIMILARS IN INFLAMMATORY DISEASES TRANSFERABLE TO THE FUTURE INTRODUCTION OF BIOSIMILARS IN ONCOLOGY?**
Klebba S¹, Makin D¹, Teale CW²,¹GfK, London, UK, ²GfK, Melton Mowbray, UK
- PCN246 J29 TBO-FILGRASTIM PATTERNS OF CARE BY TREATMENT SITE AND SETTING IN THE UNITED STATES, 2014 AND 2015**
Smoyer KE¹, Radtchenko J², Garofalo D², **Jones CA**³, Lane PB⁴, Feinberg B²,¹Envision Pharma Group, Philadelphia, PA, USA, ²Cardinal Health, Dublin, OH, USA, ³Envision Pharma Group, London, UK, ⁴Envision Pharma Group, Horsham, UK
- PCN247 J30 IS UTILIZATION OF ADJUVANT ENDOCRINE THERAPY AFFECTED MAINLY BY PATIENT DRUG COSTS? AN ANALYSIS OF TWO DATABASES**
Balkrishnan R¹, Tan X², Camacho F¹, Bhosle M¹, Anderson RT¹,¹University of Virginia School of Medicine, Charlottesville, VA, USA, ²West Virginia University, School of Pharmacy, Morgantown, WV, USA
- PCN248 J31 IMPACT OF PATIENT RACE AND GEOGRAPHY ON ACCESS AND USE OF ADJUVANT ENDOCRINE THERAPY IN MEDICARE BREAST CANCER SURVIVORS**
Balkrishnan R¹, Tan X², Camacho F¹, Bhosle M¹, Anderson RT¹,¹University of Virginia School of Medicine, Charlottesville, VA, USA, ²West Virginia University, School of Pharmacy, Morgantown, WV, USA
- PCN249 J32 GENERIC DRUG VOLUME AND COST SAVINGS IN ONCOLOGY: A 2005-2014 MIDAS ANALYSIS**
Divino V¹, Coyle K¹, Kleinrock M², Wade RL³, DeKoven M¹, Kaura S⁴,¹IMS Health, Fairfax, VA, USA, ²IMS Institute for Healthcare Informatics, Plymouth Meeting, PA, USA, ³IMS Health, Plymouth Meeting, PA, USA, ⁴Celgene Corporation, Summit, NJ, USA
- PCN250 J33 ASSESSMENT OF CLINICAL VALUE IN ONCOLOGY: COMPARATIVE ANALYSIS OF VALUE FRAMEWORKS AND HTAS**
Niven C¹, Hough NM², Zhou AY¹, Qin L³, Alexander R²,¹IMS Consulting Group, Cambridge, UK, ²IMS Consulting Group, London, UK, ³IMS Consulting Group, Munich, Germany
- PCN251 J34 ANALYSIS OF PHARMACY CLAIMS FOR HIGH COST ONCOLOGY PRODUCTS: ABIRATERONE AND ENZALUTAMIDE USAGE IN MCRPC IN IRELAND**
Spillane S, McCullagh LM, Barry M, Usher C, National Centre for Pharmacoeconomics, Dublin, Ireland
- PCN252 J35 REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH OVARIAN CANCER: AN ANALYSIS OF A LARGE US ELECTRONIC HEALTH RECORDS DATABASE**
Karve S¹, Walker G², Wang R³, Lawrence D⁴, Horsfield A⁴,¹AstraZeneca, Gaithersburg, MD, USA, ²AstraZeneca (former employee), Cambridge, UK, ³Evidera, Lexington, MA, USA, ⁴AstraZeneca, Cambridge, UK
- PCN253 J36 REFINING THE PATH TO PERSONALIZED MEDICINE WITH PSYCHOMETRIC ANALYSIS OF ORAL CANCER**

BIOMARKERS

Menke JM, A. T. Still Research Institute, Mesa, AZ, USA

- PCN254 J37 THE DECLINING VALUE OF ECONOMICS IN CANADIAN CANCER REIMBURSEMENT REVIEWS**
Siu EC, Mills F, Wyatt Health Management, Oakville, ON, Canada
- PCN255 K1 SURVIVAL AND RESOURCE USE IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN - A RETROSPECTIVE ANALYSIS OF DATA FROM NATIONAL REGISTRIES**
Redig J¹, Åkerborg Ö², Sandin R³, Jakobsson M³, Mapi Group, Stockholm, Sweden, ²Mapi Sweden AB, Stockholm, Sweden, ³Pfizer AB, Stockholm, Sweden
- PCN256 K2 HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES**
Mhatre S¹, Lin S¹, Surinach A², Vohra R¹, Satram-Hoang S¹, Simpson J¹, Wallen H¹, Ogale S¹, Gong J³, Pal SK³, George DJ⁴, ¹Genentech, Inc., South San Francisco, CA, USA, ²Genesis Research, LLC, Hoboken, NJ, USA, ³City of Hope Comprehensive Cancer Center, Duarte, CA, USA, ⁴Duke University Hospital, Durham, NC, USA
- PCN257 K3 RESOURCE USE AND ASSOCIATED COSTS FOR METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ NSCLC) PATIENTS: A RETROSPECTIVE CHART REVIEW IN SELECT EUROPEAN COUNTRIES**
Lorenzo M¹, Brown J¹, Kurosky S², Ajmera MR², Kaye JA³, ¹Eli Lilly and Company Limited, Windlesham, UK, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³RTI Health Solutions, Waltham, MA, USA
- PCN258 K4 HEALTHCARE RESOURCE UTILIZATION IN PATIENTS RECEIVING PEMBROLIZUMAB OR DOCETAXEL WITH PREVIOUSLY TREATED ADVANCED NSCLC**
Huang M, Pellissier J, Liao J, Merck & Co., Inc., North Wales, PA, USA
- PCN259 K5 LANDSCAPE OF ADVANCED NSCLC: THE IMPACT OF UPCOMING THERAPIES**
Soares M¹, Bento MJ¹, Rocha-Gonçalves FN¹, Sousa J², Rigor H², ¹IPO Porto, Porto, Portugal, ²IMS Health, Porto Salvo, Portugal
- PCN260 K6 A HEALTH POLICY STUDY MEASURING THE GAP ANALYSIS BETWEEN THE MANAGEMENT OF METASTATIC CONDITIONS AND OTHER DISEASES UNDER THE EGYPTIAN HEALTHCARE INSURANCE SYSTEM**
Abaza S¹, Abbas YM², Fawzy A³, Sallam R³, Abdelbaky A³, Anan I³, ¹Hoffman La Roche, Egypt, New Cairo, Egypt, ²Brandeis University, Waltham, MA, USA, ³Accsight, Cairo, Egypt
- PCN261 K7 BURDEN OF EARLY AND ADVANCED BREAST CANCER IN THE NETHERLANDS**
Vondeling GT¹, Rozenbaum MH², Dvortsin EP¹, Postma MJ³, Zeevat F¹, ¹University of Groningen, Groningen, The Netherlands, ²Pfizer NL, Capelle aan den IJssel, The Netherlands, ³University Medical Center Groningen, Groningen, The Netherlands
- PCN262 K8 A RETROSPECTIVE STUDY OF HEALTHCARE COSTS IN PATIENTS WITH END STAGE LUNG CANCER DURING THE LAST SIX MONTHS OF THEIR LIFE**
Kamboukou A¹, Prinou A¹, Kani C², Souliotis K², Marioli N³, Syrigos K³, Markantonis S¹, ¹National and Kapodistrian University of Athens, Athens, Greece, ²University of Peloponnese, Corinth, Greece, ³Athens Medical School, Sotiria General Hospital, Athens, Greece
- PCN263 K9 ROLE OF CLINICAL PHARMACIST IN OPTIMIZING REIMBURSEMENT ORIGINATING FROM PERFORMANCE-BASED RISK-SHARING ARRANGEMENTS: THE EXPERIENCE OF THE UNIVERSITY HOSPITAL "G. MARTINO" FROM MESSINA, ITALY**
Polimeni G¹, Isgrò V¹, Aiello A², D'Ausilio A², D'Addetta G¹, Cuzzocrea S³, Caputi AP³, Toumi M⁴, ¹University Hospital "G. Martino", University of Messina, Messina, Italy, ²Creativ Ceutical, Milano, Italy, ³University of Messina, Messina, Italy, ⁴Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille, France
- PCN264 K10 THE BURDEN OF SELECTED CANCERS IN THE UNITED STATES: HEALTH BEHAVIORS AND HEALTHCARE UTILIZATION OF SURVIVORS**
Iadaluca L, Whiteley J, Hopps M, Mardekian J, Makinson G, Pfizer Inc, New York, NY, USA
- PCN265 K11 TIMELINE OF AUTHORIZATION AND REIMBURSEMENT FOR ONCOLOGICAL DRUGS IN ITALY: AN INTEGRATED ANALYSIS, ACROSS LEGISLATION'S LEVERAGE**
Prada M, Sansone C, Bertozzi C, Mantovani M, Intexo, Roma, Italy
- PCN266 K12 MANAGEMENT OF METASTATIC COLORECTAL CANCER PATIENTS: A METHODOLOGICAL APPROACH TO IDENTIFY TREATMENT LINES**
Phelip J¹, Porte F², Setton M³, Le Lay K³, Le Calvez K², Bénard S², ¹Centre Hospitalier Universitaire of Saint-Etienne, Saint-Priest en Jarez, France, ²st[è]ve consultants, Oullins, France, ³Boehringer Ingelheim France, Paris, France
- PCN267 K13 COMPARATIVE EFFECTIVENESS ANALYSIS ON HEPATIC CARCINOMA PATIENTS WITH HEPATITIS C**
Chang C¹, Tang C², Tsai HY³, Yu M⁴, ¹Taipei Medical University, Taipei, Taiwan, ²School of Health Care Administration, Taipei Medical University, Taipei, Taiwan, ³Harvester Trading Co., Ltd., Taipei, Taiwan, ⁴Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Taipei, Taiwan
- PCN268 K14 HOW IS RADIOTHERAPY REIMBURSED ACROSS EUROPE? RESULTS OF THE HEALTH ECONOMICS IN RADIATION ONCOLOGY'S SURVEY**

Defourny N¹, Borrás Andres JM², Grau C³, Lievens Y⁴,¹European Society for Radiation Oncology, Brussels, Belgium, ²The Catalan Institute of Oncology, Barcelona, Spain, ³Aarhus University, Aarhus, Denmark, ⁴Ghent university, Ghent, Belgium

PCN269 K15 THE CANCER DRUGS FUND: THE EVOLVING ASSESSMENT PROCESS

Carroll MV¹, **Satherley A**¹, Miller PS²,¹Evidera, London, UK, ²Miller Economic Ltd, Alderley Edge, UK

PCN270 K16 MOVEMENT OF DRUGS FOR CANCER THROUGH THE PHARMACOECONOMIC EVALUATION PROCESS IN IRELAND: CONSIDERATION GIVEN TO THE QUALITY OF CLINICAL EVIDENCE

Dolan E¹, Schmitz S², Barry M³, **McCullagh L**⁴,¹Royal College of Surgeons in Ireland, Dublin, Ireland, ²Luxembourg Institute of Health, Strassen, Luxembourg, ³National Centre for Pharmacoeconomics, Dublin, Ireland, ⁴Trinity College, Dublin, Ireland

PCN271 K17 TREND TOWARDS LONGER TIME TO REIMBURSEMENT IN ONCOLOGICAL MEDICINES IN FINLAND 2005-2015

Oinonen L¹, Renlund M², Pudas H², Ihalmo P², **Hahl J**¹,¹Medaffcon Oy, Espoo, Finland, ²Janssen-Cilag Oy, Espoo, Finland

PCN272 K18 THE CANCER DRUGS FUND: PAST, PRESENT AND FUTURE

Mildred M,Boehringer Ingelheim Ltd, Bracknell, UK

PCN273 K19 COSTS AND CLINICAL OUTCOMES IN THE MANAGEMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN GREECE

Rentzeperi-Michalakou E¹, Kani C², **Souliotis K**², Aravantinos G³, Samantas E³, Ardavanis A⁴, Koumakis G⁵, Markantonis S¹,¹National and Kapodistrian University of Athens, Athens, Greece, ²University of Peloponnese, Corinth, Greece, ³Agioi Anargyroi Anticancer Hospital of Athens, Athens, Greece, ⁴St. Savas Anticancer Hospital, Athens, Greece, ⁵Agios Savvas Anticancer-Oncology Hospital of Athens, Athens, Greece

PCN274 K20 RECOMMENDED VS REIMBURSED VS ACTUALLY USED CHEMOTHERAPEUTICS IN PANCREATIC ADENOCARCINOMA IN POLAND

Burda A, Ekk-Cierniakowski P, Tatar T,Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, Poland

PCN276 K21 CONTINENTAL COMPARISON OF INNOVATIVE DRUGS PRICES, THE CASE OF ONCOLOGY USED FOR TREATMENT OF SOLID TUMORS IN GERMANY AND THE UNITED STATES

Aissaoui N¹, Bin Sawad A², Turkistani F²,¹Paris Dauphine University, Paris, France, ²MCPHS University, Boston, MA, USA

PCN277 K22 TREATMENT SWITCHING PROBLEM IN CANCER CLINICAL TRIALS – IMPLICATIONS FOR HEALTH TECHNOLOGY APPRAISAL OUTCOMES

Panasiuk A¹, Homa M¹, Pawlik D¹, **Przada-Machno P**², Kaczor MP³,¹Aestimo s.c., Kraków, Poland, ²Pfizer Polska Sp. z o.o., Warszawa, Poland, ³Jagiellonian University Medical College, Kraków, Poland

PCN278 K23 THE COST-EFFECTIVENESS THRESHOLD IN CANCER THERAPY – IS THIS A GOOD IDEA?

Serafin B¹, Kaczyński Ł¹, **Przada-Machno P**², Kaczor MP³,¹Aestimo s.c., Kraków, Poland, ²Pfizer Polska Sp. z o.o., Warszawa, Poland, ³Jagiellonian University Medical College, Kraków, Poland

PCN279 K24 THE ROLE OF BUDGET IMPACT ON HTA REJECTION OF ONCOLOGY DRUGS IN ROMANIA

Roibu C, Pacheco L,GfK Market Access, London, UK

PCN280 K25 MARKET ACCESS OF INNOVATIVE ANTICANCER DRUGS IN ALGERIA: FUNDING BASED ON CLINICAL OR ECONOMIC EVIDENCE?

Aissaoui A¹, Kaddar M², Soualmi R²,¹Paris Dauphine University, PSL, Paris, France, ²ISPOR Chapter Algeria, Algiers, Algeria

PCN281 K26 COMBINATION ONCOLOGICS: A BOON OR BURDEN TO HEALTHCARE SYSTEMS?

Ramesh V, Shah S, Kochel S, Mwamburi M, Narayanan S,Market Access Solutions LLC, Raritan, NJ, USA

PCN282 K27 GEOGRAPHIC, RACIAL, AND TEMPORAL VARIATIONS OF ADHERENCE TO SCREENING FOR CERVICAL CANCER AND HPV VACCINATION IN THE UNITED STATES, 2008-2012

Feng X¹, Chang J², Tan X¹,¹West Virginia University, School of Pharmacy, Morgantown, WV, USA, ²University of Texas at El Paso, El Paso, TX, USA

PCN283 K28 IS EXTERNAL REFERENCE PRICING A THREAT TO INTERNATIONAL EQUAL AFFORDABILITY?

Ansaripour A¹, Franken M¹, Uyl-de Groot C², Kalo Z³, Redekop WK⁴,¹Erasmus University Rotterdam, Rotterdam, The Netherlands, ²National Health Care Institute, Diemen, The Netherlands, ³Eötvös Loránd University, Budapest, Hungary, ⁴Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

PCN284 K29 COMPILING AND RECONCILING EVIDENCE TO ASSIGN RISK OF FEBRILE NEUTROPENIA TO CHEMOTHERAPY REGIMENS

Egan KS¹, Lyman GH¹, Kreizenbeck KL¹, McCune JS², Crawford JA³, Kusnir-Wong TL⁴, Stewart FM⁴, Greer BE², Ramsey SD⁵,¹Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ²University of Washington, Seattle, WA, USA, ³Duke Cancer Institute, Durham, WA, USA, ⁴Seattle Cancer Care Alliance, Seattle, WA, USA, ⁵School of Medicine, School of Pharmacy, and the Institute for Public Health Genetics, University of Washington, Seattle, WA, USA

PCN285 K30 TRENDS IN RESEARCH USING OBSERVATIONAL METHODOLOGIES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A SYSTEMATIC LITERATURE REVIEW

Mwamburi M, Dalal H, Gala S,Market Access Solutions LLC, Raritan, NJ, USA

- PCN286 K31 ADVANCED SOFT TISSUE SARCOMA: SYSTEMIC TREATMENT PATTERNS AND SURVIVAL IN GERMANY**
Mytelka DS¹, Lorenzo M², Stafkey-Mailey D³, D'Yachkova Y⁴, Nagar SP⁵, Candrilli SD⁵, Kaye JA⁶, Kasper B⁷, ¹Eli Lilly, Indianapolis, IN, USA, ²Eli Lilly and Company Limited, Windlesham, UK, ³Xcenda, LLC, Palm Harbor, FL, USA, ⁴Eli Lilly Austria GmbH, Vienna, Austria, ⁵RTI Health Solutions, Research Triangle Park, NC, USA, ⁶RTI Health Solutions, Waltham, MA, USA, ⁷Mannheim University Medical Center, Mannheim, Germany
- PCN287 K32 SKELETAL-RELATED EVENTS (SRES) AND RENAL FUNCTION IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA (MM): RESULTS FROM BELGIUM, FRANCE, GERMANY, ITALY, SPAIN, SWITZERLAND AND THE UNITED KINGDOM**
Gonzalez-McQuire S¹, Intorcchia M¹, Gatta F¹, Schoen P¹, Fink L², Gazzola C², Flinois A², Yong K³, Raab M⁴, Leleu H⁵, ¹Amgen (Europe) GmbH, Zug, Switzerland, ²Kantar Health, Paris, France, ³University College London, London, UK, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Public Health Expertise, Paris, France
- PCN288 K33 RESULTS FROM A MODEL TO FORECAST THE CURRENT AND FUTURE NUMBER OF PATIENTS ELIGIBLE FOR TREATMENT OF REFRACTORY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE, GERMANY, ITALY AND SPAIN**
Campbell DJ¹, O'Day K², Penrod JR³, Kish J⁴, Manley Daumont M⁵, Hertel N⁶, ¹Xcenda, Palm Harbor, FL, USA, ²Xcenda, LLC, Palm Harbor, FL, USA, ³Bristol-Myers Squibb, Princeton, NJ, USA, ⁴Cardinal Health, Dublin, OH, USA, ⁵Bristol-Myers Squibb, Paris, France, ⁶Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK
- PCN289 K34 REGULATORY AGENCIES PERSPECTIVE ON PROGRESSION-FREE-SURVIVAL (PFS)**
Schmitter S¹, Brock E², Holzerny P², Günzel C³, Ruckdäschel S², ¹Pfizer Deutschland GmbH, Berlin, Germany, ²HealthEcon AG, Basel, Switzerland, ³Pfizer Pharma GmbH, Berlin, Germany
- PCN290 K35 POTENTIAL IMPACT OF THE CANCER DRUGS FUND REFORM ON ORPHAN CANCERS**
Agashe VR¹, O'Day K², Arvin-berod C³, Meyer KL², Bramley TJ², ¹Xcenda UK Ltd., London, UK, ²Xcenda, LLC, Palm Harbor, FL, USA, ³Xcenda Switzerland GmbH, Bern, Switzerland
- PCN291 K36 HOW DOES HEALTH TECHNOLOGY ASSESSMENT OF PERSONALIZED MEDICINE FOR NON-SMALL CELL LUNG CANCER DIFFER IN FRANCE, GERMANY, AND ENGLAND?**
Sherwood A, Mitrofan L, IMS Health, La Défense, France
- PCN292 K37 SPECIAL CONSIDERATIONS AND PATIENT ACCESS SCHEMES FOR ONCOLOGY BY HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES: SYSTEMATIC EVALUATION IN 25 COUNTRIES**
Mwamburi M, Nanavaty M, Gala S, Nyandege A, Ramesh V, Market Access Solutions LLC, Raritan, NJ, USA
- PCN293 L1 CANCER DRUGS IN EUROPE: A COMPARISON OF HTA PROCESSES AND DECISIONS FOR NEW AND INNOVATIVE ONCOLOGY THERAPIES IN FRANCE, GERMANY AND THE UK – AN ANALYSIS USING THE PRISMACCESS DATABASE**
Droeschel D¹, Hartmann M², Vollmer L¹, Walzer S¹, de Paz B³, ¹MarS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, ²European Consulting & Contracting in Oncology, Trier, Germany, ³PRIORITIS Market Access, Paris, France
- PCN294 L2 RECONSIDERING DRUGS FUNDED VIA THE CANCER DRUGS FUND IN ENGLAND: WHAT'S NEW THIS TIME?**
Morten P¹, Lin Z², **Kusel J³**, ¹Costello Medical Consulting Ltd., Cambridge, UK, ²University of Sheffield, Sheffield, UK, ³Costello Medical Consulting Ltd, Cambridge, UK
- PCN295 L3 PAUCITY OF CLINICAL DATA IN ONCOLOGY HTA SUBMISSIONS: KEY LEARNINGS FROM RECENT CASE STUDIES**
Fountain DL, Pooley N, Olariu E, Papageorgakopoulou C, Chetty M, PHMR Ltd, London, UK
- PCN296 L4 REVIEW OF DATA CUTS USED AS BASIS FOR STATISTICAL ANALYSES AND DERIVATION OF ADDITIONAL BENEFIT PRESENTED WITHIN GERMAN BENEFIT ASSESSMENTS FOR ONCOLOGICAL DRUGS**
Kuehnast S, Kuerschner N, Leverkus F, Pfizer Deutschland GmbH, Berlin, Germany
- PCN297 L5 5-YEAR OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA BY LINE OF TREATMENT FROM THE FRENCH HEMATOLOGIC MALIGNANCY REGISTRY**
Mounier M¹, Gauthier S¹, Mayandié M², Troussard X³, Monnereau A⁴, Guillaume C⁵, Suzan F⁶, Blachier-Poisson C⁵, Despiegel N⁵, ¹Universite de Bourgogne, Dijon, France, ²Centre Hospitalier Universitaire Dijon, Dijon, France, ³Centre Hospitalier Universitaire de Caen, Caen, France, ⁴Institut Bergonié, Bordeaux, France, ⁵Amgen France, Paris, France, ⁶Amgen (Europe) GmbH, Zug, Switzerland
- PCN298 L6 EFFECTIVENESS AND SAFETY OF VEMURAFENIB AS MONOTHERAPY IN UNRESECTABLE OR METASTATIC MELANOMA FROM AN ACADEMIC DATABASE: REAL WORLD DATA TO STRENGTHEN EVIDENCE FOR PAYER**
Borget I¹, Dalle S², Leccia M³, Dutriaux C⁴, Stoeber P⁵, Dalac S⁶, Aubin F⁷, Saiag P⁸, Lacour JP⁹, Lesimple T¹⁰, Dupuy A¹¹, Mortier L¹², Beylot-Barry M¹³, Maubec E¹⁴, Descamps V¹⁴, Lok C¹⁵, Stephan A¹⁶, Guillot B¹⁷, de Quatrebarbes J¹⁸, Dreno B¹⁹, Gally S²⁰, Mourit M²⁰, Allayou C²¹, Kowal A²¹, Porcher R²², Lebbe C²¹, ¹Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France, ²Hospices Civils de Lyon Hospital, Cancer research center of Lyon, Lyon, France, ³Hôpital Albert Michallon - CHU de Grenoble, LA TRONCHE, France, ⁴Bordeaux Saint-André Hospital, Bordeaux, France, ⁵Nîmes Hospital, Nîmes, France, ⁶Dijon Hospital, Dijon, France, ⁷Besançon Hospital, Besançon, France, ⁸Ambroise Pare Hospital, Boulogne Billancourt, France, ⁹CHU de Nice - Hôpital l'Archet 2, NICE CEDEX 3, France, ¹⁰CLCC Rennes Eugene Marquis, Rennes, France, ¹¹Rennes Hospital, Rennes, France, ¹²Lille Hospital, Lille, France, ¹³Bordeaux Haut-Leveque Hospital, Bordeaux, France, ¹⁴Bichat Hospital, Paris, France, ¹⁵Amiens Hospital, Amiens, France, ¹⁶Caen Hospital, Caen, France, ¹⁷Montpellier Hospital, Montpellier, France, ¹⁸Annecy Genevois Hospital, Annecy, France, ¹⁹Centre Hospitalier Universitaire, Nantes Cedex 1,

France, ²⁰Roche S.A.S., Boulogne Billancourt, France, ²¹Saint-Louis Hospital, Paris, France, ²²Center for Clinical Epidemiology, Hotel-Dieu Hospital, Paris, France

- PCN299 L7 RED AND PROCESSED MEAT INTAKE PERCEPTION IN THE PORTUGUESE POPULATION: ASSOCIATION WITH THE WHO ALERT OF 2015 – PRELIMINARY RESULTS OF THE MALERT STUDY**
Garagarza Antunes C¹, Inácio AC², Martins C³, Neves I⁴, Preto A⁵, **Laires PA**⁶, ¹aFresenius Medical Care, Lisbon, Portugal, ²Hospital de Santa Maria—CHLN, Lisbon, Portugal, ³Smile.up Clínicas Dentárias, Lisbon, Portugal, ⁴Instituto de Medicina Preventiva e Saúde Pública, Lisbon, Portugal, ⁵MSD - Animal Health, Lisbon, Portugal, ⁶Faculdade de Medicina da Universidade de Lisboa, Lisbon Academic Medical Center, Lisbon, Portugal, Lisbon, Portugal
- PCN300 L8 EVALUATION OF SUPPORTIVE CARE IN CANCER PATIENTS RECEIVING CHEMOTHERAPY---NEED TO STRENGTHEN TREATMENT POLICIES?**
Himanshu Patel., Parthasarathi G ., JSS College of Pharmacy, Mysore, JSS University, Mysore, India
- PCN301 L9 PREDICTORS OF PD-L1 TESTING IN NON-SMALL CELL LUNG CANCER**
DiBona Ventura M¹, Meyers A², Higginbottom K³, Morimoto Y⁴, Ilacqua J³, ¹Ipsos Healthcare, New York, NY, USA, ²Ipsos Healthcare, Washington, DC, USA, ³Ipsos Healthcare, Mahwah, NJ, USA, ⁴Ipsos Healthcare, Tokyo, Japan
- PCN302 L10 APPLICATION OF PAYMENT BY RESULTS SCHEMES IN ONCOLOGY IN ITALY: RELATION BETWEEN TIMING FOR THE EVALUATION OF TREATMENT FAILURES AND MEDIAN PROGRESSION FREE SURVIVAL (PFS) FROM CLINICAL TRIALS**
Ferrario M., Vittoria G, Deroo V, Giuliani G, Roche Spa, Monza, Italy
- PCN303 L11 DOES THE TREND TOWARDS VALUE FRAMEWORKS REQUIRE NEW APPROACHES TO EVIDENCE DEVELOPMENT AND HEALTH TECHNOLOGY ASSESSMENT?**
Teale CW¹, Entwistle J¹, Freeman S², ¹GfK, Melton Mowbray, UK, ²GfK, London, UK
- PCN304 L12 THE EFFECTS OF PAY FOR RESPONSE AND MAXIMUM PRICE CAP SCHEMES ON PAYER AND PROVIDER RISK**
Hawkins N., Wu O, Adler A, University of Glasgow, Glasgow, UK
- PCN305 L13 TREATMENT PATTERN DIFFERENCES ACROSS THE UNITED STATES, WESTERN EUROPE, AND JAPAN AMONG PATIENTS WITH METASTATIC RENAL CELL CARCINOMA**
DiBona Ventura M¹, Higginbottom K², Meyers A³, Morimoto Y⁴, Ilacqua J², ¹Ipsos Healthcare, New York, NY, USA, ²Ipsos Healthcare, Mahwah, NJ, USA, ³Ipsos Healthcare, Washington, DC, USA, ⁴Ipsos Healthcare, Tokyo, Japan
- PCN306 L14 PATTERNS OF CARE AMONG PANCREATIC CANCER PATIENTS: FINDINGS FROM A U.S. REAL-WORLD CLAIMS-BASED ANALYSIS**
Kish J¹, Maida T², Feinberg BA¹, Biggs C², Mujumdar U¹, Chopra D¹, Laney J¹, Kennedy G², ¹Cardinal Health, Dublin, OH, USA, ²NewLink Genetics Inc, Austin, TX, USA
- PCN307 L15 THE ASSOCIATION BETWEEN INITIATION OF GUIDELINE RECOMMENDED FIRST-LINE SYSTEMIC THERAPY AND HEALTHCARE COSTS AND UTILIZATION IN A METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) POPULATION**
Casebeer AW¹, Hopson S¹, Drzayich Antol D², Li Y², DeClue RW², **Khoury R**³, Parikh A³, Michael T³, Stenkowski S¹, Bunce M³, ¹Humana, Inc., Louisville, VA, USA, ²Comprehensive Health Insights, Inc., Louisville, KY, USA, ³Genentech, South San Francisco, CA, USA
- PCN308 L16 REAL WORLD TREATMENT PATTERNS IN METASTATIC AND/OR UNRESECTABLE GASTRIC CANCER PATIENTS IN BRAZIL**
Novick D¹, Vieira FM¹, Victorino AP², Cubero DI³, Beato CA⁴, Minowa E⁵, Julian G⁵, ¹Eli Lilly and Company, Windlesham, Surrey, UK, ²Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil, ³Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo André, Brazil, ⁴Fundação Amaral Carvalho, Jaú, Brazil, ⁵Kantar Health, São Paulo, Brazil, ⁶Evidências - Kantar Health, São Paulo, Brazil
- PCN309 L17 TREATMENT RATES IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER AND THE FACTORS INFLUENCING TREATMENT DECISION**
Colomer R¹, Hall P², szkulcka-Debek M³, Bondi R⁴, **Flinois A**⁵, Auziere S⁵, Le Cleach J⁵, ¹Hospital Universitario La Princesa, Madrid, Spain, ²Edinburgh Cancer Research UK Centre, Edinburgh, UK, ³Roche, Warsaw, Poland, ⁴Roche, Basel, Switzerland, ⁵Kantar Health, Paris, France
- PCN310 L18 TREATMENT PATTERNS OF ALK+ NON-SMALL CELL LUNG CANCER IN WESTERN EUROPE**
DiBona Ventura M¹, Higginbottom K², Meyers A³, Ilacqua J², Morimoto Y⁴, ¹Ipsos Healthcare, New York, NY, USA, ²Ipsos Healthcare, Mahwah, NJ, USA, ³Ipsos Healthcare, Washington, DC, USA, ⁴Ipsos Healthcare, Tokyo, Japan
- PCN311 L19 TREATMENT PATTERNS OF ALK+ NON-SMALL CELL LUNG CANCER IN JAPAN**
DiBona Ventura M¹, Higginbottom K², Meyers A³, Morimoto Y⁴, Ilacqua J², ¹Ipsos Healthcare, New York, NY, USA, ²Ipsos Healthcare, Mahwah, NJ, USA, ³Ipsos Healthcare, Washington, DC, USA, ⁴Ipsos Healthcare, Tokyo, Japan
- PCN312 L20 A SYSTEMATIC REVIEW OF TREATMENT PATTERNS IN PATIENTS WITH RECURRENT GLIOBLASTOMA IN THE REAL WORLD**
Davies J. Reyes-Rivera I, F. Hoffmann-La Roche AG, Basel, Switzerland
- PCN313 L21 REAL WORLD ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENT TESTING PATTERNS, TREATMENT**

SEQUENCES AND SURVIVAL OF ALK-INHIBITOR TREATED PATIENTS

Davies J¹, Martinec M¹, Coudert M², Delmar P¹, Becker U³, Crane G¹, Green K¹,¹F. Hoffmann-La Roche AG, Basel, Switzerland, ²Roche S.A.S., Boulogne-Billancourt cedex, France, ³F. Hoffmann-La Roche Ltd., Basel, Switzerland

PCN314 L22 CURRENT STATUS OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR GASTRIC CANCER WITHIN ABSOLUTE INDICATION IN KOREA: BASED ON NATIONAL CLAIMS DATABASE

Lyu DH¹, Kim J², Park C¹, Lee NR¹, Cha Y², KIM SG³, CHOI IJ⁴, Jung H⁵,¹National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea, ²National evidence-based health care Collaborating Agency, Korea, Seoul, South Korea, ³Seoul National University College of Medicine, Seoul, South Korea, ⁴National Cancer Center, Seoul, South Korea, ⁵University of Ulsan College of Medicine Asan Medical Center, Seoul, South Korea

PCN315 L23 PHYSICIANS' BEHAVIOR INFLUENCES THE HEALTH AND ECONOMIC IMPACT OF APPLYING CIRCULATING TUMOR CELLS AS RESPONSE MARKER IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Degeling K¹, Mehra N², Koffijberg H³, de Bono JS², IJzerman MJ³,¹University of Twente, Enschede, The Netherlands, ²The Institute of Cancer Research, Sutton, UK, ³MIRA institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands

PCN316 L24 REVIEW OF CLINICAL PRACTICE GUIDELINES AND TREATMENT PATTERNS IN METASTATIC PANCREATIC CANCER IN EU-5 COUNTRIES

Kalra M, Singh B, Ahuja A, Sharma S, PAREXEL Access Consulting, Chandigarh, India

PCN317 L25 DESCRIPTIVE ANALYSIS OF THE RESECTED PANCREATIC CANCER PATIENT JOURNEY: FINDINGS FROM A U.S. REAL-WORLD CLAIMS-BASED ANALYSIS

Kish J¹, Maida T², Feinberg BA¹, Biggs C², Mujumdar U¹, Laney J¹, Chopra D¹, Kennedy G²,¹Cardinal Health, Dublin, OH, USA, ²NewLink Genetics Inc, Austin, TX, USA